<SEC-DOCUMENT>0001104659-23-026756.txt : 20230228
<SEC-HEADER>0001104659-23-026756.hdr.sgml : 20230228
<ACCEPTANCE-DATETIME>20230228163048
ACCESSION NUMBER:		0001104659-23-026756
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		17
CONFORMED PERIOD OF REPORT:	20230223
ITEM INFORMATION:		Entry into a Material Definitive Agreement
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20230228
DATE AS OF CHANGE:		20230228

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TACTILE SYSTEMS TECHNOLOGY INC
		CENTRAL INDEX KEY:			0001027838
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37799
		FILM NUMBER:		23686007

	BUSINESS ADDRESS:	
		STREET 1:		1331 TYLER STREET NE STE 200
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
		BUSINESS PHONE:		866-435-3948

	MAIL ADDRESS:	
		STREET 1:		1331 TYLER STREET NE STE 200
		CITY:			MINNEAPOLIS
		STATE:			MN
		ZIP:			55413
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>tm233510d7_8k.htm
<DESCRIPTION>FORM 8-K
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-roles="http://fasb.org/us-roles/2021-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:TCMD="http://tactilemedical.com/20230223">
<head>
     <title></title>
<meta http-equiv="Content-Type" content="text/html" />
</head>
<!-- Field: Set; Name: xdx; ID: xdx_02A_US%2DGAAP%2D2021 -->
<!-- Field: Set; Name: xdx; ID: xdx_03C_TCMD_tactilemedical.com_20230223 -->
<!-- Field: Set; Name: xdx; ID: xdx_04F_20230223_20230223 -->
<!-- Field: Set; Name: xdx; ID: xdx_05C_edei%2D%2DEntityCentralIndexKey_0001027838 -->
<!-- Field: Set; Name: xdx; ID: xdx_059_edei%2D%2DAmendmentFlag_false -->
<!-- Field: Set; Name: xdx; ID: xdx_072_SO_T%2D%2D\DeptFiles%2DiXBRL 8%2DK Covers Templates\+++%2DROOT%2DElement%2D+++\DocumentInformationLineItems.xdxs -->
<!-- Field: Set; Name: xdx; ID: xdx_06B_USD_1_iso4217%2D%2DUSD -->
<!-- Field: Set; Name: xdx; ID: xdx_062_Shares_2_xbrli%2D%2Dshares -->
<!-- Field: Set; Name: xdx; ID: xdx_06D_USDPShares_3_iso4217%2D%2DUSD_xbrli%2D%2Dshares -->
<body style="font: 10pt Times New Roman, Times, Serif">
<div style="display: none">
<ix:header>
 <ix:hidden>
  <ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityCentralIndexKey">0001027838</ix:nonNumeric>
  <ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:AmendmentFlag">false</ix:nonNumeric>
  </ix:hidden>
 <ix:references>
  <link:schemaRef xlink:href="tcmd-20230223.xsd" xlink:type="simple" />
  </ix:references>
 <ix:resources>
    <xbrli:context id="From2023-02-23to2023-02-23">
      <xbrli:entity>
        <xbrli:identifier scheme="http://www.sec.gov/CIK">0001027838</xbrli:identifier>
      </xbrli:entity>
      <xbrli:period>
        <xbrli:startDate>2023-02-23</xbrli:startDate>
        <xbrli:endDate>2023-02-23</xbrli:endDate>
      </xbrli:period>
    </xbrli:context>
    <xbrli:unit id="USD">
      <xbrli:measure>iso4217:USD</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="Shares">
      <xbrli:measure>xbrli:shares</xbrli:measure>
    </xbrli:unit>
    <xbrli:unit id="USDPShares">
      <xbrli:divide>
        <xbrli:unitNumerator>
          <xbrli:measure>iso4217:USD</xbrli:measure>
        </xbrli:unitNumerator>
        <xbrli:unitDenominator>
          <xbrli:measure>xbrli:shares</xbrli:measure>
        </xbrli:unitDenominator>
      </xbrli:divide>
    </xbrli:unit>
  </ix:resources>
 </ix:header>
</div>


<p style="margin: 0">&#160;</p>

<p style="margin: 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 2pt solid; border-bottom: Black 1pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt">&#160;</span></p>

<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>UNITED STATES<br />
SECURITIES AND EXCHANGE COMMISSION</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Washington, D.C. 20549</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>&#160;</b></p>




<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>FORM <span id="xdx_90D_edei--DocumentType_c20230223__20230223_zuYMbOwz4i7k"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:DocumentType">8-K</ix:nonNumeric></span></b></p>




<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><span style="font-size: 10pt"><b>&#160;</b></span></p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>CURRENT REPORT</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>Pursuant to Section 13 or 15(d) of</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>the Securities Exchange Act of 1934</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Date of Report (Date of earliest event
reported) <b>&#160;<span id="xdx_90A_edei--DocumentPeriodEndDate_c20230223__20230223_zcTBn3tRHrEc"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" format="ixt:datemonthdayyearen" name="dei:DocumentPeriodEndDate">February 23, 2023</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 2pt; text-align: center"><b><span>&#160;</span></b></p>


<p style="font: 18pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_901_edei--EntityRegistrantName_c20230223__20230223_zYQhnCntgMS4"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityRegistrantName">TACTILE SYSTEMS TECHNOLOGY, INC.</ix:nonNumeric></span></b></p>

<p style="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; margin: 0pt 2in 2pt; text-align: center">(Exact name of registrant as specified in
its charter)</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"></p>




<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr>
    <td style="vertical-align: top; width: 33%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 32%">&#160;</td>
    <td style="vertical-align: bottom; width: 1%">&#160;</td>
    <td style="vertical-align: top; width: 33%">&#160;</td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_90B_edei--EntityIncorporationStateCountryCode_c20230223__20230223_zGY2FEDUCStd"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" format="ixt-sec:stateprovnameen" name="dei:EntityIncorporationStateCountryCode">Delaware</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_904_edei--EntityFileNumber_c20230223__20230223_zirlkDpZBbJ8"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityFileNumber">001-37799</ix:nonNumeric></span></b></span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><b><span id="xdx_903_edei--EntityTaxIdentificationNumber_c20230223__20230223_zy5qVJ8Uoewf"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityTaxIdentificationNumber">41-1801204</ix:nonNumeric></span></b></span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(State or other jurisdiction of</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(Commission</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">(I.R.S. Employer</span></td></tr>
<tr>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">incorporation)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">File Number)</span></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif">Identification No.)</span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b><span id="xdx_908_edei--EntityAddressAddressLine1_c20230223__20230223_zgkk223AfRf2"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityAddressAddressLine1">3701 Wayzata Blvd</ix:nonNumeric></span>, <span id="xdx_903_edei--EntityAddressAddressLine2_c20230223__20230223_zcEYEaC5ojy6"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityAddressAddressLine2">Suite 300</ix:nonNumeric></span>, <span id="xdx_90E_edei--EntityAddressCityOrTown_c20230223__20230223_zpE3ozJM0LI7"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityAddressCityOrTown">Minneapolis</ix:nonNumeric></span>,
<span id="xdx_906_edei--EntityAddressStateOrProvince_c20230223__20230223_zk06CNn9adzi"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityAddressStateOrProvince">MN</ix:nonNumeric></span> <span id="xdx_906_edei--EntityAddressPostalZipCode_c20230223__20230223_zJjO2St6Gv4e"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:EntityAddressPostalZipCode">55416</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Address of principal executive offices)
(Zip Code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>(<span id="xdx_906_edei--CityAreaCode_c20230223__20230223_z9NyNAfSYbhg"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:CityAreaCode">612</ix:nonNumeric></span>) <span id="xdx_907_edei--LocalPhoneNumber_c20230223__20230223_znh3xU7usIh7"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:LocalPhoneNumber">355-5100</ix:nonNumeric></span></b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">(Registrant&#8217;s telephone number, including
area code)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_90F_edei--WrittenCommunications_c20230223__20230223_zBMW3IJq9Ei"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" format="ixt:booleanfalse" name="dei:WrittenCommunications">&#168;</ix:nonNumeric></span></span>&#160;Written communications pursuant to Rule 425 under
the Securities Act (17 CFR 230.425)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Wingdings"><span id="xdx_904_edei--SolicitingMaterial_c20230223__20230223_z7JcLnYYlzFi"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" format="ixt:booleanfalse" name="dei:SolicitingMaterial">&#168;</ix:nonNumeric></span></span>&#160;Soliciting material pursuant to Rule 14a-12 under
the Exchange Act (17 CFR 240.14a-12)</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in"><span style="font-family: Wingdings"><span id="xdx_907_edei--PreCommencementTenderOffer_c20230223__20230223_z5o6DFThirI3"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" format="ixt:booleanfalse" name="dei:PreCommencementTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in"><span style="font-family: Wingdings"><span id="xdx_900_edei--PreCommencementIssuerTenderOffer_c20230223__20230223_zYNk2Uy5oa63"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" format="ixt:booleanfalse" name="dei:PreCommencementIssuerTenderOffer">&#168;</ix:nonNumeric></span></span>&#160;Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><b>Securities registered
pursuant to Section 12(b) of the Act:</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Title of each class</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 34%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Trading Symbol(s)</b></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center; width: 33%"><span style="font: 10pt Times New Roman, Times, Serif"><b>Name of each exchange on which <br />
registered</b></span></td></tr>
<tr style="vertical-align: top">
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_902_edei--Security12bTitle_c20230223__20230223_zP0BihetjmDk"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:Security12bTitle">Common Stock, Par Value $0.001 Per Share</ix:nonNumeric></span></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_90B_edei--TradingSymbol_c20230223__20230223_zHx0CgNeYjgl"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" name="dei:TradingSymbol">TCMD</ix:nonNumeric></span></span></td>
    <td style="padding-right: 5.4pt; padding-left: 5.4pt; text-align: center"><span style="font: 10pt Times New Roman, Times, Serif"><span id="xdx_904_edei--SecurityExchangeName_c20230223__20230223_zHEkWBSjal3i"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" format="ixt-sec:exchnameen" name="dei:SecurityExchangeName">The Nasdaq Stock Market</ix:nonNumeric></span></span></td></tr>
</table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.2in; text-indent: -0.2in">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (&#167;240.12b-2 of this chapter).&#160;&#160;<span style="font-family: Wingdings"><span id="xdx_90D_edei--EntityEmergingGrowthCompany_c20230223__20230223_zT9m2mUFZdW4"><ix:nonNumeric contextRef="From2023-02-23to2023-02-23" format="ixt:booleanfalse" name="dei:EntityEmergingGrowthCompany">&#168;</ix:nonNumeric></span></span>  Emerging growth company</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. <span style="font-family: Wingdings">&#168;</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></p>

<!-- Field: Rule-Page --><div style="margin-top: 0; margin-bottom: 0; width: 100%"><div style="border-top: Black 1pt solid; border-bottom: Black 2pt solid; font-size: 1pt">&#160;</div></div><!-- Field: /Rule-Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;&#160;</p>




<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page -->

<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 1.01.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Entry into a Material Definitive Agreement.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in; text-indent: -1in; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">On
February&#160;23, 2023, Tactile Systems Technology,&#160;Inc. (the &#8220;Company&#8221;) entered into an underwriting agreement
(the &#8220;Underwriting Agreement&#8221;) with William Blair&#160;&amp; Company, L.L.C, as the underwriter (the
&#8220;Underwriter&#8221;), relating to the public offering of 2,875,000 shares of the Company&#8217;s common stock, par value
$0.001 per share (&#8220;Common Stock&#8221;), including 375,000 shares purchased by the Underwriter pursuant to an option to
purchase additional shares, at a public offering price of $13.00 per share. The offering was
made pursuant to the Company&#8217;s shelf registration statement on Form&#160;S-3 (File No.&#160;333-269287) (the &#34;Registration
Statement&#8221;), which became effective on January 25, 2023, including the related prospectus,
dated January&#160;25, 2023,&#160;as supplemented by the prospectus supplement dated February&#160;23, 2023. The Underwriting
Agreement is attached hereto as Exhibit&#160;1.1 and is incorporated herein by reference. The foregoing description of the material
terms of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the terms of
the Underwriting Agreement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white">A copy of the legal opinion
relating to the legality of the issuance and sale of Common Stock in the offering is attached hereto as Exhibit&#160;5.1 and is incorporated
by reference into the Registration Statement.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 13%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Item 8.01.</b></span></td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>Other Events.</b></span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.25in; background-color: white"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: white">On
February&#160;</span>23<span style="background-color: white">, 2023, the Company issued press releases announcing the commencement of
the public offering and the pricing of the public offering. Copies of the press releases are attached hereto as Exhibits&#160;99.1 and 99.2 and are incorporated
herein by reference.</span></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; background-color: white">
  <tr style="vertical-align: top">
    <td style="width: 13%"><b>&#160;Item 9.01.</b></td>
    <td><b>&#160;Financial Statements and Exhibits.</b></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">(d)&#160;Exhibits</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>EXHIBIT&#160;INDEX</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: bottom">
    <td style="border-bottom: black 1pt solid; width: 8%"><b>Exhibit<br /> No.</b></td>
    <td style="text-align: center; width: 2%"><b>&#160;</b></td>
    <td style="border-bottom: black 1pt solid; text-align: center; width: 90%"><b>Description</b></td></tr>
  <tr>
    <td style="vertical-align: top">&#160;</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">&#160;</td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm233510d7_ex1-1.htm">1.1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm233510d7_ex1-1.htm">Underwriting Agreement, dated as of February&#160;23, 2023, between the Company and William Blair&#160;&amp; Company, L.L.C., as the underwriter.</a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm233510d7_ex5-1.htm" style="-sec-extract: exhibit">5.1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm233510d7_ex5-1.htm" style="-sec-extract: exhibit">Opinion of Faegre Drinker Biddle&#160;&amp; Reath LLP.</a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm233510d7_ex5-1.htm" style="-sec-extract: exhibit">23.1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm233510d7_ex5-1.htm" style="-sec-extract: exhibit">Consent of Faegre Drinker Biddle&#160;&amp; Reath LLP (included in Exhibit&#160;5.1).</a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm233510d7_ex99-1.htm">99.1</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm233510d7_ex99-1.htm">Press Release dated February&#160;23, 2023, announcing the commencement of the public offering.</a></td></tr>
  <tr>
    <td style="vertical-align: top"><a href="tm233510d7_ex99-2.htm">99.2</a></td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top"><a href="tm233510d7_ex99-2.htm">Press Release dated February&#160;23, 2023, announcing the pricing of the public offering.</a></td></tr>
  <tr>
    <td style="vertical-align: top">104</td>
    <td style="vertical-align: bottom">&#160;</td>
    <td style="vertical-align: top">Cover Page&#160;Interactive Data File (embedded within the Inline XBRL document)</td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 1 -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <div style="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><b>SIGNATURES</b></p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<p style="font: 10pt Times New Roman, Times, Serif; text-align: left; margin-top: 0pt; margin-bottom: 0pt">Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>

<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<table cellspacing="0" cellpadding="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">TACTILE SYSTEMS TECHNOLOGY,&#160;INC.</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td colspan="2">&#160;</td></tr>
  <tr>
    <td style="width: 51%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date: February&#160;28, 2023</span></td>
    <td style="vertical-align: top; width: 3%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</span></td>
    <td style="border-bottom: black 1pt solid; vertical-align: top; width: 46%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">/s/ <i>Brent A. Moen</i></span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Brent A. Moen</span></td></tr>
  <tr style="vertical-align: top">
    <td>&#160;</td>
    <td>&#160;</td>
    <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Chief Financial Officer</span></td></tr>
  </table>
<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <div style="border-bottom: Black 1pt solid; margin-top: 12pt; margin-bottom: 6pt"><p style="margin: 0pt">&#160;</p></div>
    <!-- Field: /Page --><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&#160;</p>



<p style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"></p>

</body>
</html>
<!-- Field: Set; Name: xdx; ID: xdx_08B_extensions -->
<!-- eJxFjd0KgkAQhZ/Adxj2OvIHgvSupCKyCJHodskxlnRHZlfLR+ot25RoGBhmznznCDETO9qqGhmu6zyDApu2lhYhxwoZ9Q3dR7o/JOBmjndlLEttx/UHpuQYdMxiHkt3Hz97ZbBMIIj9YOlHIYRREkawOgrvq6ekK1WitkrWIHUJZ6aWFVrJw+RQyBdpaoYx6YJsFOkEwnkwyW+IAud3ol4+iR8GsiwV3mwsT+yYuvYb0xlLDWxqbFyWmdB/ex/ZakkQ -->
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-1.1
<SEQUENCE>2
<FILENAME>tm233510d7_ex1-1.htm
<DESCRIPTION>EXHIBIT 1.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;1.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">UNDERWRITING AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">TACTILE SYSTEMS TECHNOLOGY,&nbsp;INC.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">2,500,000 Shares of Common Stock</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Underwriting Agreement</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">February&nbsp;23, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William Blair&nbsp;&amp; Company, L.L.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">150 North Riverside Plaza</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chicago,&nbsp;Illinois 60606</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Tactile Systems Technology,&nbsp;Inc., a Delaware
corporation (the &ldquo;Company&rdquo;), proposes to issue and sell to you, the underwriter listed in Schedule 1 hereto (the &ldquo;Underwriter&rdquo;),
an aggregate of 2,500,000 shares of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;), of the Company (the &ldquo;Underwritten
Shares&rdquo;) and, at the option of the Underwriter, up to an additional 375,000 shares of Common Stock of the Company (the &ldquo;Option
Shares&rdquo;). The Underwritten Shares and the Option Shares are herein referred to as the &ldquo;Shares&rdquo;. The shares of Common
Stock of the Company to be outstanding after giving effect to the sale of the Shares are referred to herein as the &ldquo;Stock&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Company hereby confirms its agreement with
the Underwriter concerning the purchase and sale of the Shares, as follows:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Registration
Statement. The Company has prepared and filed with the Securities and Exchange Commission (the &ldquo;Commission&rdquo;) under the Securities
Act of 1933, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the &ldquo;Securities Act&rdquo;),
a registration statement on Form&nbsp;S-3 (File No.&nbsp;333-269287), including a prospectus, relating to the Shares. Such registration
statement, as amended at the time it became effective, including the information, if any, deemed pursuant to Rule&nbsp;430A, 430B or 430C
under the Securities Act to be part of the registration statement at the time of its effectiveness (&ldquo;Rule&nbsp;430 Information&rdquo;),
is referred to herein as the &ldquo;Registration Statement&rdquo;; and as used herein, the term &ldquo;Preliminary Prospectus&rdquo; means
the prospectus included in the Registration Statement at the time of its effectiveness that omits Rule&nbsp;430 Information (the &ldquo;Base
Prospectus&rdquo;) and the prospectus supplement dated February&nbsp;23, 2023, thereto relating to the Shares, and the term &ldquo;Prospectus&rdquo;
means the Base Prospectus and the prospectus supplement relating to the Shares in the form first used (or made available upon request
of purchasers pursuant to Rule&nbsp;173 under the Securities Act) in connection with confirmation of sales of the Shares. If the Company
has filed an abbreviated registration statement pursuant to Rule&nbsp;462(b)&nbsp;under the Securities Act (the &ldquo;Rule&nbsp;462 Registration
Statement&rdquo;), then any reference herein to the term Registration Statement shall be deemed to include such Rule&nbsp;462 Registration
Statement. Any reference in this underwriting agreement (the &ldquo;Agreement&rdquo;) to the Registration Statement, any Preliminary Prospectus
or the Prospectus shall be deemed to refer to and include the documents incorporated by reference therein pursuant to Item 12 of Form&nbsp;S-3
under the Securities Act, as of the effective date of the Registration Statement or the date of such Preliminary Prospectus or the Prospectus,
as the case may be, and any reference to &ldquo;amend&rdquo;, &ldquo;amendment&rdquo; or &ldquo;supplement&rdquo; with respect to the
Registration Statement, any Preliminary Prospectus or the Prospectus shall be deemed to refer to and include any documents filed after
such date under the Securities Exchange Act of 1934, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively,
the &ldquo;Exchange Act&rdquo;) that are deemed to be incorporated by reference therein. Capitalized terms used but not defined herein
shall have the meanings given to such terms in the Registration Statement and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">At or prior to the Applicable Time (as defined
below), the Company had prepared the following information (collectively with the pricing information set forth on Annex A, the &ldquo;Pricing
Disclosure Package&rdquo;): a Preliminary Prospectus dated February&nbsp;23, 2023 and each &ldquo;free-writing prospectus&rdquo; (as defined
pursuant to Rule&nbsp;405 under the Securities Act) listed on Annex A hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">&ldquo;Applicable Time&rdquo; means 7:05 p.m.,
New York City time, on February&nbsp;23, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Purchase
of the Shares by the Underwriter</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company agrees to issue and sell the Underwritten Shares to the Underwriter as provided in this Agreement, and the Underwriter, on the
basis of the representations, warranties and agreements set forth herein and subject to the conditions set forth herein, agrees to purchase
from the Company the respective number of Underwritten Shares set forth opposite the Underwriter&rsquo;s name in Schedule 1 hereto at
a price per share (the &ldquo;Purchase Price&rdquo;) of $12.22.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">In addition, the Company agrees to issue and sell
the Option Shares to the Underwriter as provided in this Agreement, and the Underwriter, on the basis of the representations, warranties
and agreements set forth herein and subject to the conditions set forth herein, shall have the option to purchase from the Company the
Option Shares at the Purchase Price less an amount per share equal to any dividends or distributions declared by the Company and payable
on the Underwritten Shares but not payable on the Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">The Underwriter may exercise the option to purchase
Option Shares at any time in whole, or from time to time in part, on or before the thirtieth day following the date of the Prospectus,
by written notice from the Underwriter to the Company. Such notice shall set forth the aggregate number of Option Shares as to which the
option is being exercised and the date and time when the Option Shares are to be delivered and paid for, which may be the same date and
time as the Closing Date (as hereinafter defined) but shall not be earlier than the Closing Date nor later than the tenth full business
day (as hereinafter defined) after the date of such notice (unless such time and date are postponed in accordance with the provisions
of Section&nbsp;10 hereof or unless otherwise agreed to in writing by the Underwriter and the Company). Any such notice shall be given
at least two business days prior to the date and time of delivery specified therein.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company understands that the Underwriter intends to make a public offering of the Shares as soon after the effectiveness of this Agreement
as in the judgment of the Underwriter is advisable, and initially to offer the Shares on the terms set forth in the Prospectus. The Company
acknowledges and agrees that the Underwriter may offer and sell Shares to or through any affiliate of the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Payment
for the Shares shall be made by wire transfer in immediately available funds to the account specified by the Company to the Underwriter
in the case of the Underwritten Shares, at the offices of Latham&nbsp;&amp; Watkins LLP at 10:00 A.M., New York City time, on February&nbsp;28,
2023, or at such other time or place on the same or such other date, not later than the fifth business day thereafter, as the Underwriter
and the Company may agree upon in writing or, in the case of the Option Shares, on the date and at the time and place specified by the
Underwriter in the written notice of the Underwriter&rsquo;s election to purchase such Option Shares. The time and date of such payment
for the Underwritten Shares is referred to herein as the &ldquo;Closing Date,&rdquo; and the time and date for such payment for the Option
Shares, if other than the Closing Date, is herein referred to as the &ldquo;Additional Closing Date&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">Payment for the Shares to be purchased on the Closing
Date or the Additional Closing Date, as the case may be, shall be made against delivery to the Underwriter&rsquo;s account of the Shares
to be purchased on such date with any transfer taxes payable in connection with the sale of such Shares duly paid by the Company. Delivery
of the Shares shall be made through the facilities of The Depository Trust Company unless the Underwriter shall otherwise instruct.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>The
Company acknowledges and agrees that the Underwriter is acting solely in the capacity of an arm&rsquo;s length contractual counterparty
to the Company with respect to the offering of Shares contemplated hereby (including in connection with determining the terms of the offering)
and not as a financial advisor or a fiduciary to, or an agent of, the Company or any other person. Additionally, the Underwriter is not
advising the Company or any other person as to any legal, tax, investment, accounting or regulatory matters in any jurisdiction. The Company
shall consult with its own advisors concerning such matters and shall be responsible for making its own independent investigation and
appraisal of the transactions contemplated hereby, and the Underwriter shall have no responsibility or liability to the Company with respect
thereto. Any review by the Underwriter of the Company, the transactions contemplated hereby or other matters relating to such transactions
will be performed solely for the benefit of the Underwriter and shall not be on behalf of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Representations
and Warranties of the Company</U>. The Company represents and warrants to the Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Preliminary
Prospectus.</I> No order preventing or suspending the use of any Preliminary Prospectus has been issued by the Commission, and each Preliminary
Prospectus included in the Pricing Disclosure Package, at the time of filing thereof, complied in all material respects with the Securities
Act, and no Preliminary Prospectus, at the time of filing thereof, contained any untrue statement of a material fact or omitted to state
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U> that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon
and in conformity with information relating to the Underwriter furnished to the Company in writing by the Underwriter expressly for use
in any Preliminary Prospectus, it being understood and agreed that the only such information furnished by the Underwriter consists of
the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Pricing
Disclosure Package</I>. The Pricing Disclosure Package as of the Applicable Time did not, and as of the Closing Date and as of the Additional
Closing Date, as the case may be, will not, contain any untrue statement of a material fact or omit to state a material fact necessary
in order to make the statements therein, in the light of the circumstances under which they were made, not misleading; <U>provided</U>
that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon and in conformity
with information relating to the Underwriter furnished to the Company in writing by the Underwriter expressly for use in such Pricing
Disclosure Package, it being understood and agreed that the only such information furnished by the Underwriter consists of the information
described as such in Section&nbsp;7(b)&nbsp;hereof. No statement of material fact included in the Prospectus has been omitted from the
Pricing Disclosure Package and no statement of material fact included in the Pricing Disclosure Package that is required to be included
in the Prospectus has been omitted therefrom.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Issuer
Free Writing Prospectus. </I>Other than the Registration Statement, the Preliminary Prospectus and the Prospectus, the Company (including
its agents and representatives, other than the Underwriter in its capacity as such) has not prepared, used, authorized, approved or referred
to and will not prepare, use, authorize, approve or refer to any &ldquo;written communication&rdquo; (as defined in Rule&nbsp;405 under
the Securities Act) that constitutes an offer to sell or solicitation of an offer to buy the Shares (each such communication by the Company
or its agents and representatives (other than a communication referred to in clause (i)&nbsp;below) an &ldquo;Issuer Free Writing Prospectus&rdquo;)
other than (i)&nbsp;any document not constituting a prospectus pursuant to Section&nbsp;2(a)(10)(a)&nbsp;of the Securities Act or Rule&nbsp;134
under the Securities Act or (ii)&nbsp;the documents listed on Annex A hereto, each electronic road show and any other written communications
approved in writing in advance by the Underwriter. Each such Issuer Free Writing Prospectus complied in all material respects with the
Securities Act, has been or will be (within the time period specified in Rule&nbsp;433) filed in accordance with the Securities Act (to
the extent required thereby) and does not conflict with the information contained in the Registration Statement or the Pricing Disclosure
Package, and, when taken together with the Preliminary Prospectus accompanying, or delivered prior to delivery of, such Issuer Free Writing
Prospectus, did not, and as of the Closing Date and as of the Additional Closing Date, as the case may be, will not, contain any untrue
statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances
under which they were made, not misleading; <U>provided</U> that the Company makes no representation and warranty with respect to any
statements or omissions made in each such Issuer Free Writing Prospectus or Preliminary Prospectus in reliance upon and in conformity
with information relating to the Underwriter furnished to the Company in writing by the Underwriter through expressly for use in such
Issuer Free Writing Prospectus or Preliminary Prospectus, it being understood and agreed that the only such information furnished by the
Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Registration
Statement and Prospectus.</I> The Registration Statement has been filed with the Commission not earlier than three years prior to the
date hereof; and no notice of objection of the Commission to the use of such registration statement or any post-effective amendment thereto
pursuant to Rule&nbsp;401(g)(2)&nbsp;under the Securities Act has been received by the Company. No order suspending the effectiveness
of the Registration Statement has been issued by the Commission, and no proceeding for that purpose or pursuant to Section&nbsp;8A of
the Securities Act against the Company or related to the offering of the Shares has been initiated or, to the knowledge of the Company,
threatened by the Commission; as of the effective date of the Registration Statement, the Registration Statement complied in all material
respects with the Securities Act, and did not contain any untrue statement of a material fact or omit to state a material fact required
to be stated therein or necessary in order to make the statements therein not misleading; and as of the date of the Prospectus and any
amendment or supplement thereto and as of the Closing Date or Additional Closing Date, as the case may be, the Prospectus complied and
will comply in all material respects with the Securities Act and will not contain any untrue statement of a material fact or omit to state
a material fact necessary in order to make the statements therein, in the light of the circumstances under which they were made, not misleading;
<U>provided</U> that the Company makes no representation and warranty with respect to any statements or omissions made in reliance upon
and in conformity with information relating to the Underwriter furnished to the Company in writing by the Underwriter expressly for use
in the Registration Statement and the Prospectus and any amendment or supplement thereto, it being understood and agreed that the only
such information furnished by the Underwriter consists of the information described as such in Section&nbsp;7(b)&nbsp;hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Incorporated
Documents.</I> The documents incorporated by reference in the Registration Statement, the Prospectus and the Pricing Disclosure Package,
when they were filed with the Commission conformed in all material respects to the requirements of the Exchange Act, and none of such
documents contained any untrue statement of a material fact or omitted to state a material fact necessary to make the statements therein,
in the light of the circumstances under which they were made, not misleading; and any further documents so filed and incorporated by reference
in the Registration Statement, the Prospectus or the Pricing Disclosure Package, when such documents are filed with the Commission, will
conform in all material respects to the requirements of the Exchange Act and will not contain any untrue statement of a material fact
or omit to state a material fact necessary to make the statements therein, in the light of the circumstances under which they were made,
not misleading.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Financial
Statements.</I> The financial statements (including the related notes thereto) of the Company and its subsidiary included or incorporated
by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus comply in all material respects with the
applicable requirements of the Securities Act and the Exchange Act, as applicable, and present fairly the financial position of the Company
and its subsidiary as of the dates indicated and the results of their operations and the changes in their cash flows for the periods specified;
such financial statements have been prepared in conformity with generally accepted accounting principles in the United States applied
on a consistent basis throughout the periods covered thereby, except as may be otherwise specified therein or to the extent unaudited
interim financial statements exclude footnotes or may be condensed or summary statements, and any supporting schedules included or incorporated
by reference in the Registration Statement present fairly the information required to be stated therein; and the other financial information
included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus has been derived
from the accounting records of the Company and its subsidiary and presents fairly the information shown thereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<I>No
Material Adverse Change.</I> Since the date of the most recent financial statements o</FONT>f the Company included or incorporated by
reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus, (i)&nbsp;there has not been any change in
the capital stock (other than the issuance of shares of Common Stock upon the exercise of stock options and warrants, and the vesting
of restricted stock units and the grant of options and awards under existing equity incentive plans as described in the Registration Statement,
the Pricing Disclosure Package and the Prospectus), any debt of the Company or its subsidiary, or any dividend or distribution of any
kind declared, set aside for payment, paid or made by the Company on any class of capital stock, or any material adverse change, or any
development involving a prospective material adverse change, in or affecting the business, properties, management, financial position,
stockholders&rsquo; equity, results of operations or prospects of the Company and its subsidiary taken as a whole; (ii)&nbsp;neither the
Company nor its subsidiary has entered into any transaction or agreement (whether or not in the ordinary course of business) that is material
to the Company and its subsidiary taken as a whole or incurred any liability or obligation, direct or contingent, that is material to
the Company and its subsidiary taken as a whole; and (iii)&nbsp;neither the Company nor its subsidiary has sustained any loss or interference
with its business that is material to the Company and its subsidiary taken as a whole and that is either from fire, explosion, flood or
other calamity, whether or not covered by insurance, or from any labor disturbance or dispute or any action, order or decree of any court
or arbitrator or governmental or regulatory authority, except, in each case, as otherwise disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Organization
and Good Standing.</I> The Company and its subsidiary have been duly organized and are validly existing and in good standing under the
laws of their respective jurisdictions of organization, are duly qualified to do business and are in good standing in each jurisdiction
in which their respective ownership or lease of property or the conduct of their respective businesses requires such qualification, and
have all power and authority necessary to own or hold their respective properties and to conduct the businesses in which they are engaged,
except where the failure to be so qualified or in good standing or have such power or authority would not, individually or in the aggregate,
reasonably be expected to have a material adverse effect on the business, properties, management, financial position, stockholders&rsquo;
equity, results of operations or prospects of the Company and its subsidiary, taken as a whole or on the performance by the Company of
its obligations under this Agreement (a &ldquo;Material Adverse Effect&rdquo;). The subsidiary listed in Schedule 2 to this Agreement
is the only significant subsidiary of the Company within the meaning of Regulation S-X under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Capitalization.</I>
The Company has an authorized capitalization as set forth in the Registration Statement, the Pricing Disclosure Package and the Prospectus
under the heading &ldquo;Capitalization&rdquo; and &ldquo;Description of Capital Stock&rdquo;; all the outstanding shares of capital stock
of the Company have been duly and validly authorized and issued and are fully paid and non-assessable and are not subject to any pre-emptive
or similar rights; except as described in or expressly contemplated by the Pricing Disclosure Package and the Prospectus, there are no
outstanding rights (including, without limitation, pre-emptive rights), warrants or options to acquire, or instruments convertible into
or exchangeable for, any shares of capital stock or other equity interest in the Company or its subsidiary, or any contract, commitment,
agreement, understanding or arrangement of any kind relating to the issuance of any capital stock of the Company or its subsidiary, any
such convertible or exchangeable securities or any such rights, warrants or options; the capital stock of the Company conforms in all
material respects to the description thereof contained in the Registration Statement, the Pricing Disclosure Package and the Prospectus;
and all the outstanding shares of capital stock or other equity interests of the Company&rsquo;s subsidiary owned, directly or indirectly,
by the Company have been duly and validly authorized and issued, are fully paid and non-assessable and are owned directly or indirectly
by the Company, free and clear of any lien, charge, encumbrance, security interest, restriction on voting or transfer or any other claim
of any third party.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Stock
Options</I>. With respect to the stock options (the &ldquo;Stock Options&rdquo;) granted pursuant to the stock-based compensation plans
of the Company and its subsidiary (the &ldquo;Company Stock Plans&rdquo;), (i)&nbsp;each Stock Option intended to qualify as an &ldquo;incentive
stock option&rdquo; under Section&nbsp;422 of the Code so qualifies, (ii)&nbsp;each grant of a Stock Option was duly authorized no later
than the date on which the grant of such Stock Option was by its terms to be effective (the &ldquo;Grant Date&rdquo;) by all necessary
corporate action, including, as applicable, approval by the board of directors of the Company (or a duly constituted and authorized committee
thereof) and any required stockholder approval by the necessary number of votes or written consents, and the award agreement governing
such grant (if any) was duly executed and delivered by each party thereto, (iii)&nbsp;each such grant was made in accordance with the
terms of the Company Stock Plans, the Exchange Act and all other applicable laws and regulatory rules&nbsp;or requirements, including
the rules&nbsp;of the Nasdaq Global Market (the &ldquo;Nasdaq Market&rdquo;) and any other exchange on which Company securities are traded,
and (iv)&nbsp;each such grant was properly accounted for in accordance with GAAP in the financial statements (including the related notes)
of the Company and disclosed in the Company's filings with the Commission in accordance with the Exchange Act and all other applicable
laws in all material respects. The Company has not knowingly granted, and there is no and has been no policy or practice of the Company
of granting, Stock Options prior to, or otherwise coordinating the grant of Stock Options with, the release or other public announcement
of material information regarding the Company or its subsidiary or their results of operations or prospects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Due
Authorization.</I> The Company has all necessary and sufficient right, power and authority to execute and deliver this Agreement and to
perform its obligations hereunder; and all action required to be taken for the due and proper authorization, execution and delivery by
it of this Agreement and the consummation by it of the transactions contemplated hereby has been duly and validly taken.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Underwriting
Agreement. </I> This Agreement has been duly authorized, executed and delivered by the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>The
Shares. </I>The Shares to be issued and sold by the Company hereunder have been duly authorized and, when issued and delivered and paid
for as provided herein, will be duly and validly issued, will be fully paid and nonassessable and will conform to the descriptions thereof
in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the issuance of the Shares if not subject to any
preemptive or similar rights.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Descriptions
of the Underwriting Agreement.</I> This Agreement conforms in all material respects to the description thereof contained in the Registration
Statement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Violation or Default.</I> Neither the Company nor its subsidiary is (i)&nbsp;in violation of its charter or by-laws or similar organizational
documents; (ii)&nbsp;in default, and no event has occurred that, with notice or lapse of time or both, would constitute such a default,
in the due performance or observance of any term, covenant or condition contained in any indenture, mortgage, deed of trust, loan agreement
or other agreement or instrument to which the Company or its subsidiary is a party or by which the Company or its subsidiary is bound
or to which any of the property or assets of the Company or its subsidiary is subject; or (iii)&nbsp;in violation of any applicable law
or statute or any judgment, order, rule&nbsp;or regulation of any court or arbitrator or governmental or regulatory authority having jurisdiction
over the Company or its subsidiary, except, in the case of clauses (ii)&nbsp;and (iii)&nbsp;above, for any such default or violation that
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(p)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Conflicts. </I>The execution, delivery and performance by the Company of this Agreement, the issuance and sale of the Shares and the consummation
of the transactions contemplated by this Agreement or the Pricing Disclosure Package and the Prospectus will not (i)&nbsp;conflict with
or result in a breach or violation of any of the terms or provisions of, or constitute a default under, or result in the creation or imposition
of any lien, charge or encumbrance upon any property or assets of the Company or its subsidiary pursuant to, any indenture, mortgage,
deed of trust, loan agreement or other agreement or instrument to which the Company or its subsidiary is a party or by which the Company
or its subsidiary is bound or to which any of the property or assets of the Company or its subsidiary is subject, (ii)&nbsp;result in
any violation of the provisions of the charter or by-laws or similar organizational documents of the Company or its subsidiary or (iii)&nbsp;result
in the violation of any applicable law or statute or any judgment, order, rule&nbsp; or regulation of any court or arbitrator or governmental
or regulatory authority having jurisdiction over the Company or its subsidiary, except, in the case of clauses (i)&nbsp;and (iii)&nbsp;above,
for any such conflict, breach, violation or default that would not, individually or in the aggregate, have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(q)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Consents Required.</I> No consent, approval, authorization, order, license, registration or qualification of or with any court or arbitrator
or governmental or regulatory authority is required for the execution, delivery and performance by the Company of this Agreement, the
issuance and sale of the Shares and the consummation of the transactions contemplated by this Agreement, except for the registration of
the Shares under the Securities Act and such consents, approvals, authorizations, orders and registrations or qualifications as may be
required under applicable state securities laws in connection with the purchase and distribution of the Shares by the Underwriter. The
Company meets the requirements for use of Form&nbsp;S-3 under the Securities Act specified in the Financial Industry Regulatory Authority,&nbsp;Inc.
(&ldquo;FINRA&rdquo;) Rule&nbsp;5110(h)(1)(C)&nbsp;and is an experienced issuer (as defined in FINRA Rule&nbsp;5110(j)(6)).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(r)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Legal
Proceedings.</I> Except as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there are no legal,
governmental or regulatory investigations, actions, suits or proceedings pending to which the Company or its subsidiary is or may reasonably
be expected to be a party or to which any property of the Company or its subsidiary is or may be the subject that, individually or in
the aggregate, if determined adversely to the Company or its subsidiary, would reasonably be expected to have a Material Adverse Effect;
to the knowledge of the Company, no such investigations, actions, suits or proceedings are threatened or contemplated by any governmental
or regulatory authority or threatened by others; and (i)&nbsp;there are no current or pending legal, governmental or regulatory actions,
suits or proceedings that are required under the Securities Act to be described in the Registration Statement, the Pricing Disclosure
Package or the Prospectus that are not so described in the Registration Statement, the Pricing Disclosure Package and the Prospectus and
(ii)&nbsp;there are no statutes, regulations or contracts or other documents that are required under the Securities Act to be filed as
exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package or the Prospectus that
are not so filed as exhibits to the Registration Statement or described in the Registration Statement, the Pricing Disclosure Package
and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(s)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Independent
Accountants</I>. Grant Thornton LLP, who has certified certain financial statements of the Company and its subsidiary, is an independent
registered public accounting firm with respect to the Company and its subsidiary within the applicable rules&nbsp;and regulations adopted
by the Commission and the Public Company Accounting Oversight Board (United States) and as required by the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(t)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Title
to Real and Personal Property</I>. The Company and its subsidiary have good and marketable title in fee simple (in the case of real property)
to, or have valid and marketable rights to lease or otherwise use, all items of real and personal property and assets that are material
to the respective businesses of the Company and its subsidiary, in each case free and clear of all liens, encumbrances, claims and defects
and imperfections of title except those that (i)&nbsp;do not materially interfere with the use made and proposed to be made of such property
by the Company and its subsidiary or (ii)&nbsp;would not reasonably be expected, individually or in the aggregate, to have a Material
Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(u)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Title
to Intellectual Property</I>. Except to the extent as described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus, the Company or its subsidiary owns or has a license to use all Intellectual Property (as defined below) necessary for the
conduct of the Company&rsquo;s or its subsidiary&rsquo;s business as now conducted or as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus to be conducted, and there are no unreleased liens, security interests, or encumbrances
which have been filed against any of such Intellectual Property owned by the Company or its subsidiary.&nbsp; To the Company&rsquo;s knowledge,
the Intellectual Property owned by or licensed to the Company or its subsidiary is valid, enforceable and subsisting. Furthermore, (i)&nbsp;to
the knowledge of the Company, there is no infringement, misappropriation, dilution or violation by third parties of any such Intellectual
Property; (ii)&nbsp;there are no third parties who have rights to any Intellectual Property purported to be owned by the Company or its
subsidiary, except for customary reversionary rights of third-party licensors with respect to such Intellectual Property that are disclosed
in the Registration Statement, the Pricing Disclosure Package and the Prospectus as licensed to the Company or its subsidiary, there is
no pending or, to the knowledge of the Company, threatened, action, suit, proceeding or other claim challenging the Company&rsquo;s or
its subsidiary&rsquo;s rights in or to any Intellectual Property owned by or licensed to the Company or its subsidiary, and the Company
is unaware of any facts which would form a reasonable basis for any such claim; (iii)&nbsp;the Intellectual Property owned by the Company
or its subsidiary, and to the knowledge of the Company, the Intellectual Property licensed to the Company or its subsidiary, has not been
adjudged invalid or unenforceable, in whole or in part, and there is no pending or, to the knowledge of the Company, threatened action,
suit, proceeding or other claim challenging the validity, enforceability, scope, registration, ownership or use of any such Intellectual
Property, and the Company is not aware of any facts which would form a reasonable basis for any such claim; (iv)&nbsp;there is no pending
or, to the knowledge of the Company, threatened action, suit, proceeding or other claim that the conduct of the business of the Company
or its subsidiary in the manner described in the Registration Statement, the Pricing Disclosure Package and the Prospectus infringes,
misappropriates, dilutes or otherwise violates any Intellectual Property or other proprietary rights of others, neither the Company nor
its subsidiary has received any written notice of such claim and the Company is unaware of any other fact which would form a reasonable
basis for any such claim; (v)&nbsp;the Company and its subsidiary have complied with the material terms of each agreement pursuant to
which Intellectual Property has been licensed to the Company or its subsidiary, and all such agreements are in full force and effect and
the Company is unaware of any fact which would form a reasonable basis for any termination of any such agreement or any Intellectual Property
licensed thereunder; (vi)&nbsp;the product candidates described in the Registration Statement, the Pricing Disclosure Package and the
Prospectus as under development by the Company or its subsidiary fall within the scope of the claims of one or more patents or applications
relating to the product candidate or its intended use owned by, or exclusively licensed to, the Company or its subsidiary; (vii)&nbsp;the
Company has taken reasonable measures to maintain and safeguard the Intellectual Property owned by the Company or its subsidiary, including,
the execution of appropriate nondisclosure and confidentiality agreements; (viii)&nbsp;except as disclosed in the Registration Statement,
the Pricing Disclosure Package or the Prospectus, each of the Company and its subsidiary is the sole owner of the Intellectual Property
owned by it and has the valid and enforceable right to use such Intellectual Property without the obligation to obtain consent to sublicense
and without a duty of accounting to co-owner, as applicable; (ix)&nbsp;except as disclosed in the Registration Statement, the Pricing
Disclosure Package or the Prospectus, neither the Company nor its subsidiary is obligated to pay a material royalty, grant a license or
option, or provide other material consideration to any third party in connection with the Intellectual Property owned by or licensed to
the Company or its subsidiary; and (x)&nbsp;to the Company&rsquo;s knowledge, no employee, consultant or independent contractor of the
Company or its subsidiary is in or has ever been in violation of any term of any employment contract, patent disclosure agreement, invention
assignment agreement, non-competition agreement, non-solicitation agreement, nondisclosure agreement or any restrictive covenant to or
with a former employer or independent contractor where the basis of such violation relates to such employee&rsquo;s employment or independent
contractor&rsquo;s engagement with the Company or its subsidiary or actions undertaken by the employee or independent contractor while
employed or engaged with the Company or its subsidiary, except, in the case of clause (x), as would not reasonably be expected to have
a Material Adverse Effect.&nbsp; Furthermore, (A)&nbsp;all patents and patent applications within Intellectual Property disclosed in the
Registration Statement, the Pricing Disclosure Package and the Prospectus as being owned by the Company have, to the knowledge of the
Company, been duly and properly filed and maintained; (B)&nbsp;to the knowledge of the Company, there are no material defects in any of
such patents or patent applications; (C)&nbsp;to the knowledge of the Company, the parties prosecuting such applications have complied
with their duty of candor and disclosure to the United States Patent and Trademark Office (the &ldquo;USPTO&rdquo;), and all such requirements
in the relevant foreign patent authority having similar requirements as the case may be, in connection with such applications; and (D)&nbsp;the
Company is not aware of any facts required to be disclosed to the USPTO or relevant foreign patent authority that were not disclosed to
the USPTO or such relevant foreign patent authority and which would preclude the grant of a patent in connection with any such application
or could form the basis of a finding of invalidity with respect to any patents that have issued with respect to such applications.&nbsp;
 &ldquo;Intellectual Property&rdquo; shall mean all patents, patent applications, trade and service marks, trade and service mark registrations,
trade names, copyrights, licenses, inventions, trade secrets, domain names, technology, know-how and other intellectual property.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(v)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Trade
Secrets</I>. The Company and its subsidiary have taken reasonable and customary actions to protect their rights in and prevent the unauthorized
use and disclosure of material trade secrets and confidential business information (including confidential source code, ideas, research
and development information, know-how, formulas, compositions, technical data, designs, drawings, specifications, research records, records
of inventions, test information, financial, marketing and business data, customer and supplier lists and information, pricing and cost
information, business and marketing plans and proposals) owned by the Company and its subsidiary, including, the execution of appropriate
nondisclosure and confidentiality agreements, and, to the knowledge of the Company, there has been no unauthorized use or disclosure,
except, in each case, as would not reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(w)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>IT
Assets</I>. The Company&rsquo;s and its subsidiary&rsquo;s information technology assets and equipment, computers, systems, networks,
hardware, software, websites, applications, and databases (collectively, &ldquo;IT Assets&rdquo;) are adequate for, and operate and perform
in all material respects as required in connection with the operation of the business of the Company as currently conducted, free and
clear of all material bugs, errors, defects, Trojan horses, time bombs, malware and other corruptants. Except as would not, individually
or in the aggregate, be expected to have a Material Adverse Effect, there has been no security breach or incident, unauthorized access
or disclosure, or other compromise of or relating to the Company&rsquo;s or its subsidiary&rsquo;s IT Assets or data (including all personal,
personally identifiable, sensitive, confidential or regulated data, and all data and information of their respective customers, employees,
suppliers, vendors and any third party maintained, processed or stored by or on behalf of the Company and its subsidiary (collectively,
 &ldquo;Data&rdquo;)) used in connection with its business. The Company and its subsidiary have implemented commercially reasonable controls,
policies, procedures, and technological safeguards (A)&nbsp;designed to maintain and protect the integrity, continuous operation, redundancy
and security of their IT Assets and Data reasonably consistent with industry standards and practices, or as required by applicable regulatory
standards and (B)&nbsp;for taking commercially reasonable steps to confirm, audit, verify, or otherwise ensure the security of any third
party service providers. The Company and its subsidiary have implemented backup and disaster recovery technology consistent with industry
standards and practices.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(x)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Data
Privacy and Security Laws</I>. Except as would not reasonably be expected to have a Material Adverse Effect, the Company and its subsidiary
are, and at all prior times were, in compliance with all applicable state and federal data privacy and security laws and all judgements,
orders, rules&nbsp;and regulations of any court or arbitrator or governmental or regulatory authority, policies, applicable industry standards
such as the Payment Card industry Data Security Standards, and contractual obligations relating (i)&nbsp;to the privacy and security of
IT Assets and Data, including the collection, storage, transfer, processing and/or use of Data, and (ii)&nbsp;to the protection of such
IT Assets and Data from unauthorized use, access, misappropriation or modification (collectively, the &ldquo;Data Protection Requirements&rdquo;).
To ensure compliance with the Data Protection Requirements, the Company and its subsidiary have in place, comply with, and take appropriate
steps reasonably designed to ensure compliance in all material respects with their policies and procedures relating to data privacy and
security and the collection, storage, use, disclosure, handling, and analysis of Data (the &ldquo;Policies&rdquo;). The Company and its
subsidiary have at all times made all disclosures to users or customers required by applicable Data Protection Requirements, and none
of such disclosures made or contained in any Policy have, to the knowledge of the Company, been inaccurate or in violation of any applicable
laws and regulatory rules&nbsp;or requirements in any material respect. The Company further certifies that neither it nor its subsidiary:
(A)&nbsp;has received notice of any actual or potential liability under or relating to, or actual or potential violation of, any of the
Data Protection Requirements, and has no knowledge of any unauthorized use or disclosure of Data or any event or condition that would
reasonably be expected to result in any such notice; (B)&nbsp;is currently conducting or paying for, in whole or in part, any investigation,
remediation, or other corrective action pursuant to any Data Protection Requirement; or (C)&nbsp;is a party to any order, decree, or agreement
that imposes any obligation or liability under any Data Protection Requirement. The execution, delivery and performance of this Agreement
or any other agreement referred to in this Agreement will not result in a material breach of any Data Protection Requirements.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(y)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Complaints</I>. There is no complaint to or audit, proceeding, investigation (formal or informal) or claim currently pending against the
Company or its subsidiary or, to the knowledge of the Company, any of its customers (specific to the customer&rsquo;s use of the products
or services of the Company) by the Federal Trade Commission, the U.S. Department of Health and Human Services and any office contained
therein, or any similar authority in any jurisdiction other than the Unites States or any other governmental entity, or by any person
in respect of the collection, use or disclosure of Data by the Company or its subsidiary, and, to the knowledge of the Company, no such
complaint, audit, proceeding, investigation or claim is threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(z)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Compliance
with Health Care Laws</I>. The Company and its subsidiary are, and at all times have been, in compliance with all applicable Health Care
Laws in all material respects. For purposes of this Agreement, &ldquo;Health Care Laws&rdquo; means: (i)&nbsp;the Federal Food, Drug,
and Cosmetic Act (21 U.S.C. &sect; 301 et seq.), the Public Health Service Act (42 U.S.C. &sect; 201 et seq.), and the regulations promulgated
thereunder; (ii)&nbsp;all federal, state, local and foreign health care laws, including, without limitation, the federal Anti-Kickback
Statute (42 U.S.C. Section&nbsp;1320a-7b(b)), the Stark Law (42 U.S.C. Section&nbsp;1395nn), the Civil Monetary Penalties Law (42 U.S.C.
 &sect; 1320a-7a), the federal civil False Claims Act (31 U.S.C. Section&nbsp;3729 et seq.), the federal criminal False Claims Law (42
U.S.C. Section&nbsp;1320a-7b(a)), the U.S. Physician Payments Sunshine Act (42 U.S.C. Section&nbsp;1320a-7h), all criminal laws relating
to healthcare fraud and abuse, including but not limited to 18 U.S.C. Sections 286, 287, 1035, 1347, 1349 and the health care fraud criminal
provisions under HIPAA (42 U.S.C. Section&nbsp;1320d et seq.), the exclusion laws (42 U.S.C.&sect; 1320a-7), Medicare (Title XVIII of
the Social Security Act), Medicaid (Title XIX of the Social Security Act) and any other law or regulation government healthcare program,
each as amended, the regulations promulgated pursuant to such laws; (iii)&nbsp;HIPAA, as amended by the Health Information Technology
for Economic and Clinical Health Act (42 U.S.C. Section&nbsp;17921 et seq.); (iv)&nbsp;the 21st Century Cures Act (Pub. L. 114-255) and
the regulations promulgated thereunder; (v)&nbsp;licensure, quality, safety and accreditation requirements under applicable state, local
or foreign laws or regulatory bodies; and (vi)&nbsp;any other local, state, federal, national, supranational and foreign laws, regulations,
government memoranda, opinion letters or other issuances, which impose legal requirements on the manufacturing, development, testing,
labeling, marketing or distribution of medical device and durable medical equipment products, recordkeeping, quality, safety, privacy,
security, licensure, accreditation or any other aspect of producing medical device and durable medical equipment products. None of the
Company, its subsidiary, or any of their respective officers, directors, employees or, to the Company&rsquo;s knowledge, agents have engaged
in activities which are, as applicable, cause for material liability under a Health Care Law. Neither the Company nor its subsidiary has
received written notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from
any court or arbitrator or governmental or regulatory authority or third party alleging that any product, operation or activity is in
violation of any Health Care Laws nor, to the Company&rsquo;s knowledge, is any such claim, action, suit, proceeding, hearing, enforcement,
investigation, arbitration or other action threatened. The Company and its subsidiary have filed, maintained or submitted all material
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments as required by any Health
Care Laws, and all such reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were
complete and accurate on the date filed in all material respects (or were corrected or supplemented by a subsequent submission). Neither
the Company nor its subsidiary is a party to any corporate integrity agreements, deferred or non-prosecution agreements, monitoring agreements,
consent decrees, settlement orders, or similar agreements with or imposed by any governmental or regulatory authority. Additionally, none
of the Company, its subsidiary or any of their respective employees, officers, directors, or, to the Company&rsquo;s knowledge, agents
has been excluded, suspended or debarred from participation in any U.S. federal health care program or human clinical research or, to
the knowledge of the Company, is subject to a governmental inquiry, investigation, proceeding, or other similar action that would reasonably
be expected to result in debarment, suspension, or exclusion.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Billing
Compliance.</I> Except as would not reasonably be expected to have a Material Adverse Effect, the Company and its subsidiary meet all
applicable Health Care Program requirements and conditions of participation and are a party to valid participation or other agreements
required for payment by such Health Care Programs. Except as would not reasonably be expected to have a Material Adverse Effect, all billing,
claims, reporting and documentation practices of the Company and its subsidiary are in compliance and have been in compliance with all
Health Care Laws and legally enforceable Health Care Program requirements. Except as would not reasonably be expected to have a Material
Adverse Effect, or except as has been cured by the Company, during the last three years, neither the Company nor its subsidiary has billed,
received or retained any payment or reimbursement in violation of applicable Health Care Laws or legally enforceable Health Care Program
requirements. Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus (including unpaid amounts
set forth in accounts receivable), there are no pending recoupments, appeals, or challenges in excess of $500,000 with respect to any
billings or claims submissions. No audit, investigation, validation review or program integrity review related to the Company or its subsidiary
has been conducted by any Health Care Program or governmental authority within the past three years that would, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect. For purposes of this Agreement, &ldquo;<U>Health Care Program</U>&rdquo;
means any health care insurance and other similar programs under which the Company or its subsidiary are directly or indirectly receiving
payments, including any federal or state healthcare program, Medicare, Medicaid, the Tricare program, the Veterans Health Administration,
private or commercial insurance programs, third-party administrators, preferred provider organizations, managed care organizations, health
maintenance organizations, health plans, self-insured health plans, or any fiscal intermediary or contractor of any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Enforcement </I>Actions. The Company has not had any product or manufacturing site (whether Company-owned or that of a third-party manufacturer)
subject to a governmental authority (including United States Food and Drug Administration (the &ldquo;FDA&rdquo;)) shutdown or import
or export prohibition, nor received any FDA Form&nbsp;483 or other governmental authority and/or accreditation authority notice of inspectional
observations or deficiencies, &ldquo;warning letters,&rdquo; &ldquo;untitled letters,&rdquo; requests to make changes to the Company products,
processes or operations, or similar correspondence or notice from the FDA or other governmental authority alleging or asserting material
noncompliance with any applicable Health Care Laws. The Company has received no written notice that either the FDA or any other governmental
authority is considering such action.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(cc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Undisclosed Relationships</I>. No relationship, direct or indirect, exists between or among the Company or its subsidiary, on the one
hand, and the directors, officers, stockholders, customers or suppliers of the Company or its subsidiary, on the other, that is required
by the Securities Act to be described in the Registration Statement and the Prospectus and that is not so described in such documents
and in the Pricing Disclosure Package.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(dd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Investment
Company Act</I>. The Company is not and, after giving effect to the offering and sale of the Shares and the application of the proceeds
thereof as described in the Registration Statement, the Pricing Disclosure Package and the Prospectus, will not be required to register
as an &ldquo;investment company&rdquo; or an entity &ldquo;controlled&rdquo; by an &ldquo;investment company&rdquo; within the meaning
of the Investment Company Act of 1940, as amended, and the rules&nbsp;and regulations of the Commission thereunder (collectively, the
 &ldquo;Investment Company Act&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ee)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Taxes.</I>
Subject to any permitted extensions, the Company and its subsidiary have paid all federal, state, local and foreign taxes and filed all
tax returns required to be paid or filed through the date hereof; and except as otherwise disclosed in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, there is no tax deficiency that has been, or would reasonably be expected to be, asserted
against the Company or its subsidiary or any of their respective properties or assets, in each case except as would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ff)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Licenses
and Permits.</I> The Company and its subsidiary possess all licenses, certificates, clearances, approvals, exemptions, registrations,
permits, enrollments, supplier numbers, accreditations and other authorizations (&ldquo;Permits&rdquo;) issued by, and have made all declarations
and filings with, the appropriate federal, state, local or foreign governmental or regulatory authorities that are necessary for the ownership
or lease of their respective properties or the conduct of their respective businesses as described in the Registration Statement, the
Pricing Disclosure Package and the Prospectus, except where the failure to possess or make the same would not, individually or in the
aggregate, reasonably be expected to have a Material Adverse Effect; and except as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus, neither the Company nor its subsidiary has received written, or to the knowledge of the Company,
other notice of any revocation or modification of any such Permit or notice that any such Permit will not be renewed in the ordinary course.
To the Company&rsquo;s knowledge, no party granting any such Permits has taken any action to limit, suspend or revoke the same in any
material respect. The Company and its subsidiary have filed, obtained, maintained or submitted all reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments as required and that all such reports, documents, forms, notices,
applications, records, claims, submissions and supplements or amendments were materially complete and correct on the date filed (or were
corrected or supplemented by a subsequent submission) as required for maintenance of their Permits that are necessary for the conduct
of their respective businesses, in each case, except as would not, individually or in the aggregate, reasonably be expected to have a
Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(gg)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Labor Disputes.</I> No labor disturbance by or dispute with employees of the Company or its subsidiary exists or, to the knowledge of
the Company, is contemplated or threatened, and the Company is not aware of any existing or imminent labor disturbance by, or dispute
with, the employees of any of its or its subsidiary&rsquo;s principal suppliers, contractors or customers, except as would not reasonably
be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(hh)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Clinical
Trials.</I> The studies, tests and preclinical and clinical trials conducted by or on behalf of, or sponsored by, the Company or its subsidiary,
or in which the Company or its subsidiary have participated were and, if still pending, are being conducted in all material respects in
accordance with all applicable statutes, rules&nbsp;and regulations, including 21 C.F.R. Parts 50, 54, 56, 58, and 812 and any other Health
Care Laws; the Company has no knowledge of any studies, tests or trials not described in the Registration Statement, the Pricing Disclosure
Package and the Prospectus, the results of which reasonably call into question in any material respect the results of the studies, tests
and trials described in the Registration Statement, the Pricing Disclosure Package and the Prospectus; and the Company has not received
any written notices or correspondence from the FDA or any other foreign, federal, state or local governmental body exercising comparable
authority or any Institutional Review Board or comparable authority requiring or threatening the premature termination or suspension of
any studies, tests or preclinical or clinical trials conducted by or on behalf of, or sponsored by, the Company or its subsidiary or in
which the Company or its subsidiary has participated, and, to the Company&rsquo;s knowledge, there are no reasonable grounds for the same.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ii)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Manufacturing
Compliance</I>. The manufacture of the Company&rsquo;s and its subsidiary&rsquo;s products by or, to the knowledge of the Company, on
behalf of the Company or its subsidiary is being and has been conducted in compliance in all material respects with all applicable Health
Care Laws, including, without limitation, the FDA&rsquo;s current good manufacturing practice regulations at 21 C.F.R. Part&nbsp;820,
and, to the extent applicable, the respective counterparts thereof promulgated by governmental authorities in countries outside the United
States.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(jj)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Safety Notices</I>. (i)&nbsp;Except as disclosed in the Registration Statement, the Pricing Disclosure Package and the Prospectus, there
have been no recalls, field notifications, field corrections, market withdrawals or replacements, warnings, &ldquo;dear doctor&rdquo;
letters, investigator notices, safety alerts or other notice of action relating to an alleged lack of safety, efficacy, or regulatory
compliance of the Company&rsquo;s or its subsidiary&rsquo;s products (&ldquo;Safety Notices&rdquo;) during the last three years, except
as would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (ii)&nbsp;to the Company&rsquo;s
knowledge, there are no facts that would be reasonably likely to result in (x)&nbsp;a Safety Notice with respect to the Company&rsquo;s
or its subsidiary&rsquo;s products or services, (y)&nbsp;a material change in labeling of any the Company&rsquo;s or its subsidiary&rsquo;s
products or services, or (z)&nbsp;a termination or suspension of marketing or testing of any the Company&rsquo;s or its subsidiary&rsquo;s
products or services.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(kk)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Compliance
with and Liability under Environmental Laws.</I> (i)&nbsp;The Company and its subsidiary (a)&nbsp;are, and at all times during the last
five years have been, in compliance in all material respects with any and all applicable federal, state, local and foreign laws, rules,
regulations, requirements, decisions, judgments, decrees, orders and the common law relating to pollution or the protection of the environment,
natural resources or human health or safety in respect of Hazardous Materials (defined below), including those relating to the generation,
storage, treatment, use, handling, transportation, Release (as defined below) or threat of Release of Hazardous Materials (collectively,
 &ldquo;Environmental Laws&rdquo;), (b)&nbsp;have received and are in compliance with all permits, licenses, certificates or other authorizations
or approvals required of them under applicable Environmental Laws to conduct their respective businesses, (c)&nbsp;have not received any
written or, to the knowledge of the Company, other notice of any actual or potential liability under or relating to, or actual or potential
violation of, any Environmental Laws, including for the investigation or remediation of any Release or threat of Release of Hazardous
Materials, (d)&nbsp;are not conducting or paying for, in whole or in part, any investigation, remediation or other corrective action pursuant
to any Environmental Law at any location, and (e)&nbsp;are not a party to any order, decree or agreement that imposes any obligation or
liability under any Environmental Law, and (ii)&nbsp;there are no costs or liabilities associated with Environmental Laws of or relating
to the Company or its subsidiary, except in the case of each of (i)&nbsp;and (ii)&nbsp;above, for any such matter, as would not, individually
or in the aggregate, reasonably be expected to have a Material Adverse Effect; and (iii)&nbsp;except as described in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, (a)&nbsp;there are no proceedings that are pending, or that are known to
be contemplated, against the Company or its subsidiary under any Environmental Laws in which a governmental entity is also a party, other
than such proceedings regarding which it is reasonably believed no monetary sanctions of $100,000 or more will be imposed, (b)&nbsp;the
Company and its subsidiary are not aware of any facts or issues regarding compliance with Environmental Laws, or liabilities or other
obligations under Environmental Laws, including the Release or threat of Release of Hazardous Materials, that would reasonably be expected
to have a material effect on the capital expenditures, earnings or competitive position of the Company and its subsidiary, and (c)&nbsp;none
of the Company and its subsidiary anticipates material capital expenditures relating to any Environmental Laws. &ldquo;Hazardous Materials&rdquo;
means any material, chemical, substance, waste, pollutant, contaminant, or constituent thereof, including petroleum (including crude oil
or any fraction thereof) and petroleum products and asbestos and asbestos containing materials, which are regulated or for which liability
is imposed under any Environmental Law. &ldquo;Release&rdquo; means any spilling, leaking, seepage, pumping, pouring, emitting, emptying,
discharging, injecting, escaping, leaching, dumping, disposing, depositing, dispersing in, into or through the environment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ll)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Hazardous
Materials</I>. There has been no storage, generation, transportation, use, handling, treatment, or Release of Hazardous Materials by or
caused by the Company or its subsidiary (or, to the knowledge of the Company and its subsidiary, any other entity (including any predecessor)
for whose acts or omissions the Company or its subsidiary is or would reasonably be expected to be liable) at, on, under or from any property
or facility now or previously owned, operated or leased by the Company or its subsidiary, or at, on, under or from any other property
or facility, in violation of any Environmental Laws or in a manner or amount or to a location that would reasonably be expected to result
in any liability under any Environmental Law on the part of the Company or its subsidiary, except for any violation or liability which
would not, individually or in the aggregate, reasonably be expected to have a Material Adverse Effect.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(mm)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Compliance
with ERISA.</I> (i)&nbsp;Each employee benefit plan, within the meaning of Section&nbsp;3(3)&nbsp;of the Employee Retirement Income Security
Act of 1974, as amended (&ldquo;ERISA&rdquo;), for which the Company or any member of its &ldquo;Controlled Group&rdquo; (defined as any
organization which is a member of a controlled group of corporations within the meaning of Section&nbsp;414 of the Internal Revenue Code
of 1986, as amended (the &ldquo;Code&rdquo;)) would have any liability (each, a &ldquo;Plan&rdquo;) has been maintained in all material
respects in compliance with its terms and the requirements of any applicable statutes, orders, rules&nbsp;and regulations, including but
not limited to ERISA and the Code, except for noncompliance that would not reasonably be expected to result in material liability to the
Company or its subsidiary; (ii)&nbsp;no prohibited transaction, within the meaning of Section&nbsp;406 of ERISA or Section&nbsp;4975 of
the Code, has occurred with respect to any Plan excluding transactions effected pursuant to a statutory or administrative exemption that
would reasonably be expected to have a Material liability to the Company or its subsidiary; (iii)&nbsp;for each Plan that is subject to
the funding rules&nbsp;of Section&nbsp;412 of the Code or Section&nbsp;302 of ERISA, the minimum funding standard of Section&nbsp;412
of the Code or Section&nbsp;302 of ERISA, as applicable, has been satisfied (without taking into account any waiver thereof or extension
of any amortization period) and is reasonably expected to be satisfied in the future (without taking into account any waiver thereof or
extension of any amortization period); (iv)&nbsp;the fair market value of the assets of each Plan exceeds the present value of all benefits
accrued under such Plan (determined based on those assumptions used to fund such Plan); (v)&nbsp;no &ldquo;reportable event&rdquo; (within
the meaning of Section&nbsp;4043(c)&nbsp;of ERISA) has occurred or is reasonably expected to occur that either has resulted, or would
reasonably be expected to result, in material liability to the Company or its subsidiary; (vi)&nbsp;neither the Company nor any member
of the Controlled Group has incurred, nor reasonably expects to incur, any liability under Title IV of ERISA (other than contributions
to the Plan or premiums to the PBGC, in the ordinary course and without default) in respect of a Plan (including a &ldquo;multiemployer
plan&rdquo;, within the meaning of Section&nbsp;4001(a)(3)&nbsp;of ERISA); and (vii)&nbsp;to the Company&rsquo;s knowledge, there is no
pending audit or investigation by the Internal Revenue Service, the U.S. Department of Labor, the Pension Benefit Guaranty Corporation
or any other governmental agency or any foreign regulatory agency with respect to any Plan that would reasonably be expected to result
in material liability to the Company or its subsidiary. None of the following events has occurred or is reasonably likely to occur: (x)&nbsp;a
material increase in the aggregate amount of contributions required to be made to all Plans by the Company or its subsidiary in the current
fiscal year of the Company and its subsidiary compared to the amount of such contributions made in the Company and its subsidiary&rsquo;s
most recently completed fiscal year; or (y)&nbsp;a material increase in the Company and its subsidiary&rsquo;s &ldquo;accumulated post-retirement
benefit obligations&rdquo; (within the meaning of Statement of Financial Accounting Standards 106) compared to the amount of such obligations
in the Company and its subsidiary&rsquo;s most recently completed fiscal year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(nn)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Disclosure
Controls</I>. The Company and its subsidiary maintain an effective system of &ldquo;disclosure controls and procedures&rdquo; (as defined
in Rule&nbsp;13a-15(e)&nbsp;of the Exchange Act) that complies with the requirements of the Exchange Act and that has been designed to
ensure that information required to be disclosed by the Company in reports that it files or submits under the Exchange Act is recorded,
processed, summarized and reported within the time periods specified in the Commission&rsquo;s rules&nbsp;and forms, including controls
and procedures designed to ensure that such information is accumulated and communicated to the Company&rsquo;s management as appropriate
to allow timely decisions regarding required disclosure. The Company and its subsidiary have carried out evaluations of the effectiveness
of their disclosure controls and procedures as required by Rule&nbsp;13a-15 of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(oo)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Accounting
Controls.</I> The Company and its subsidiary maintain systems of &ldquo;internal control over financial reporting&rdquo; (as defined in
Rule&nbsp;13a-15(f)&nbsp;of the Exchange Act) that comply with the requirements of the Exchange Act and have been designed by, or under
the supervision of, their respective principal executive and principal financial officers, or persons performing similar functions, to
provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external
purposes in accordance with generally accepted accounting principles, including, but not limited to, internal accounting controls sufficient
to provide reasonable assurance that (i)&nbsp;transactions are executed in accordance with management&rsquo;s general or specific authorizations;
(ii)&nbsp;transactions are recorded as necessary to permit preparation of financial statements in conformity with generally accepted accounting
principles and to maintain asset accountability; (iii)&nbsp;access to assets is permitted only in accordance with management&rsquo;s general
or specific authorization; (iv)&nbsp;the recorded accountability for assets is compared with the existing assets at reasonable intervals
and appropriate action is taken with respect to any differences and (v)&nbsp;interactive data in eXtensible Business Reporting Language
included or incorporated by reference in the Registration Statement fairly presents the information called for in all material respects
and is prepared in accordance with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto. Except as disclosed in the Registration
Statement, the Pricing Disclosure Package and the Prospectus, there are no material weaknesses in the Company&rsquo;s internal controls.
The Company&rsquo;s auditors and the Audit Committee of the Board of Directors of the Company have been advised of: (i)&nbsp;all significant
deficiencies and material weaknesses in the design or operation of internal controls over financial reporting which have adversely affected
or are reasonably likely to adversely affect the Company&rsquo;s ability to record, process, summarize and report financial information;
and (ii)&nbsp;any fraud, whether or not material, that involves management or other employees who have a significant role in the Company&rsquo;s
internal controls over financial reporting.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(pp)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>eXtensible
Business Reporting Language.</I> The interactive data in eXtensible Business Reporting Language included or incorporated by reference
in the Registration Statement fairly presents the information called for in all material respects and has been prepared in accordance
with the Commission&rsquo;s rules&nbsp;and guidelines applicable thereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(qq)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Insurance.
</I>The Company and its subsidiary have insurance covering their respective properties, operations, personnel and businesses, including
business interruption insurance, which insurance is in amounts and insures against such losses and risks which the Company reasonably
believes are adequate to protect the Company and its subsidiary and their respective businesses; and neither the Company nor its subsidiary
has (i)&nbsp;received notice from any insurer or agent of such insurer that capital improvements or other expenditures are required or
necessary to be made in order to continue such insurance or (ii)&nbsp;any reason to believe that it will not be able to renew its existing
insurance coverage as and when such coverage expires or to obtain similar coverage at reasonable cost from similar insurers as may be
necessary to continue its business in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(rr)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Unlawful Payments.</I> Neither the Company nor its subsidiary nor any director, officer or employee of the Company or its subsidiary nor,
to the knowledge of the Company, any agent, affiliate or other person while acting for or on behalf of the Company its subsidiary has
(i)&nbsp;used any corporate funds for any unlawful contribution, gift, entertainment or other unlawful expense relating to political activity;
(ii)&nbsp;made or taken an act in furtherance of an offer, promise or authorization of any direct or indirect unlawful payment or benefit
to any foreign or domestic government official or employee, including of any government-owned or controlled entity or of a public international
organization, or any person acting in an official capacity for or on behalf of any of the foregoing, or any political party or party official
or candidate for political office; (iii)&nbsp;violated or is in violation of any provision of the Foreign Corrupt Practices Act of 1977,
as amended, or any applicable law or regulation implementing the OECD Convention on Combating Bribery of Foreign Public Officials in International
Business Transactions, or committed an offence under the Bribery Act 2010 of the United Kingdom or any other applicable anti-bribery or
anti-corruption law; or (iv)&nbsp;made, offered, agreed, requested or taken an act in furtherance of any unlawful bribe or other unlawful
benefit, including, without limitation, any rebate, payoff, influence payment, kickback or other unlawful or improper payment or benefit.
The Company and its subsidiary have instituted, maintain and enforce policies and procedures designed to promote and ensure compliance
with all applicable anti-bribery and anti-corruption laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ss)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Compliance
with Anti-Money Laundering Laws</I>. The operations of the Company and its subsidiary are and have been conducted at all times in compliance
with applicable financial recordkeeping and reporting requirements, including those of the Currency and Foreign Transactions Reporting
Act of 1970, as amended, the applicable money laundering statutes of all jurisdictions where the Company or its subsidiary conducts business,
the rules&nbsp;and regulations thereunder and any related or similar rules, regulations or guidelines issued, administered or enforced
by any governmental agency (collectively, the &ldquo;Anti-Money Laundering Laws&rdquo;) and no action, suit or proceeding by or before
any court or governmental agency, authority or body or any arbitrator involving the Company or its subsidiary with respect to the Anti-Money
Laundering Laws is pending or, to the knowledge of the Company, threatened.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(tt)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Conflicts with Sanctions Laws. </I>Neither the Company nor its subsidiary, directors, officers, or employees, nor, to the knowledge of
the Company, any agent, affiliate or other person authorized to act on behalf of the Company or its subsidiary is currently the subject
or the target of any sanctions administered or enforced by the U.S. government, (including, without limitation, the Office of Foreign
Assets Control of the U.S. Department of the Treasury or the U.S. Department of State and including, without limitation, the designation
as a &ldquo;specially designated national&rdquo; or &ldquo;blocked person&rdquo;), the United Nations Security Council, the European Union,
Her Majesty&rsquo;s Treasury or other relevant sanctions authority (collectively, &ldquo;Sanctions&rdquo;), nor is the Company, its subsidiary
located, organized or resident in a country or territory that is the subject or target of Sanctions, including, without limitation, Cuba,&nbsp;Iran,
North Korea, Syria, the Crimean region of Ukraine, the so-called Donetsk People&rsquo;s Republic and the so-called Luhansk People&rsquo;s
Republic (each, a &ldquo;Sanctioned Country&rdquo;); and the Company will not directly or indirectly use the proceeds of the offering
of the Shares hereunder, or lend, contribute or otherwise make available such proceeds to its subsidiary, joint venture partner or other
person or entity (i)&nbsp;to fund or facilitate any activities of or business with any person that, at the time of such funding or facilitation,
is the subject or target of Sanctions, (ii)&nbsp;to fund or facilitate any activities of or business in any Sanctioned Country or (iii)&nbsp;in
any other manner that will result in a violation by any person (including any person participating in the transaction, whether as underwriter,
advisor, investor or otherwise) of Sanctions. For the past five years, the Company and its subsidiary have not knowingly engaged in and
are not now knowingly engaged in any dealings or transactions with any person that at the time of the dealing or transaction is or was
the subject or the target of Sanctions or with any Sanctioned Country.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(uu)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Restrictions on Subsidiaries</I>. The Company&rsquo;s subsidiary is not currently prohibited, directly or indirectly, under any agreement
or other instrument to which it is a party or is subject, from paying any dividends to the Company, from making any other distribution
on such subsidiary&rsquo;s capital stock, from repaying to the Company any loans or advances to such subsidiary from the Company or from
transferring any of such subsidiary&rsquo;s properties or assets to the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(vv)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Broker&rsquo;s Fees.</I> Neither the Company nor its subsidiary is a party to any contract, agreement or understanding with any person
(other than this Agreement) that would give rise to a valid claim against the Company or its subsidiary or the Underwriter for a brokerage
commission, finder&rsquo;s fee or like payment in connection with the offering and sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ww)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Registration Rights</I>. No person has the right to require the Company or its subsidiary to register any securities for sale under the
Securities Act by reason of the filing of the Registration Statement with the Commission or the issuance and sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(xx)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Stabilization.</I> The Company has not taken, directly or indirectly, any action designed to or that would reasonably be expected to cause
or result in any stabilization or manipulation of the price of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(yy)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Margin
Rules</I>. The application of the proceeds received by the Company from the issuance, sale and delivery of the Shares as described in
the Registration Statement, the Pricing Disclosure Package and the Prospectus will not violate Regulation T, U or X of the Board of Governors
of the Federal Reserve System or any other regulation of such Board of Governors.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(zz)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Forward-Looking
Statements.</I> No forward-looking statement (within the meaning of Section&nbsp;27A of the Securities Act and Section&nbsp;21E of the
Exchange Act) contained in the Registration Statement, the Pricing Disclosure Package or the Prospectus has been made or reaffirmed without
a reasonable basis or has been disclosed other than in good faith.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(aaa)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Statistical
and Market Data.</I> Nothing has come to the attention of the Company that has caused the Company to believe that the statistical and
market-related data included or incorporated by reference in the Registration Statement, the Pricing Disclosure Package and the Prospectus
is not based on or derived from sources that are reliable and accurate in all material respects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(bbb)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Sarbanes-Oxley
Act</I>. There is and has been no failure on the part of the Company or any of the Company&rsquo;s directors or officers, in their capacities
as such, to comply with any provision of the Sarbanes-Oxley Act of 2002, as amended and the rules&nbsp;and regulations promulgated in
connection therewith, including Section&nbsp;402 related to loans and Sections 302 and 906 related to certifications.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ccc)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Status
under the Securities Act</I>. At the time of filing the Registration Statement and any post-effective amendment thereto, at the earliest
time thereafter that the Company or any offering participant made a bona fide offer (within the meaning of Rule&nbsp;164(h)(2)&nbsp;under
the Securities Act) of the Shares and at the date hereof, the Company was not and is not an &ldquo;ineligible issuer,&rdquo; as defined
in Rule&nbsp;405 under the Securities Act. The Company has paid the registration fee for this offering pursuant to Rule&nbsp;456(b)(1)&nbsp;under
the Securities Act or will pay such fee within the time period required by such rule&nbsp;(without giving effect to the proviso therein)
and in any event prior to the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(ddd)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Ratings</I>. There are (and prior to the Closing Date, will be) no debt securities or preferred stock issued or guaranteed by the Company
or its subsidiary that are rated by a &ldquo;nationally recognized statistical rating organization&rdquo;, as such term is defined in
Section&nbsp;3(a)(62) of the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Further
Agreements of the Company</U>. The Company covenants and agrees with the Underwriter that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Required
Filings. The Company will file the final Prospectus with the Commission within the time periods specified by Rule&nbsp;424(b)&nbsp;and
Rule&nbsp;430A, 430B or 430C under the Securities Act, will file any Issuer Free Writing Prospectus to the extent required by Rule&nbsp;433
under the Securities Act; will file promptly all reports and any definitive proxy or information statements required to be filed by the
Company with the Commission pursuant to Section&nbsp;13(a), 13(c), 14 or 15(d)&nbsp;of the Exchange Act subsequent to the date of the
Prospectus and for so long as the delivery of a prospectus is required in connection with the offering or sale of the Shares; and will
furnish copies of the Prospectus and each Issuer Free Writing Prospectus (to the extent not previously delivered) to the Underwriter in
New York City prior to 10:00 A.M., New York City time, on the business day next succeeding the date of this Agreement in such quantities
as the Underwriter may reasonably request. The Company will pay the registration fee for this offering within the time period required
by Rule&nbsp;456(b)(1)&nbsp;under the Securities Act (without giving effect to the proviso therein) and in any event prior to the Closing
Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Delivery
of Copies.</I> Upon the reasonable request of the Underwriter, the Company will deliver, without charge, (i)&nbsp;to the Underwriter,
two signed copies of the Registration Statement as originally filed and each amendment thereto, in each case including all exhibits and
consents filed therewith and documents incorporated by reference therein; and (ii)&nbsp;to the Underwriter (A)&nbsp;a conformed copy of
the Registration Statement as originally filed and each amendment thereto (without exhibits) and (B)&nbsp;during the Prospectus Delivery
Period (as defined below), as many copies of the Prospectus (including all amendments and supplements thereto and documents incorporated
by reference therein and each Issuer Free Writing Prospectus) as the Underwriter may reasonably request. As used herein, the term &ldquo;Prospectus
Delivery Period&rdquo; means such period of time after the first date of the public offering of the Shares as in the opinion of counsel
for the Underwriter a prospectus relating to the Shares is required by law to be delivered (or would be required to be delivered but for
Rule&nbsp;172 under the Securities Act) in connection with sales of the Shares by the Underwriter or dealer.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Amendments
or Supplements,&nbsp;Issuer Free Writing Prospectuses.</I> Before preparing, using, authorizing, approving, referring to or filing any
Issuer Free Writing Prospectus, and before filing any amendment or supplement to the Registration Statement or Prospectus, for so long
as the delivery of a prospectus is required in connection with offering or sale of the Shares, the Company will furnish to the Underwriter
and counsel for the Underwriter a copy of the proposed Issuer Free Writing Prospectus, amendment or supplement for review and will not
prepare, use, authorize, approve, refer to or file any such Issuer Free Writing Prospectus or file any such proposed amendment or supplement
to which the Underwriter reasonably objects.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Notice
to the Underwriter.</I> The Company will advise the Underwriter promptly, and confirm such advice in writing: (i)&nbsp;when any amendment
to the Registration Statement has been filed or becomes effective, for so long as the delivery of a prospectus is required in connection
with offering or sale of the Shares; (ii)&nbsp;when any supplement to the Prospectus, or any Issuer Free Writing Prospectus or any amendment
to the Prospectus has been filed or distributed; (iii)&nbsp;of any request by the Commission for any amendment to the Registration Statement
or any amendment or supplement to the Prospectus or the receipt of any comments from the Commission relating to the Registration Statement
or any other request by the Commission for any additional information; (iv)&nbsp;of the issuance by the Commission of any order suspending
the effectiveness of the Registration Statement or preventing or suspending the use of any Preliminary Prospectus, any of the Pricing
Disclosure Package, or the Prospectus or the initiation or threatening of any proceeding for that purpose or pursuant to Section&nbsp;8A
of the Securities Act; (v)&nbsp;of the occurrence of any event or development within the Prospectus Delivery Period as a result of which
the Prospectus, the Pricing Disclosure Package, or any Issuer Free Writing Prospectus as then amended or supplemented would include any
untrue statement of a material fact or omit to state a material fact necessary in order to make the statements therein, in the light of
the circumstances existing when the Prospectus, the Pricing Disclosure Package, or any such Issuer Free Writing Prospectus is delivered
to a purchaser, not misleading; (vi)&nbsp;of the receipt by the Company of any notice of objection of the Commission to the use of the
Registration Statement or any post-effective amendment thereto pursuant to Rule&nbsp;401(g)(2)&nbsp;under the Securities Act; and (vii)&nbsp;of
the receipt by the Company of any notice with respect to any suspension of the qualification of the Shares for offer and sale in any jurisdiction
or the initiation or threatening of any proceeding for such purpose; and the Company will use its commercially reasonable efforts to prevent
the issuance of any such order suspending the effectiveness of the Registration Statement, preventing or suspending the use of any Preliminary
Prospectus, any of the Pricing Disclosure Package or the Prospectus or suspending any such qualification of the Shares and, if any such
order is issued, will obtain as soon as possible the withdrawal thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<!-- Field: Split-Segment; Name: split 0002 -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Ongoing
Compliance.</I> (i)&nbsp;If during the Prospectus Delivery Period (1)&nbsp;any event or development shall occur or condition shall exist
as a result of which the Prospectus as then amended or supplemented would include any untrue statement of a material fact or omit to state
any material fact necessary in order to make the statements therein, in the light of the circumstances existing when the Prospectus is
delivered to a purchaser, not misleading or (2)&nbsp;it is necessary to amend or supplement the Prospectus to comply with law, the Company
will immediately notify the Underwriter thereof and forthwith prepare and, subject to paragraph (c)&nbsp;above, file with the Commission
and furnish to the Underwriter and to such dealers as the Underwriter may designate such amendments or supplements to the Prospectus (or
any document to be filed with the Commission and incorporated by reference therein) as may be necessary so that the statements in the
Prospectus as so amended or supplemented (or any document to be filed with the Commission and incorporated by reference therein) will
not, in the light of the circumstances existing when the Prospectus is delivered to a purchaser, be misleading or so that the Prospectus
will comply with law and (ii)&nbsp;if at any time prior to the Closing Date (1)&nbsp;any event or development shall occur or condition
shall exist as a result of which the Pricing Disclosure Package as then amended or supplemented would include any untrue statement of
a material fact or omit to state any material fact or necessary in order to make the statements therein, in the light of the circumstances
existing when the Pricing Disclosure Package is delivered to a purchaser, not misleading or (2)&nbsp;it is necessary to amend or supplement
the Pricing Disclosure Package to comply with law, the Company will immediately notify the Underwriter thereof and forthwith prepare and,
subject to paragraph (c)&nbsp;above, file with the Commission (to the extent required) and furnish to the Underwriter and to such dealers
as the Underwriter may designate such amendments or supplements to the Pricing Disclosure Package (or any document to be filed with the
Commission and incorporated by reference therein) as may be necessary so that the statements in the Pricing Disclosure Package as so amended
or supplemented will not, in the light of the circumstances existing when the Pricing Disclosure Package is delivered to a purchaser,
be misleading or so that the Pricing Disclosure Package will comply with law.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Blue
Sky Compliance.</I> The Company will qualify the Shares for offer and sale under the securities or Blue Sky laws of such jurisdictions
as the Underwriter shall reasonably request and will continue such qualifications in effect so long as required for distribution of the
Shares; <U>provided</U> that the Company shall not be required to (i)&nbsp;qualify as a foreign corporation or other entity or as a dealer
in securities in any such jurisdiction where it would not otherwise be required to so qualify, (ii)&nbsp;file any general consent to service
of process in any such jurisdiction or (iii)&nbsp;subject itself to taxation in any such jurisdiction if it is not otherwise so subject.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Earnings
Statement. </I>The Company will make generally available to its security holders and the Underwriter as soon as practicable an earnings
statement that satisfies the provisions of Section&nbsp;11(a)&nbsp;of the Securities Act and Rule&nbsp;158 of the Commission promulgated
thereunder covering a period of at least twelve months beginning with the first fiscal quarter of the Company occurring after the &ldquo;effective
date&rdquo; (as defined in Rule&nbsp;158) of the Registration Statement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Clear
Market.</I> For a period of 90 days after the date of the Prospectus, the Company will not (i)&nbsp;offer, pledge, sell, contract to sell,
sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, or otherwise
transfer or dispose of, directly or indirectly, or file with the Commission a registration statement under the Securities Act relating
to, any shares of Stock or any securities convertible into or exercisable or exchangeable for Stock, or publicly disclose the intention
to make any offer, sale, pledge, disposition or filing, or (ii)&nbsp;enter into any swap or other agreement that transfers, in whole or
in part, any of the economic consequences of ownership of the Stock or any such other securities, whether any such transaction described
in clause (i)&nbsp;or (ii)&nbsp;above is to be settled by delivery of Stock or such other securities, in cash or otherwise, without the
prior written consent of the Underwriter, other than (i)&nbsp;the Shares to be sold hereunder, (ii)&nbsp;grants of options, restricted
stock units, performance stock units and other awards to purchase or receive shares of Stock under our 2016 Equity Incentive Plan (the
 &ldquo;2016 Plan&rdquo;), and (iii)&nbsp;any shares of Stock of the Company issued upon the exercise of options or the settlement of other
awards granted under the 2016 Plan or the issuance of Stock pursuant to a purchase under our Employee Stock Purchase Plan.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Use
of Proceeds.</I> The Company will apply the net proceeds from the sale of the Shares as described in the Registration Statement, the Pricing
Disclosure Package and the Prospectus under the heading &ldquo;Use of Proceeds&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Stabilization.</I> The Company will not take, directly or indirectly, any action designed to or that would reasonably be expected to cause
or result in any stabilization or manipulation of the price of the Stock.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Exchange
Listing. </I>The Company will use its commercially reasonable efforts to list for quotation the Shares on the Nasdaq Market.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Reports.</I>
For a period of two years from the date of this Agreement, so long as the Shares are outstanding, the Company will furnish to the Underwriter,
as soon as commercially reasonable after the date they are available, copies of all reports or other communications (financial or other)
furnished to holders of the Shares, and copies of any reports and financial statements furnished to or filed with the Commission or any
national securities exchange or automatic quotation system; <U>provided</U> the Company will be deemed to have furnished such reports
and financial statements to the Underwriter to the extent they are filed on the Commission&rsquo;s Electronic Data Gathering, Analysis,
and Retrieval system.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Record
Retention</I>. The Company will, pursuant to reasonable procedures developed in good faith, retain copies of each Issuer Free Writing
Prospectus that is not filed with the Commission in accordance with Rule&nbsp;433 under the Securities Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Agreements of the Underwriter</U>.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The Underwriter hereby represents and agrees that:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>It
has not used, authorized use of, referred to or participated in the planning for use of, and will not use, authorize use of, refer to
or participate in the planning for use of, any &ldquo;free writing prospectus&rdquo;, as defined in Rule&nbsp;405 under the Securities
Act (which term includes use of any written information furnished to the Commission by the Company and not incorporated by reference into
the Registration Statement and any press release issued by the Company) other than (i)&nbsp;a free writing prospectus that contains no
 &ldquo;issuer information&rdquo; (as defined in Rule&nbsp;433(h)(2)&nbsp;under the Securities Act) that was not included (including through
incorporation by reference) in the Preliminary Prospectus or a previously filed Issuer Free Writing Prospectus, (ii)&nbsp;any Issuer Free
Writing Prospectus listed on Annex A or prepared pursuant to Section&nbsp;3(c)&nbsp;or Section&nbsp;4(c)&nbsp;above (including any electronic
road show), or (iii)&nbsp;any free writing prospectus prepared by the Underwriter and approved by the Company in advance in writing (each
such free writing prospectus referred to in clauses (i)&nbsp;or (iii), an &ldquo;Underwriter Free Writing Prospectus&rdquo;).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>It
has not and will not, without the prior written consent of the Company, use any free writing prospectus that contains the final pricing
terms of the Shares unless such terms have previously been included in a free writing prospectus filed with the Commission; <I>provided</I>
that the Underwriter may use a term sheet substantially in the form of Annex B hereto without the consent of the Company; <I>provided
further</I> that the Underwriter using such term sheet shall notify the Company, and provide a copy of such term sheet to the Company,
prior to, or substantially concurrently with, the first use of such term sheet.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>It
is not subject to any pending proceeding under Section&nbsp;8A of the Securities Act with respect to the offering (and will promptly notify
the Company if any such proceeding against it is initiated during the Prospectus Delivery Period).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">6.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Conditions
of Underwriter&rsquo;s Obligations.</U> The obligation of the Underwriter to purchase the Underwritten Shares on the Closing Date or the
Option Shares on the Additional Closing Date, as the case may be, as provided herein is subject to the performance by the Company of its
covenants and other obligations hereunder and to the following additional conditions:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Registration
Compliance; No Stop Order.</I> No order suspending the effectiveness of the Registration Statement shall be in effect, and no proceeding
for such purpose, pursuant to Rule&nbsp;401(g)(2)&nbsp;or pursuant to Section&nbsp;8A under the Securities Act shall be pending before
or, to the knowledge of the Company, threatened by the Commission; the Prospectus and each Issuer Free Writing Prospectus shall have been
timely filed with the Commission under the Securities Act (in the case of an Issuer Free Writing Prospectus, to the extent required by
Rule&nbsp;433 under the Securities Act) and in accordance with Section&nbsp;4(a)&nbsp;hereof; and all requests by the Commission for additional
information shall have been complied with to the reasonable satisfaction of the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Representations
and Warranties.</I> The representations and warranties of the Company contained herein shall be true and correct on the date hereof and
on and as of the Closing Date or the Additional Closing Date, as the case may be; and the statements of the Company and its officers made
in any certificates delivered pursuant to this Agreement shall be true and correct on and as of the Closing Date or the Additional Closing
Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Downgrade.</I> Subsequent to the earlier of (A)&nbsp;the Applicable Time and (B)&nbsp;the execution and delivery of this Agreement, if
there are any debt securities or preferred stock of, or guaranteed by, the Company or its subsidiary that are rated by a &ldquo;nationally
recognized statistical rating organization,&rdquo; as such term is defined under Section&nbsp;3(a)(62) under the Exchange Act, (i)&nbsp;no
downgrading shall have occurred in the rating accorded any such debt securities or preferred stock and (ii)&nbsp;no such organization
shall have publicly announced that it has under surveillance or review, or has changed its outlook with respect to, its rating of any
such debt securities or preferred stock (other than an announcement with positive implications of a possible upgrading).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Material Adverse Change.</I> There has not been, since the time of execution of this Agreement or since the respective dates as of which
information is given in the Registration Statement, the Pricing Disclosure Package or the Prospectus, any material adverse change in the
business, properties, management, financial position, stockholders&rsquo; equity, results of operations or prospects of the Company and
its subsidiary taken as a whole, and the effect of which in the judgment of the Underwriter makes it impracticable or inadvisable to proceed
with the offering, sale or delivery of the Shares on the Closing Date or the Additional Closing Date, as the case may be, on the terms
and in the manner contemplated by this Agreement, the Pricing Disclosure Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 3 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Officer&rsquo;s
Certificate.</I> The Underwriter shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be,
a certificate of the chief financial officer or chief accounting officer of the Company and one additional senior executive officer of
the Company who is satisfactory to the Underwriter (i)&nbsp;confirming that such officers have carefully reviewed the Registration Statement,
the Pricing Disclosure Package and the Prospectus and, to the knowledge of such officers, the representations set forth in Sections 3(b)&nbsp;and
3(d)&nbsp;hereof are true and correct, (ii)&nbsp;confirming that the other representations and warranties of the Company in this Agreement
are true and correct and that the Company has complied with all agreements and satisfied all conditions on its part to be performed or
satisfied hereunder at or prior to the Closing Date or the Additional Closing Date, as the case may be, and (iii)&nbsp;to the effect set
forth in paragraphs (a), (c)&nbsp;and (d)&nbsp;above.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Comfort
Letters.</I> (i)&nbsp;On the date of this Agreement and on the Closing Date or the Additional Closing Date, as the case may be, Grant
Thornton LLP shall have furnished to the Underwriter, at the request of the Company, letters, dated the respective dates of delivery thereof
and addressed to the Underwriter, in form and substance reasonably satisfactory to the Underwriter, containing statements and information
of the type customarily included in accountants&rsquo; &ldquo;comfort letters&rdquo; to underwriters with respect to the financial statements
and certain financial information contained or incorporated by reference in the Registration Statement, the Pricing Disclosure Package
and the Prospectus; provided, that the letter delivered on the Closing Date or the Additional Closing Date, as the case may be, shall
use a &ldquo;cut-off&rdquo; date no more than three business days prior to such Closing Date or such Additional Closing Date, as the case
may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">(ii)&nbsp;[Reserved].</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Opinion
and 10b-5 Statement of Counsel for the Company.</I> Faegre Drinker Biddle&nbsp;&amp; Reath LLP, counsel for the Company, shall have furnished
to the Underwriter, at the request of the Company, their written opinion and 10b-5 statement, which shall be included in its written opinion,
dated the Closing Date or the Additional Closing Date, as the case may be, and addressed to the Underwriter, in form and substance reasonably
satisfactory to the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Opinion
of Intellectual Property Counsel for the Company</I>. Mueting, Raasch&nbsp;&amp; Gebhardt, P.A., intellectual property counsel for the
Company, shall have furnished to the Underwriter, at the request of the Company, their written opinion, dated the Closing Date or the
Additional Closing Date, as the case may be, and addressed to the Underwriter, in form and substance reasonably satisfactory to the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(i)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Opinion
and 10b-5 Statement of Regulatory Counsel for the Company</I>. On the Closing Date or the Additional Closing Date, as the case may be,
and addressed to the Underwriter, (i)&nbsp;DuVal&nbsp;&amp; Associates, P.A., regulatory counsel for the Company, shall have furnished
to the Underwriter, at the request of the Company, their written opinion (including a negative assurance statement), and (ii)&nbsp;Fredrikson&nbsp;&amp;
Byron, P.A., regulatory counsel for the Company, shall have furnished to the Underwriter, at the request of the Company, their written
opinion (including a negative assurance statement).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(j)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Opinion
and 10b-5 Statement of Counsel for the Underwriter.</I> The Underwriter shall have received on and as of the Closing Date or the Additional
Closing Date, as the case may be, an opinion and 10b-5 statement of Latham&nbsp;&amp; Watkins LLP, counsel for the Underwriter, with respect
to such matters as the Underwriter may reasonably request, and such counsel shall have received such documents and information as they
may reasonably request to enable them to pass upon such matters.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 4 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(k)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>No
Legal Impediment to Issuance.</I> No action shall have been taken and no statute, rule, regulation or order shall have been enacted, adopted
or issued by any federal, state or foreign governmental or regulatory authority that would, as of the Closing Date or the Additional Closing
Date, as the case may be, prevent the issuance or sale of the Shares; and no injunction or order of any federal, state or foreign court
shall have been issued that would, as of the Closing Date or the Additional Closing Date, as the case may be, prevent the issuance or
sale of the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(l)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Good
Standing</I>. The Underwriter shall have received on and as of the Closing Date or the Additional Closing Date, as the case may be, satisfactory
evidence of the good standing of the Company and its subsidiary in their respective jurisdictions of organization and their good standing
as foreign entities in such other jurisdictions as the Underwriter may reasonably request, in each case in writing or any standard form
of telecommunication from the appropriate governmental authorities of such jurisdictions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(m)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Exchange
Listing.</I> The Company shall have provided notification to the Nasdaq Global Market that the Company intends to issue the Shares and
there shall not be any written objection from the Nasdaq Global Market with respect to such notification as of the Closing Date.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(n)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Lock-up
Agreements</I>. The &ldquo;lock-up&rdquo; agreements, each substantially in the form of Exhibit&nbsp;A hereto, shall be delivered to the
Underwriter on or before the date hereof by each of the officers and directors of the Company listed in Schedule 3 hereto relating to
sales and certain other dispositions of shares of Stock or certain other securities, and shall be full force and effect on the Closing
Date or Additional Closing Date, as the case may be.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(o)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Additional
Documents.</I> On or prior to the Closing Date or the Additional Closing Date, as the case may be, the Company shall have furnished to
the Underwriter such further certificates and documents as the Underwriter may reasonably request.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">All opinions, letters, certificates and evidence
mentioned above or elsewhere in this Agreement shall be deemed to be in compliance with the provisions hereof only if they are in form
and substance reasonably satisfactory to counsel for the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">7.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Indemnification
and Contribution</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Indemnification
of the Underwriter.</I> The Company agrees to indemnify and hold harmless the Underwriter, its affiliates, directors and officers and
each person, if any, who controls the Underwriter within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20 of the
Exchange Act, from and against any and all losses, claims, damages and liabilities (including, without limitation, reasonable legal fees
and other expenses incurred in connection with any suit, action or proceeding or any claim asserted, as such fees and expenses are incurred),
joint or several, that arise out of, or are based upon, (i)&nbsp;any untrue statement or alleged untrue statement of a material fact contained
in the Registration Statement or caused by any omission or alleged omission to state therein a material fact required to be stated therein
or necessary in order to make the statements therein, not misleading, or (ii)&nbsp;any untrue statement or alleged untrue statement of
a material fact contained in the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus, any &ldquo;issuer
information&rdquo; filed or required to be filed pursuant to Rule&nbsp;433(d)&nbsp;under the Securities Act, any road show as defined
in Rule&nbsp;433(h)&nbsp;under the Securities Act (a &ldquo;road show&rdquo;) or any Pricing Disclosure Package (including any Pricing
Disclosure Package that has subsequently been amended), or caused by any omission or alleged omission to state therein a material fact
necessary in order to make the statements therein, in light of the circumstances under which they were made, not misleading, in each case
except insofar as such losses, claims, damages or liabilities arise out of, or are based upon, any untrue statement or omission or alleged
untrue statement or omission made in reliance upon and in conformity with any information relating to the Underwriter furnished to the
Company in writing by the Underwriter expressly for use therein, it being understood and agreed that the only such information furnished
by any Underwriter consists of the information described as such in subsection (b)&nbsp;below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 5 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Indemnification
of the Company.</I> The Underwriter agrees to indemnify and hold harmless the Company, its directors, its officers who signed the Registration
Statement and each person, if any, who controls the Company within the meaning of Section&nbsp;15 of the Securities Act or Section&nbsp;20
of the Exchange Act to the same extent as the indemnity set forth in paragraph (a)&nbsp;above, but only with respect to any losses, claims,
damages or liabilities that arise out of, or are based upon, any untrue statement or omission or alleged untrue statement or omission
made in reliance upon and in conformity with any information relating to the Underwriter furnished to the Company in writing by the Underwriter
expressly for use in the Registration Statement, the Prospectus (or any amendment or supplement thereto), any Issuer Free Writing Prospectus,
any road show or any Pricing Disclosure Package (including any Pricing Disclosure Package that has subsequently been amended), it being
understood and agreed upon that the only such information furnished by the Underwriter consists of the following information in the Prospectus
furnished on behalf of the Underwriter: the concession and reallowance figures appearing in the fourth paragraph under the caption &ldquo;Underwriting&rdquo;,
the information contained in the twelfth, fourteenth and the second sentence of the fifteenth paragraph under the caption &ldquo;Underwriting&rdquo;.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Notice
and Procedures.</I> If any suit, action, proceeding (including any governmental or regulatory investigation), claim or demand shall be
brought or asserted against any person in respect of which indemnification may be sought pursuant to either paragraph (a)&nbsp;or (b)&nbsp;above,
such person (the &ldquo;Indemnified Person&rdquo;) shall promptly notify the person against whom such indemnification may be sought (the
 &ldquo;Indemnifying Person&rdquo;) in writing; <U>provided</U> that the failure to notify the Indemnifying Person shall not relieve it
from any liability that it may have under paragraph (a)&nbsp;or (b)&nbsp;above except to the extent that it has been materially prejudiced
(through the forfeiture of substantive rights or defenses) by such failure; and <U>provided</U>, <U>further</U>, that the failure to notify
the Indemnifying Person shall not relieve it from any liability that it may have to an Indemnified Person otherwise than under paragraph
(a)&nbsp;or (b)&nbsp;above. If any such proceeding shall be brought or asserted against an Indemnified Person and it shall have notified
the Indemnifying Person thereof, the Indemnifying Person shall retain counsel reasonably satisfactory to the Indemnified Person (who shall
not, without the consent of the Indemnified Person, be counsel to the Indemnifying Person) to represent the Indemnified Person in such
proceeding and shall pay the fees and expenses of such counsel related to such proceeding, as incurred. In any such proceeding, any Indemnified
Person shall have the right to retain its own counsel, but the fees and expenses of such counsel shall be at the expense of such Indemnified
Person unless (i)&nbsp;the Indemnifying Person and the Indemnified Person shall have mutually agreed in writing to the contrary; (ii)&nbsp;the
Indemnifying Person has failed within a reasonable time to retain counsel reasonably satisfactory to the Indemnified Person; (iii)&nbsp;the
Indemnified Person shall have reasonably concluded that there may be legal defenses available to it that are different from or in addition
to those available to the Indemnifying Person that would make separate representation advisable under the circumstances; or (iv)&nbsp;the
named parties in any such proceeding (including any impleaded parties) include both the Indemnifying Person and the Indemnified Person
and representation of both parties by the same counsel would be inappropriate due to actual or potential differing interest between them.
It is understood and agreed that the Indemnifying Person shall not, in connection with any proceeding or related proceedings in the same
jurisdiction, be liable for the fees and expenses of more than one separate firm (in addition to any local counsel) for all Indemnified
Persons, and that all such fees and expenses shall be paid or reimbursed as they are incurred. Any such separate firm for the Underwriter,
its affiliates, directors and officers and any control persons of the Underwriter shall be designated in writing by the Underwriter and
any such separate firm for the Company, its directors, its officers who signed the Registration Statement and any control persons of the
Company shall be designated in writing by the Company. The Indemnifying Person shall not be liable for any settlement of any proceeding
effected without its written consent, but if settled with such consent or if there be a final judgment for the plaintiff for which the
Indemnified Person is entitled to indemnification pursuant to this Section&nbsp;7, the Indemnifying Person agrees to indemnify each Indemnified
Person from and against any loss or liability by reason of such settlement or judgment. Notwithstanding the foregoing sentence, if at
any time an Indemnified Person shall have requested that an Indemnifying Person reimburse the Indemnified Person for fees and expenses
of counsel as contemplated by this paragraph, the Indemnifying Person shall be liable for any settlement of any proceeding effected without
its written consent if (i)&nbsp;such settlement is entered into more than 30 days after receipt by the Indemnifying Person of such request
and (ii)&nbsp;the Indemnifying Person shall not have reimbursed the Indemnified Person in accordance with such request prior to the date
of such settlement. No Indemnifying Person shall, without the written consent of the Indemnified Person, effect any settlement of any
pending or threatened proceeding in respect of which any Indemnified Person is or could have been a party and indemnification could have
been sought hereunder by such Indemnified Person, unless such settlement (x)&nbsp;includes an unconditional release of such Indemnified
Person, in form and substance reasonably satisfactory to such Indemnified Person, from all liability on claims that are the subject matter
of such proceeding and (y)&nbsp;does not include any statement as to or any admission of fault, culpability or a failure to act by or
on behalf of any Indemnified Person.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 6 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Contribution.</I>
If the indemnification provided for in paragraphs (a)&nbsp;and (b)&nbsp;above is unavailable to an Indemnified Person or insufficient
in respect of any losses, claims, damages or liabilities referred to therein, then each Indemnifying Person under such paragraph, in lieu
of indemnifying such Indemnified Person thereunder, shall contribute to the amount paid or payable by such Indemnified Person as a result
of such losses, claims, damages or liabilities (i)&nbsp;in such proportion as is appropriate to reflect the relative benefits received
by the Company, on the one hand, and the Underwriter on the other, from the offering of the Shares or (ii)&nbsp;if the allocation provided
by clause (i)&nbsp;is not permitted by applicable law, in such proportion as is appropriate to reflect not only the relative benefits
referred to in clause (i)&nbsp;but also the relative fault of the Company, on the one hand, and the Underwriter on the other, in connection
with the statements or omissions that resulted in such losses, claims, damages or liabilities, as well as any other relevant equitable
considerations. The relative benefits received by the Company, on the one hand, and the Underwriter on the other, shall be deemed to be
in the same respective proportions as the net proceeds (after deducting the underwriting discounts and commissions but before deducting
expenses) received by the Company from the sale of the Shares and the total underwriting discounts and commissions received by the Underwriter
in connection therewith, in each case as set forth in the table on the cover of the Prospectus, bear to the aggregate offering price of
the Shares. The relative fault of the Company, on the one hand, and the Underwriter on the other, shall be determined by reference to,
among other things, whether the untrue or alleged untrue statement of a material fact or the omission or alleged omission to state a material
fact relates to information supplied by the Company or by the Underwriter and the parties&rsquo; relative intent, knowledge, access to
information and opportunity to correct or prevent such statement or omission.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Limitation
on Liability.</I> The Company and the Underwriter agree that it would not be just and equitable if contribution pursuant to paragraph
(d)&nbsp;above were determined by <U>pro rata</U> allocation or by any other method of allocation that does not take account of the equitable
considerations referred to in paragraph (d)&nbsp;above. The amount paid or payable by an Indemnified Person as a result of the losses,
claims, damages and liabilities referred to in paragraph (d)&nbsp;above shall be deemed to include, subject to the limitations set forth
above, any legal or other expenses incurred by such Indemnified Person in connection with any such action or claim. Notwithstanding the
provisions of paragraphs (d)&nbsp;and (e), in no event shall the Underwriter be required to contribute any amount in excess of the amount
by which the total underwriting discounts and commissions received by the Underwriter with respect to the offering of the Shares exceeds
the amount of any damages that the Underwriter has otherwise been required to pay by reason of such untrue or alleged untrue statement
or omission or alleged omission. No person guilty of fraudulent misrepresentation (within the meaning of Section&nbsp;11(f)&nbsp;of the
Securities Act) shall be entitled to contribution from any person who was not guilty of such fraudulent misrepresentation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 7 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Non-Exclusive
Remedies.</I> The remedies provided for in this Section&nbsp;7 are not exclusive and shall not limit any rights or remedies which may
otherwise be available to any Indemnified Person at law or in equity.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">8.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Effectiveness
of Agreement</U>. This Agreement shall become effective upon the execution and delivery hereof by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">9.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Termination</U>.
This Agreement may be terminated in the absolute discretion of the Underwriter, by notice to the Company, if after the execution and delivery
of this Agreement and prior to the Closing Date or, in the case of the Option Shares, prior to the Additional Closing Date: (a)&nbsp;there
has been, in the judgment of the Underwriter, since the time of execution of this Agreement or since the respective dates as of which
information is given in the Registration Statement, the Pricing Disclosure Package or the Prospectus, any material adverse change in the
business, properties, management, financial position, stockholders&rsquo; equity, results of operations or prospects of the Company and
its subsidiary taken as a whole, (b)&nbsp;trading generally shall have been suspended or materially limited on or by either the New York
Stock Exchange or the Nasdaq Stock Market; (c)&nbsp;trading of any securities issued or guaranteed by the Company shall have been suspended
on any exchange or in any over-the-counter market; (d)&nbsp;a general moratorium on commercial banking activities shall have been declared
by federal or New York State authorities; (e)&nbsp;there shall have occurred any major disruption of settlements of securities, payment
or clearance services in the United States or any other country where such securities are listed; or (f)&nbsp;there shall have occurred
any outbreak or escalation of hostilities or declaration by the United States of a national emergency or war, or any change in financial
markets or any calamity or crisis, either within or outside the United States, that, in the judgment of the Underwriter, is material and
adverse and makes it impracticable or inadvisable to proceed with the offering, sale or delivery of the Shares on the Closing Date or
the Additional Closing Date, as the case may be, on the terms and in the manner contemplated by this Agreement, the Pricing Disclosure
Package and the Prospectus.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">10.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>[Reserved]</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">11.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Payment
of Expenses</U><I>.</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>Whether
or not the transactions contemplated by this Agreement are consummated or this Agreement is terminated, the Company will pay or cause
to be paid the following: (i)&nbsp;the fees, disbursements and expenses of the Company&rsquo;s counsel and accountants in connection with
the registration of the Shares under the Act and all other expenses in connection with the preparation, printing, reproduction and filing
of the Registration Statement, the Basic Prospectus, the Pricing Prospectus, any Issuer Free Writing Prospectus and the Prospectus and
amendments and supplements thereto and the mailing and delivering of copies thereof to the Underwriter and dealers; (ii)&nbsp;the cost
of printing or producing this Agreement, the Blue Sky survey, closing documents (including any compilations thereof) and any other documents
in connection with the offering, purchase, sale and delivery of the Shares; (iii)&nbsp;all expenses in connection with the qualification
of the Shares for offering and sale under state securities laws; (iv)&nbsp;all fees and expenses in connection with listing the Shares
on the Nasdaq; (v)&nbsp;the filing fees incident to and in connection with, any required review by FINRA of the terms of the sale of the
Shares ; (vi)&nbsp;the cost of preparing stock and warrant certificates, if applicable; (vii)&nbsp;the cost and charges of any transfer
agent, warrant agent or registrar; (viii)&nbsp;the costs and expenses of the Company relating to investor presentations on any &ldquo;road
show&rdquo; undertaken in connection with the marketing of the Shares, including without limitation, expenses associated with the production
of road show slides and graphics, fees; and (ix)&nbsp;all other costs and expenses incident to the performance of its obligations hereunder
which are not otherwise specifically provided for in this Section&nbsp;11. It is understood, however, that, except as provided in this
Section&nbsp;11 and Section&nbsp;7 hereof, the Underwriter will pay all of its own costs and expenses, including the fees of its counsel,
transfer taxes on resale of any of the Shares by them, and any advertising expenses connected with any offers they may make; provided,
however, that the Company will reimburse the Underwriter for all out-of-pocket expenses (including fees and expenses of its counsel) reasonably
incurred and documented by it in connection with its engagement hereunder, regardless of whether the offering of Shares is consummated;
provided, further, that the aggregate amount of such expenses subject to reimbursement shall not exceed $150,000 without the express written
approval of the Company.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 8 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT>If
(i)&nbsp;this Agreement is terminated pursuant to Section&nbsp;9 on account of an event described in clause (a)&nbsp;or (c)&nbsp;therein
or, (ii)&nbsp;the Company for any reason fails to tender the Shares for delivery to the Underwriter or (iii)&nbsp;the Underwriter declines
to purchase the Shares for any reason permitted under this Agreement, the Company agrees to reimburse the Underwriter for all accountable
out-of-pocket costs and expenses (including the fees and expenses of its counsel) actually incurred by the Underwriter in connection with
this Agreement and the offering contemplated hereby; provided, however, that in the event any such termination is effected after the Closing
Date but prior to any Additional Closing Date with respect to the purchase of any Option Shares, the Company shall only reimburse the
Underwriter for all accountable out-of-pocket expenses (including the fees and expenses of its counsel) actually incurred by the Underwriter
after the Closing Date in connection with the proposed purchase of any such Option Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">12.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Persons
Entitled to Benefit of Agreement</U>. This Agreement shall inure to the benefit of and be binding upon the parties hereto and their respective
successors and the officers and directors and any controlling persons referred to in Section&nbsp;7 hereof. Nothing in this Agreement
is intended or shall be construed to give any other person any legal or equitable right, remedy or claim under or in respect of this Agreement
or any provision contained herein. No purchaser of Shares from the Underwriter shall be deemed to be a successor merely by reason of such
purchase.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Survival</U>.
The respective indemnities, rights of contribution, representations, warranties and agreements of the Company and the Underwriter contained
in this Agreement or made by or on behalf of the Company or the Underwriter pursuant to this Agreement or any certificate delivered pursuant
hereto shall survive the delivery of and payment for the Shares and shall remain in full force and effect, regardless of any termination
of this Agreement or any investigation made by or on behalf of the Company or the Underwriter.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">14.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Certain
Defined Terms</U>. For purposes of this Agreement, (a)&nbsp;except where otherwise expressly provided, the term &ldquo;affiliate&rdquo;
has the meaning set forth in Rule&nbsp;405 under the Securities Act; (b)&nbsp;the term &ldquo;business day&rdquo; means any day other
than a day on which banks are permitted or required to be closed in New York City; (c)&nbsp;the term &ldquo;subsidiary&rdquo; has the
meaning set forth in Rule&nbsp;405 under the Securities Act ; and (d)&nbsp;the term &ldquo;significant subsidiary&rdquo; has the meaning
set forth in Rule&nbsp;1-02 of Regulation S-X under the Exchange Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 9 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">15.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><U>Compliance
with USA Patriot Act</U>. In accordance with the requirements of the USA Patriot Act (Title III of Pub. L. 107-56 (signed into law October&nbsp;26,
2001)), the Underwriter is required to obtain, verify and record information that identifies its respective clients, including the Company,
which information may include the name and address of its respective clients, as well as other information that will allow the Underwriter
to properly identify its respective clients.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">16.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<U>Miscellaneous</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Notices.</I>
All notices and other communications hereunder shall be in writing and shall be deemed to have been duly given if mailed or transmitted
and confirmed by any standard form of telecommunication. Notices to the Underwriter shall be given to William Blair&nbsp;&amp; Company,
L.L.C., 150 North Riverside Plaza, Chicago,&nbsp;Illinois 60606, Attention: General Counsel (fax: (312) 551-4646). Notices to the Company
shall be given to it at 3701 Wayzata Blvd., Suite&nbsp;300, Minneapolis, MN 55416, Attention: Brent Moen, Chief Financial Officer, with
a copy to (which shall not constitute notice) Faegre Drinker Biddle&nbsp;&amp; Reath LLP, 2200 Wells Fargo Center, 90 South 7th Street,
Minneapolis, Minnesota 55402, Attention: Jonathan R. Zimmerman.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Governing
Law.</I> This Agreement and any claim, controversy or dispute arising under or related to this Agreement shall be governed by and construed
in accordance with the laws of the State of New York applicable to agreements made and to be performed in such state.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Submission
to Jurisdiction</I>. The Company hereby submits to the exclusive jurisdiction of the U.S. federal and New York state courts in the Borough
of Manhattan in The City of New York in any suit or proceeding arising out of or relating to this Agreement or the transactions contemplated
hereby. The Company waives any objection which it may now or hereafter have to the laying of venue of any such suit or proceeding in such
courts. The Company agrees that final judgment in any such suit, action or proceeding brought in such court shall be conclusive and binding
upon the Company and may be enforced in any court to the jurisdiction of which Company is subject by a suit upon such judgment.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Waiver
of Jury Trial</I>. The Company hereby irrevocably waives, to the fullest extent permitted by applicable law, any and all right to trial
by jury in any legal proceeding arising out of or relating to this Agreement or the transactions contemplated hereby.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(e)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Counterparts.</I>
This Agreement may be signed in counterparts (which may include counterparts delivered by any standard form of telecommunication), each
of which shall be an original and all of which together shall constitute one and the same instrument. Counterparts may be delivered via
facsimile, electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions
Act, the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(f)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Amendments
or Waivers.</I> No amendment or waiver of any provision of this Agreement, nor any consent or approval to any departure therefrom, shall
in any event be effective unless the same shall be in writing and signed by the parties hereto.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(g)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Headings.</I>
The headings herein are included for convenience of reference only and are not intended to be part of, or to affect the meaning or interpretation
of, this Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(h)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</FONT><I>Integration.
</I>This Agreement supersedes all prior agreements and understandings (whether written or oral) between the Company and the Underwriter,
or any of them, with respect to the subject matter hereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 10 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">If the foregoing is in accordance with your understanding,
please indicate your acceptance of this Agreement by signing in the space provided below.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">TACTILE SYSTEMS TECHNOLOGY, INC.</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">By:</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%">/s/ Brent Moen</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Name: Brent Moen</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Title: Chief Financial Officer</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Accepted:
    As of the date first written above</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">WILLIAM BLAIR &amp; COMPANY, L.L.C.</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif; text-transform: uppercase">&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">By:</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">/s/ Steve Maletzky</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 6%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 41%">Authorized Signatory</TD>
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><I>[Signature page&nbsp;to Underwriting Agreement]</I></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 11 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Schedule 1</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font: 10pt Times New Roman, Times, Serif">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif">Underwriter</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; text-align: center; font: 10pt Times New Roman, Times, Serif">Number of Shares</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 87%; text-align: left">William Blair&nbsp;&amp; Company, L.L.C.</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 10%; text-align: right">2,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1%; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: White">
    <TD STYLE="font-size: 10pt; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif; text-align: right">&nbsp;</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom; background-color: rgb(204,238,255)">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: right">Total</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD><TD STYLE="border-bottom: Black 2.5pt double; font: 10pt Times New Roman, Times, Serif; text-align: right">2,500,000</TD><TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: left">&nbsp;</TD></TR>
  </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 12 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Schedule 2</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Significant Subsidiaries</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" WIDTH="100%" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt"><TR STYLE="vertical-align: top">
<TD STYLE="width: 0.25in"></TD><TD STYLE="width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">1.</FONT></TD><TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Swelling Solutions,&nbsp;Inc. </FONT>&ndash; Delaware</TD></TR></TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 13 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Schedule 3</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>List of Persons and Entities Subject to Lock-up</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Non-Employee Directors</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Valerie Asbury</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">William Burke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Sheri Dodd</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Raymond Huggenberger</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Deepti Jain</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">D. Brent Shafer</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Carmen Volkart</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in"><U>Officers</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Kristie Burns</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Brent Moen</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 1in">Eric Pauls</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-indent: 0.5in">Daniel Reuvers</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 14 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">a.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Pricing
Disclosure Package</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">b.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<B>Pricing
Information Provided Orally by The Underwriter</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 1.5in">Price to Public:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">$13.00</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD COLSPAN="3" STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">Number of Shares:</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif">2,500,000 shares (with option to purchase 375,000 option shares)</TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 15 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">ANNEX B</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Tactile Systems Technology,&nbsp;Inc.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><U>Pricing Term Sheet</U></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">None.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 16 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">Exhibit&nbsp;A</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">FORM&nbsp;OF
LOCK</FONT>-UP AGREEMENT</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right">February&nbsp;<U>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</U>,
2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William Blair&nbsp;&amp; Company, L.L.C.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">150 North Riverside Plaza</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Chicago,&nbsp;Illinois 60606</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Re:&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Tactile
Systems Technology,&nbsp;Inc. </FONT><FONT STYLE="font-size: 10pt">&mdash;</FONT> Public Offering</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">As an inducement to William
Blair&nbsp;&amp; Company, L.L.C. (the &ldquo;Underwriter&rdquo;) to execute an underwriting agreement (the &ldquo;Underwriting Agreement&rdquo;)
providing for a public offering (the &ldquo;Offering&rdquo;) of common stock, par value $0.001 per share (the &ldquo;Common Stock&rdquo;),
of Tactile Systems Technology,&nbsp;Inc., a Delaware corporation (the &ldquo;Company&rdquo;), pursuant to a Registration Statement on
Form&nbsp;S-3 (the &ldquo;Registration Statement&rdquo;), the undersigned hereby agrees that without, in each case, the prior written
consent of the Underwriter during the period specified in the second succeeding paragraph (the &ldquo;Lock-Up Period&rdquo;), the undersigned
(or any affiliate of the undersigned or any person part of a &ldquo;group&rdquo; (within the meaning of Section&nbsp;13(d)(3)&nbsp;under
the Securities Exchange Act of 1934, as amended (the &ldquo;Exchange Act&rdquo;)) with the undersigned or an affiliate of the undersigned)
will not: (1)&nbsp;offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to
sell, grant any option, right or warrant to purchase, make any short sale or otherwise transfer or dispose of, directly or indirectly,
any shares of Common Stock or any securities convertible into, exercisable or exchangeable for or that represent the right to receive
Common Stock (including without limitation, Common Stock which may be deemed to be beneficially owned by the undersigned in accordance
with the rules&nbsp;and regulations of the Securities and Exchange Commission (the &ldquo;SEC&rdquo;) and securities which may be issued
upon exercise of a stock option or warrant), whether now owned or hereafter acquired (the &ldquo;Undersigned&rsquo;s Securities&rdquo;);
(2)&nbsp;enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences of ownership of
the Undersigned&rsquo;s Securities, whether any such transaction described in clause (1)&nbsp;above or this clause (2)&nbsp;is to be settled
by delivery of Common Stock or such other securities, in cash or otherwise; (3)&nbsp;make any demand for, or exercise any right with respect
to, the registration under the Securities Act of 1933, as amended (the &ldquo;Securities Act&rdquo;), of any Common Stock or any security
convertible into or exercisable or exchangeable for Common Stock; or (4)&nbsp;publicly disclose the intention to do any of the foregoing.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned agrees that
the foregoing restrictions preclude the undersigned from engaging, during the Lock-Up Period, in any hedging or other transaction that
is designed to or that reasonably could be expected to lead to or result in a sale or disposition of the Undersigned&rsquo;s Securities,
even if such Undersigned&rsquo;s Securities would be disposed of by someone other than the undersigned. Such prohibited hedging or other
transactions would include without limitation any short sale or any purchase, sale or grant of any right (including without limitation
any put or call option) with respect to any of the Undersigned&rsquo;s Securities or with respect to any security that includes, relates
to, or derives any significant part of its value from such Undersigned&rsquo;s Securities.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 17 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The Lock-Up Period will commence
on the date of this lock-up agreement (this &ldquo;Lock-Up Agreement&rdquo;) and continue and include the date 90 days after the date
of the final prospectus supplement used to sell Common Stock in the Offering pursuant to the Underwriting Agreement relating to the Offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">Notwithstanding the foregoing,
the undersigned may transfer the Undersigned&rsquo;s Securities: (i)&nbsp;as a bona fide gift or gifts; (ii)&nbsp;to any trust, partnership,
limited liability company or other entity for the direct or indirect benefit of the undersigned or the immediate family of the undersigned;
(iii)&nbsp;by operation of law pursuant to a qualified domestic order or in connection with a divorce settlement, divorce decree, separation
agreement or other related court order; (iv)&nbsp;if the undersigned is a corporation, partnership, limited liability company, trust or
other business entity, (a)&nbsp;to another corporation, partnership, limited liability company, trust or other business entity that is
a direct or indirect affiliate (as defined in Rule&nbsp;405 promulgated under the Securities Act) of the undersigned or (b)&nbsp;in distributions
of shares of Common Stock or any security convertible into or exercisable for Common Stock to limited partners, limited liability company
members or stockholders of the undersigned; (v)&nbsp;if the undersigned is a trust, to the trustees, beneficiaries or settlors of such
trust; (vi)&nbsp;by testate succession or intestate succession; (vii)&nbsp;to the Company pursuant to arrangements in effect on the date
hereof and described in the Registration Statement and the prospectus for the Offering (the &ldquo;Prospectus&rdquo;) pursuant to which
the Company has (a)&nbsp;an option to repurchase such Undersigned&rsquo;s Securities or (b)&nbsp;a right of first refusal with respect
to transfers of such Undersigned&rsquo;s Securities, provided, in the case of clause (b), that the transfer triggering such right of first
refusal is otherwise permitted under this lock-up; (viii)&nbsp;to the Company in connection with the termination of the undersigned&rsquo;s
service for the Company pursuant to an arrangement in effect on the date hereof that provides the Company with an option to repurchase
such Undersigned&rsquo;s Securities; or (ix)&nbsp;to the Company as forfeitures to satisfy tax withholding obligations of the undersigned
in connection with the vesting or exercise of equity awards currently outstanding pursuant to the Company&rsquo;s equity incentive plans
in effect on the date hereof and described in the Registration Statement and the Prospectus, provided that any shares of Common Stock
received upon such vesting or exercise shall be subject to the restrictions set forth in this Lock-Up Agreement; provided, in the case
of clauses (i)-(ix), that (x)&nbsp;such transfer shall not involve a disposition for value, (y)&nbsp;the transferee agrees in writing
with the Underwriter to be bound by the terms of this Lock-Up Agreement and (z)&nbsp;no filing by any party under Section&nbsp;16(a)&nbsp;of
the Exchange Act, shall be required or shall be made voluntarily in connection with such transfer (other than, in connection with a repurchase
of the Undersigned&rsquo;s Securities by the Company pursuant to clause (vii)&nbsp;or a forfeiture to satisfy tax withholding obligations
pursuant to clause (ix), a Form&nbsp;4 or Form&nbsp;5 required to be filed under the Exchange Act if the undersigned is subject to Section&nbsp;16
reporting with respect to the Company under the Exchange Act, provided, however, that if such Form&nbsp;4 or Form&nbsp;5 is filed during
the Lock-Up Period, such Form&nbsp;4 or Form&nbsp;5 shall indicate by footnote disclosure or otherwise that such Form&nbsp;4 or Form&nbsp;5
relates to a repurchase of Common Stock by the Company in connection with the termination of the undersigned&rsquo;s employment with the
Company or a forfeiture to satisfy tax withholding obligations, as applicable, and that any shares of Common Stock and other securities
subject to the Lock-Up Agreement that continue to be held by the undersigned remain subject to the terms of the Lock-Up Agreement). For
purposes of this Lock-Up Agreement, &ldquo;immediate family&rdquo; shall mean any relationship by blood, marriage, domestic partnership
or adoption, not more remote than first cousin.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 18 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In addition, the foregoing
restrictions shall not apply to: (i)&nbsp;(a)&nbsp;the undersigned&rsquo;s exercise or the vesting of equity-based awards granted pursuant
to the Company&rsquo;s equity incentive plans in place as of the date of this Lock-Up Agreement; or (b)&nbsp;the transfer, sale or other
disposition of any shares of Common Stock held by the undersigned or issued upon the exercise of any stock options or upon the vesting
of any other equity-based awards held by the undersigned through the net issuance by the Company of shares of Common Stock, a broker-assisted
cashless exercise or otherwise, in each case in order to satisfy any exercise price or tax obligations due as a result of such exercise
or vesting; provided, that (y)&nbsp;in the case of clause (a), such restrictions shall apply to any of the Undersigned&rsquo;s Securities
issued upon such exercise or vesting and (z)&nbsp;in each case, that if any filing is required under Section&nbsp;16(a)&nbsp;of the Exchange
Act in connection with such exercise, vesting or disposition, such filing shall include a statement to the effect that such filing is
the result of the exercise or vesting of equity-based securities pursuant to the Company&rsquo;s equity incentive plans; (ii)&nbsp;any
transaction with respect to shares of Common Stock acquired in market transactions after completion of the Offering; provided, that no
filing by the undersigned reporting a reduction in beneficial ownership under Section&nbsp;16(a)&nbsp;of the Exchange Act shall be required
or shall be made voluntarily in connection with any such transaction; (iii)&nbsp;the establishment of any contract, instruction or plan
(a &ldquo;Plan&rdquo;) that satisfies all of the requirements of Rule&nbsp;10b5-1(c)(1)(i)(B)&nbsp;under the Exchange Act; provided, that
no sales of the Undersigned&rsquo;s Securities shall be made pursuant to such a Plan prior to the expiration of the Lock-Up Period, and
such a Plan may only be established if no public announcement of the establishment or existence thereof and no filing with the SEC or
other regulatory authority in respect thereof or transactions thereunder or contemplated thereby, by the undersigned, the Company or any
other person, shall be made by the undersigned, the Company or any other person, prior to the expiration of the Lock-Up Period; or (iv)&nbsp;transfers
of Common Stock made pursuant to a Plan that satisfies all of the requirements of Rule&nbsp;10b5-1 under the Exchange Act and that is
in effect on the date hereof (and any related filings in connection with such sale or disposition that are required under the Exchange
Act; provided that any such filings shall indicate by footnote disclosure or otherwise (1)&nbsp;that such sale or disposition was made
in connection with a Plan and (2)&nbsp;the date such Plan was entered into).</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">In furtherance of the foregoing,
the Company and its transfer agent and registrar are hereby authorized to decline to make any transfer of shares of Common Stock if such
transfer would constitute a violation or breach of this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned hereby represents
and warrants that the undersigned has full power and authority to enter into this Lock-Up Agreement and that upon request, the undersigned
will execute any additional documents necessary to ensure the validity or enforcement of this Lock-Up Agreement. All authority herein
conferred or agreed to be conferred and any obligations of the undersigned shall be binding upon the successors, assigns, heirs or personal
representatives of the undersigned.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Lock-up Agreement may be delivered via facsimile,
electronic mail (including any electronic signature covered by the U.S. federal ESIGN Act of 2000, Uniform Electronic Transactions Act,
the Electronic Signatures and Records Act or other applicable law, e.g., www.docusign.com) or other transmission method and any counterpart
so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that the undersigned shall be automatically released from all obligations under this Lock-Up Agreement if (i)&nbsp;the Company notifies
the Underwriter in writing that it does not intend to proceed with the Offering, (ii)&nbsp;the Underwriter notifies the Company in writing
that it has determined not to proceed with the Offering, (iii)&nbsp;the Underwriting Agreement (other than the provisions thereof which
survive termination) shall terminate or be terminated prior to payment for and delivery of the Common Stock to be sold thereunder or (iv)&nbsp;the
Underwriting Agreement does not become effective by May&nbsp;31, 2023.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">The undersigned understands
that the Underwriter is entering into the Underwriting Agreement and proceeding with the Offering in reliance upon this Lock-Up Agreement.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">[<I>Signature Page&nbsp;Follows</I>]</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 19 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in">This Lock-Up Agreement and any claim, controversy
or dispute arising under or related to this Lock-Up Agreement shall be governed by and construed in accordance with the laws of the State
of New York, without regard to the conflict of laws principles thereof.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%">
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Very
    truly yours,</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Security Holder <I>(Print exact name)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:_______________________________________</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%">&nbsp;</TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Signature</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
    not signing in an individual capacity:</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of Authorized Signatory <I>(Print)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="border-bottom: Black 1pt solid; font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of Authorized Signatory <I>(Print)</I></FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: italic 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(indicate
    capacity of person signing if signing as custodian, trustee, or on behalf of an entity)</FONT></TD></TR>
  </TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 20; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="font-size: 10pt; text-align: center; margin-top: 0pt; margin-bottom: 0pt"></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-5.1
<SEQUENCE>3
<FILENAME>tm233510d7_ex5-1.htm
<DESCRIPTION>EXHIBIT 5.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="text-align: right; margin: 0"><B>Exhibit 5.1</B></P>

<P STYLE="margin: 0">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="width: 44%; font-size: 10pt; text-align: left"><IMG SRC="tm233510d7_ex5-1img001.jpg" ALT="" STYLE="height: 61px; width: 116px"></TD>
    <TD STYLE="width: 30%">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; width: 26%; font-size: 10pt; text-align: left"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">faegredrinker.com</FONT></TD></TR>
  <TR STYLE="font-size: 8pt; vertical-align: bottom">
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="font-size: 8pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; font-size: 8pt">&nbsp;</TD></TR>
  <TR STYLE="font-size: 5pt; vertical-align: bottom">
    <TD STYLE="border-top: rgb(15,127,64) 1.5pt solid; font-size: 5pt">&nbsp;</TD>
    <TD STYLE="border-top: rgb(15,127,64) 1.5pt solid; font-size: 5pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; border-top: rgb(15,127,64) 1.5pt solid; font-size: 5pt">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: bottom">
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="padding-top: 2pt">&nbsp;</TD>
    <TD STYLE="white-space: nowrap; padding-top: 2pt">
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><B>Faegre Drinker Biddle &amp; Reath LLP</B></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">2200 Wells Fargo Center</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">90 South Seventh Street</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Minneapolis, Minnesota 55402</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">+1 612 766 7000 main</P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">+1 612 766 1600 fax</P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">February 28, 2023</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Tactile Systems Technology, Inc.<BR>
3701 Wayzata Blvd, Suite 300</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Minneapolis, Minnesota 55416</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">Ladies and Gentlemen:</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We have acted as counsel to Tactile
Systems Technology, Inc., a Delaware corporation (the &#8220;Company&#8221;), in connection with the public offering by the Company of
$37,375,000 in the aggregate of shares (the &#8220;Shares&#8221;) of the Company&#8217;s common stock, par value $0.001 per share (&#8220;Common
Stock&#8221;), which includes shares subject to the underwriter&#8217;s option to purchase additional shares (the &#8220;Offering&#8221;).
The Shares are being offered pursuant to the Registration Statement on Form S-3 (File No. 333-269287) (the &#8220;Registration Statement&#8221;),
filed by the Company on January 18, 2023 with the Securities and Exchange Commission (the &#8220;Commission&#8221;) under the Securities
Act of 1933, as amended (the &#8220;Act&#8221;), and which was declared effective on January 25, 2023, including a related prospectus
supplement, dated February 23, 2023 (the &#8220;Prospectus&#8221;). The Shares are to be sold by the Company as described in the Registration
Statement and the Prospectus. This opinion is being furnished in connection with the requirements of Item 601(b)(5) of Regulation S-K
under the Act.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In this capacity, we have examined
originals or copies, certified or otherwise identified to our satisfaction, of the following documents: (i) the Registration Statement
and Prospectus, (ii) the Underwriting Agreement by and between William Blair &amp; Company, L.L.C. (the &#8220;Underwriter&#8221;) and
the Company, dated February 23, 2023 (the &#8220;Underwriting Agreement&#8221;), (iii) Amended and Restated Certificate of Incorporation
of the Company, as amended through May 9, 2019, as may be amended from time to time (the &#8220;Certificate of Incorporation&#8221;),
(iv) the Amended and Restated Bylaws of the Company, effective as of December 19, 2022 (the &#8220;Bylaws&#8221;), and (v) the resolutions
of the Board of Directors of the Company authorizing the Company&#8217;s issuance of the Shares. We have also examined a certificate of
an Officer of the Company dated the date hereof (the &#8220;Certificate&#8221;) and originals, or copies certified or otherwise authenticated
to our satisfaction, of such corporate records and other records, agreements, instruments, certificates of public officials and documents
as we have deemed necessary as a basis for the opinions hereinafter expressed and have reviewed such matters of law as we have deemed
relevant hereto. As to all issues of fact material to this opinion letter, we have relied on certificates, statements or representations
of public officials, of officers and representatives of the Company (including the Certificate) and of others, without any independent
verification thereof or other investigation.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">In our examination, we
have assumed, without investigation: (i) the legal capacity of all natural persons signing any of the documents and corporate
records examined by us; (ii) the genuineness of all signatures, including electronic signatures; (iii) the authenticity of all
documents submitted to us as originals; (iv) the conformity to original documents of all documents submitted to us as certified,
conformed, photostatic or facsimile copies; (v) the authenticity of the originals of such latter documents; (vi) the truth, accuracy
and completeness of the information, representations and warranties contained in the agreements, documents, instruments,
certificates and records we have reviewed<FONT STYLE="font-size: 10pt">; and (vii) the absence of any undisclosed modifications to
the agreements and instruments reviewed by us. </FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Based upon and subject to
the foregoing qualifications, assumptions and limitations and the further limitations set forth below, we are of the opinion that upon
payment therefor and issuance and delivery thereof in accordance with the Underwriting Agreement, including delivery of certificates representing
the Shares duly executed by the duly authorized officers of the Company, countersigned by the transfer agent therefor, to the purchasers
thereof (or in the case of Shares issued without certificates, the due registration of issuance and constructive delivery through book
entry of such Shares), the Shares will be validly issued, fully paid and non-assessable.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">Our opinion set forth herein
is limited to the General Corporation Law of the State of Delaware, and we express no opinion as to the effect of any other laws.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">This opinion letter is rendered
as of the date first written above, and we assume no responsibility for updating this opinion letter or the opinion or statements set
forth herein to take into account any event, action, interpretation or change in law occurring subsequent to the date hereof that may
affect the validity of such opinion or statements. This opinion is expressly limited to the matters set forth above, and we render no
opinion, whether by implication or otherwise, as to any other matters relating to the Company or the Shares.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left; text-indent: 0.5in">We hereby consent to the filing
of this opinion letter as an exhibit to the 8-K filed on the date hereof related to the Offering and to being named in the Prospectus
under the caption &#8220;Legal Matters&#8221; with respect to the matters stated therein. In giving these consents, we do not imply or
admit that we are &#8220;experts&#8221; within the meaning of the Act or that we are within the category of persons whose consent is required
under Section 7 of the Act or the rules and regulations of the Commission issued thereunder with respect to any part of the Registration
Statement, including this exhibit.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 50%">Very truly yours,</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" BORDER="0" STYLE="width: 100%; margin-top: 0pt; margin-bottom: 0pt; font: 10pt Times New Roman, Times, Serif">
<TR STYLE="vertical-align: top">
  <TD STYLE="text-align: justify; width: 50%">&nbsp;</TD>
  <TD STYLE="text-align: justify; width: 50%">FAEGRE DRINKER BIDDLE &amp; REATH LLP</TD></TR>
</TABLE>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<TABLE CELLPADDING="0" CELLSPACING="0" STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"><TR STYLE="vertical-align: top; text-align: justify">
<TD STYLE="width: 50%"></TD><TD STYLE="width: 3%; text-align: left">By:</TD><TD STYLE="border-bottom: Black 1pt solid; text-align: justify; width: 47%">/s/ Jonathan
                                            R. Zimmerman</TD>
</TR><TR STYLE="vertical-align: top; text-align: justify">
<TD>&nbsp;</TD><TD STYLE="text-align: left">&nbsp;</TD><TD STYLE="text-align: justify">Jonathan R. Zimmerman</TD></TR>
     </TABLE>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify"></P>

<!-- Field: Page; Sequence: 2; Options: NewSection Last; Value: 2 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="text-align: center; font-size: 10pt; margin-top: 0pt; margin-bottom: 0pt"><!-- Field: Sequence; Type: Arabic; Name: PageNo -->2<!-- Field: /Sequence --></P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 3in; text-align: justify">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>4
<FILENAME>tm233510d7_ex99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit&nbsp;99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>Tactile Systems Technology,&nbsp;Inc. Announces
Proposed Public Offering of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">MINNEAPOLIS,
Minn.&mdash;(GLOBE NEWSWIRE)&mdash;Feb.&nbsp;23, 2023&mdash;&nbsp;</FONT>Tactile Systems Technology,&nbsp;Inc. (&ldquo;Tactile Medical&rdquo;)
(Nasdaq: TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic
diseases at home, announced today that it intends to offer and sell shares of its common stock in an underwritten public offering. Tactile
Medical intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the shares of common stock offered in
the offering at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock to be sold
in the proposed offering will be sold by Tactile Medical. The offering is subject to market and other conditions, and there can be no
assurance as to whether or when the offering may be completed or as to the actual terms of the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The net proceeds
of the offering are expected to be used to </FONT>(i)&nbsp;expand commercial activities, (ii)&nbsp;fund milestone payments, (iii)&nbsp;support
new product development, (iv)&nbsp;broaden reimbursement coverage for Tactile Medical&rsquo;s patient population, (v)&nbsp;fund potential
acquisitions and (vi)&nbsp;provide working capital and for other general corporate purposes, which may include general debt reduction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">William Blair&nbsp;&amp; Company, L.L.C.&nbsp;is acting as sole book-running
manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif">The shares
are being offered by Tactile Medical pursuant to a shelf registration statement on Form&nbsp;S-3 (Registration No.&nbsp;333-269287) that
was initially filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on January&nbsp;18, 2023 and declared effective by
the SEC on January&nbsp;25, 2023. The offering will be made only by means of a preliminary prospectus supplement and accompanying prospectus
that form part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to, and describing
the terms of, the offering will be filed with the&nbsp;SEC&nbsp;and will be available on the SEC&rsquo;s website at&nbsp;</FONT><U>www.sec.gov</U>.
A copy of the preliminary prospectus supplement and the accompanying prospectus relating to this offering, when available, may be obtained
by contacting:&nbsp;William Blair&nbsp;&amp; Company, L.L.C., Attention: Prospectus Department,&nbsp;150 North Riverside Plaza,&nbsp;Chicago,&nbsp;IL&nbsp;60606,
by telephone at (800) 621-0687, or by email at&nbsp;<U>prospectus@williamblair.com</U>.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">This press release does not constitute an offer to sell or the solicitation
of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or
sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Tactile Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif">T</FONT>actile
Medical&nbsp;is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including
lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at
home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall
healthcare costs and improve the quality of life for tens of thousands of patients each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Legal Notice Regarding Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif">This
release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like &ldquo;may,&rdquo;
 &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;intend,&rdquo; &ldquo;continue,&rdquo; &ldquo;confident,&rdquo; &ldquo;outlook,&rdquo; &ldquo;guidance,&rdquo;
 &ldquo;project,&rdquo; &ldquo;goals,&rdquo; &ldquo;look forward,&rdquo; &ldquo;poised,&rdquo; &ldquo;designed,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;return,&rdquo; &ldquo;focused,&rdquo; &ldquo;prospects&rdquo; or &ldquo;remain&rdquo; or the negative of these words or other
variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements,
as these statements are subject to numerous factors and uncertainties outside of Tactile Medical&rsquo;s control that can make such statements
untrue, including, but not limited to, Tactile Medical&rsquo;s plans to consummate its proposed public offering, its expectations with
respect to granting the underwriter a 30-day option to purchase additional shares and its intended use of net proceeds therefrom; the
impacts of the COVID-19 pandemic on Tactile Medical&rsquo;s business, financial condition and results of operations, and Tactile Medical&rsquo;s
inability to mitigate such impacts; the adequacy of Tactile Medical&rsquo;s liquidity to pursue its business objectives; Tactile Medical&rsquo;s
ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives, including prior to identifying
a successor; adverse economic conditions or intense competition; loss of a key supplier; entry of new competitors and products; adverse
federal, state and local government regulation; technological obsolescence of Tactile Medical&rsquo;s products; technical problems with
Tactile Medical&rsquo;s research and products; Tactile Medical&rsquo;s ability to expand its business through strategic acquisitions;
Tactile Medical&rsquo;s ability to integrate acquisitions and related businesses; wage and component price inflation; the effects of
current and future&nbsp;U.S.&nbsp;and foreign trade policy and tariff actions; or the inability to carry out research, development and
commercialization plans. In addition, other factors that could cause actual results to differ materially are discussed in Tactile Medical&rsquo;s
filings with the&nbsp;SEC. Investors and security holders are urged to read these documents free of charge on the SEC&rsquo;s website
at&nbsp;</FONT><U>http://www.sec.gov</U>. Tactile Medical undertakes no obligation to publicly update or revise its forward-looking statements
as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; color: Red"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif"><B>Investors:</B></FONT><BR>
Mike Piccinino, CFA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">ICR Westwicke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">443-213-0500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">investorrelations@tactilemedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>5
<FILENAME>tm233510d7_ex99-2.htm
<DESCRIPTION>EXHIBIT 99.2
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right; background-color: white"><B>&nbsp;Exhibit 99.2</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; background-color: white"><B>Tactile Systems Technology,
Inc. Announces Pricing of $32.5 Million Public Offering of Common Stock</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">MINNEAPOLIS,
Minn.&mdash;(GLOBE</FONT> NEWSWIRE)&mdash; Feb. 23, 2023&mdash; Tactile Systems Technology, Inc. (&ldquo;Tactile Medical&rdquo;) (Nasdaq:
TCMD), a medical technology company focused on developing medical devices for the treatment of patients with underserved chronic diseases
at home, today announced the pricing of an underwritten public offering of 2,500,000 shares of its common stock at a price to the public
of $13.00 per share. The gross proceeds to Tactile Medical from the offering, before deducting the underwriting discounts and commissions
and estimated offering expenses, are expected to be $32.5 million. Additionally, Tactile Medical has granted the underwriter a 30-day
option to purchase up to an additional 375,000 shares of its common stock at the public offering price, less the underwriting discounts
and commissions. Tactile Medical anticipates using the net proceeds of the offering to (i) expand commercial activities, (ii) fund milestone
payments, (iii) support new product development, (iv) broaden reimbursement coverage for Tactile Medical&rsquo;s patient population, (v)
fund potential acquisitions and (vi) provide working capital and for other general corporate purposes, which may include general debt
reduction. All of the shares are being offered by Tactile Medical, and the offering is expected to close on or about February 28, 2023,
subject to customary closing conditions.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">William Blair &amp; Company, L.L.C. is acting
as sole book-running manager for the offering.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
shares are being offered by Tactile Medical pursuant to a shelf registration statement on Form S-3 (Registration No. 333-269287) that
was initially filed with the Securities and Exchange Commission (&ldquo;SEC&rdquo;) on January 18, 2023 and declared effective by the
SEC on January 25, 2023. </FONT>The offering is being made by means of a prospectus supplement and accompanying prospectus that form part
of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to, and describing the terms of,
the offering has been filed with the SEC and is available on the SEC&rsquo;s website at&nbsp;www.sec.gov. A final prospectus supplement
and accompanying prospectus relating to the offering will be filed with the SEC. Copies of the prospectus supplement and the accompanying
prospectus relating to this offering, when available, may be obtained by contacting: William Blair &amp; Company, L.L.C., Attention: Prospectus
Department, 150 North Riverside Plaza, Chicago, IL 60606, by telephone at (800) 621-0687, or by email at&nbsp;prospectus@williamblair.com.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">This press release does not constitute an
offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in
which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such
state or jurisdiction.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>About Tactile Medical</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">T</FONT>actile
Medical&nbsp;is a leader in developing and marketing at-home therapies for people suffering from underserved, chronic conditions including
lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease by helping them live better and care for themselves at
home. Tactile Medical collaborates with clinicians to expand clinical evidence, raise awareness, increase access to care, reduce overall
healthcare costs and improve the quality of life for tens of thousands of patients each year.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 12pt"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Legal Notice Regarding Forward-Looking
Statements</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
release contains forward-looking statements. Forward-looking statements are generally identifiable by the use of words like &ldquo;may,&rdquo;
 &ldquo;will,&rdquo; &ldquo;should,&rdquo; &ldquo;could,&rdquo; &ldquo;expect,&rdquo; &ldquo;anticipate,&rdquo; &ldquo;estimate,&rdquo;
 &ldquo;believe,&rdquo; &ldquo;intend,&rdquo; &ldquo;continue,&rdquo; &ldquo;confident,&rdquo; &ldquo;outlook,&rdquo; &ldquo;guidance,&rdquo;
 &ldquo;project,&rdquo; &ldquo;goals,&rdquo; &ldquo;look forward,&rdquo; &ldquo;poised,&rdquo; &ldquo;designed,&rdquo; &ldquo;plan,&rdquo;
 &ldquo;return,&rdquo; &ldquo;focused,&rdquo; &ldquo;prospects&rdquo; or &ldquo;remain&rdquo; or the negative of these words or other
variations on these words or comparable terminology. The reader is cautioned not to put undue reliance on these forward-looking statements,
as these statements are subject to numerous factors and uncertainties outside of Tactile Medical&rsquo;s control that can make such statements
untrue, including, but not limited to, the closing of Tactile Medical&rsquo;s public offering and the anticipated gross proceeds therefrom;
the impacts of the COVID-19 pandemic on Tactile Medical&rsquo;s business, financial condition and results of operations, and Tactile
Medical&rsquo;s inability to mitigate such impacts; the adequacy of Tactile Medical&rsquo;s liquidity to pursue its business objectives;
Tactile Medical&rsquo;s ability to obtain reimbursement from third party payers for its products; loss or retirement of key executives,
including prior to identifying a successor; adverse economic conditions or intense competition; loss of a key supplier; entry of new
competitors and products; adverse federal, state and local government regulation; technological obsolescence of Tactile Medical&rsquo;s
products; technical problems with Tactile Medical&rsquo;s research and products; Tactile Medical&rsquo;s ability to expand its business
through strategic acquisitions; Tactile Medical&rsquo;s ability to integrate acquisitions and related businesses; wage and component
price inflation; the effects of current and future&nbsp;U.S.&nbsp;and foreign trade policy and tariff actions; or the inability to carry
out research, development and commercialization plans. In addition, other factors that could cause actual results to differ materially
are discussed in Tactile Medical&rsquo;s filings with the&nbsp;SEC. Investors and security holders are urged to read these documents
free of charge on the SEC&rsquo;s website at&nbsp;</FONT><U>http://www.sec.gov</U>. Tactile Medical undertakes no obligation to publicly
update or revise its forward-looking statements as a result of new information, future events or otherwise.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: #FEFEFE"><B>Contacts</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investors:</B></FONT><BR>
Mike Piccinino, CFA</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">ICR Westwicke</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; background-color: white">443-213-0500</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">investorrelations@tactilemedical.com</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 12pt; margin-bottom: 6pt; border-bottom: Black 1pt solid"><P STYLE="margin: 0pt">&nbsp;</P></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>6
<FILENAME>tcmd-20230223.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" ?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
    <!-- Field: Doc-Info; Name: Misc; Value: +aA5w7xRiXgen8uLa3ZcWa6AubOdzZR+uYkxtmB6bbkq/yYhYRJAQSJzgVemMUEL -->
<schema xmlns="http://www.w3.org/2001/XMLSchema" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:TCMD="http://tactilemedical.com/20230223" elementFormDefault="qualified" targetNamespace="http://tactilemedical.com/20230223">
    <annotation>
      <appinfo>
	<link:roleType roleURI="http://tactilemedical.com/role/Cover" id="Cover">
	  <link:definition>00000001 - Document - Cover</link:definition>
	  <link:usedOn>link:presentationLink</link:usedOn>
	  <link:usedOn>link:calculationLink</link:usedOn>
	  <link:usedOn>link:definitionLink</link:usedOn>
	</link:roleType>
	<link:linkbaseRef xlink:type="simple" xlink:href="tcmd-20230223_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Presentation Links" />
	<link:linkbaseRef xlink:type="simple" xlink:href="tcmd-20230223_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Label Links" />
      </appinfo>
    </annotation>
    <import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
    <import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" />
    <import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd" />
    <import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd" />
    <import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd" />
    <import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
    <import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd" />
    <import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd" />
    <import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd" />
</schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>7
<FILENAME>tcmd-20230223_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" />
    <link:roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" roleURI="http://www.xbrl.org/2009/role/netLabel" />
    <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US">Cover [Abstract]</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US">Document Type</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US">Amendment Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="dei_AmendmentDescription" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentDescription" xlink:to="dei_AmendmentDescription_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentDescription_lbl" xml:lang="en-US">Amendment Description</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="dei_DocumentRegistrationStatement" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentRegistrationStatement" xlink:to="dei_DocumentRegistrationStatement_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentRegistrationStatement_lbl" xml:lang="en-US">Document Registration Statement</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US">Document Annual Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="dei_DocumentQuarterlyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentQuarterlyReport" xlink:to="dei_DocumentQuarterlyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentQuarterlyReport_lbl" xml:lang="en-US">Document Quarterly Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US">Document Transition Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="dei_DocumentShellCompanyReport" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyReport" xlink:to="dei_DocumentShellCompanyReport_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyReport_lbl" xml:lang="en-US">Document Shell Company Report</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="dei_DocumentShellCompanyEventDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentShellCompanyEventDate" xlink:to="dei_DocumentShellCompanyEventDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentShellCompanyEventDate_lbl" xml:lang="en-US">Document Shell Company Event Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="dei_DocumentPeriodStartDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodStartDate" xlink:to="dei_DocumentPeriodStartDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodStartDate_lbl" xml:lang="en-US">Document Period Start Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US">Document Period End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US">Document Fiscal Period Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US">Document Fiscal Year Focus</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US">Current Fiscal Year End Date</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US">Entity File Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US">Entity Registrant Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US">Entity Central Index Key</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="dei_EntityPrimarySicNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPrimarySicNumber" xlink:to="dei_EntityPrimarySicNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPrimarySicNumber_lbl" xml:lang="en-US">Entity Primary SIC Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US">Entity Tax Identification Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US">Entity Address, Address Line One</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="dei_EntityAddressAddressLine2" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine2" xlink:to="dei_EntityAddressAddressLine2_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine2_lbl" xml:lang="en-US">Entity Address, Address Line Two</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="dei_EntityAddressAddressLine3" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine3" xlink:to="dei_EntityAddressAddressLine3_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine3_lbl" xml:lang="en-US">Entity Address, Address Line Three</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US">Entity Address, City or Town</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US">Entity Address, State or Province</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="dei_EntityAddressCountry" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCountry" xlink:to="dei_EntityAddressCountry_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCountry_lbl" xml:lang="en-US">Entity Address, Country</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="dei_CountryRegion" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CountryRegion" xlink:to="dei_CountryRegion_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CountryRegion_lbl" xml:lang="en-US">Country Region</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US">City Area Code</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US">Local Phone Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="dei_Extension" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Extension" xlink:to="dei_Extension_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Extension_lbl" xml:lang="en-US">Extension</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="dei_WrittenCommunications" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_WrittenCommunications" xlink:to="dei_WrittenCommunications_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_WrittenCommunications_lbl" xml:lang="en-US">Written Communications</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="dei_SolicitingMaterial" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SolicitingMaterial" xlink:to="dei_SolicitingMaterial_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SolicitingMaterial_lbl" xml:lang="en-US">Soliciting Material</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="dei_PreCommencementTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementTenderOffer" xlink:to="dei_PreCommencementTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementTenderOffer_lbl" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="dei_PreCommencementIssuerTenderOffer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_PreCommencementIssuerTenderOffer" xlink:to="dei_PreCommencementIssuerTenderOffer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_PreCommencementIssuerTenderOffer_lbl" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US">Title of 12(b) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="dei_NoTradingSymbolFlag" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_NoTradingSymbolFlag" xlink:to="dei_NoTradingSymbolFlag_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_NoTradingSymbolFlag_lbl" xml:lang="en-US">No Trading Symbol Flag</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US">Trading Symbol</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US">Security Exchange Name</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="dei_Security12gTitle" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12gTitle" xlink:to="dei_Security12gTitle_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12gTitle_lbl" xml:lang="en-US">Title of 12(g) Security</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="dei_SecurityReportingObligation" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityReportingObligation" xlink:to="dei_SecurityReportingObligation_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityReportingObligation_lbl" xml:lang="en-US">Security Reporting Obligation</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="dei_AnnualInformationForm" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AnnualInformationForm" xlink:to="dei_AnnualInformationForm_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AnnualInformationForm_lbl" xml:lang="en-US">Annual Information Form</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="dei_AuditedAnnualFinancialStatements" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditedAnnualFinancialStatements" xlink:to="dei_AuditedAnnualFinancialStatements_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditedAnnualFinancialStatements_lbl" xml:lang="en-US">Audited Annual Financial Statements</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US">Entity Voluntary Filers</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US">Entity Current Reporting Status</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US">Entity Interactive Data Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US">Entity Filer Category</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US">Entity Small Business</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US">Entity Emerging Growth Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US">Elected Not To Use the Extended Transition Period</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="dei_DocumentAccountingStandard" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAccountingStandard" xlink:to="dei_DocumentAccountingStandard_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAccountingStandard_lbl" xml:lang="en-US">Document Accounting Standard</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="dei_OtherReportingStandardItemNumber" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_OtherReportingStandardItemNumber" xlink:to="dei_OtherReportingStandardItemNumber_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_OtherReportingStandardItemNumber_lbl" xml:lang="en-US">Other Reporting Standard Item Number</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US">Entity Shell Company</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US">Entity Public Float</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityBankruptcyProceedingsReportingCurrent" xlink:to="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityBankruptcyProceedingsReportingCurrent_lbl" xml:lang="en-US">Entity Bankruptcy Proceedings, Reporting Current</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock" />
      <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xlink:type="arc" />
      <link:label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentsIncorporatedByReferenceTextBlock_lbl" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>8
<FILENAME>tcmd-20230223_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
    <!-- Field: Doc-Info; Name: Generator; Value: GoFiler Complete; Version: 5.17a -->
    <!-- Field: Doc-Info; Name: VendorURI; Value: https://www.novaworks.com -->
    <!-- Field: Doc-Info; Name: Status; Value: 0x00000000 -->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
    <link:roleRef roleURI="http://tactilemedical.com/role/Cover" xlink:href="tcmd-20230223.xsd#Cover" xlink:type="simple" />
    <link:presentationLink xlink:type="extended" xlink:role="http://tactilemedical.com/role/Cover" xlink:title="00000001 - Document - Cover">
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CoverAbstract" xlink:label="loc_deiCoverAbstract" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="loc_deiDocumentType" />
      <link:presentationArc order="0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentType" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="loc_deiAmendmentFlag" />
      <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentDescription" xlink:label="loc_deiAmendmentDescription" />
      <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAmendmentDescription" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentRegistrationStatement" xlink:label="loc_deiDocumentRegistrationStatement" />
      <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentRegistrationStatement" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="loc_deiDocumentAnnualReport" />
      <link:presentationArc order="40" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAnnualReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentQuarterlyReport" xlink:label="loc_deiDocumentQuarterlyReport" />
      <link:presentationArc order="50" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentQuarterlyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="loc_deiDocumentTransitionReport" />
      <link:presentationArc order="60" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentTransitionReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyReport" xlink:label="loc_deiDocumentShellCompanyReport" />
      <link:presentationArc order="70" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyReport" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentShellCompanyEventDate" xlink:label="loc_deiDocumentShellCompanyEventDate" />
      <link:presentationArc order="80" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentShellCompanyEventDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodStartDate" xlink:label="loc_deiDocumentPeriodStartDate" />
      <link:presentationArc order="90" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodStartDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="loc_deiDocumentPeriodEndDate" />
      <link:presentationArc order="100" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentPeriodEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="loc_deiDocumentFiscalPeriodFocus" />
      <link:presentationArc order="110" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalPeriodFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="loc_deiDocumentFiscalYearFocus" />
      <link:presentationArc order="120" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentFiscalYearFocus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="loc_deiCurrentFiscalYearEndDate" />
      <link:presentationArc order="130" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCurrentFiscalYearEndDate" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="loc_deiEntityFileNumber" />
      <link:presentationArc order="140" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFileNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="loc_deiEntityRegistrantName" />
      <link:presentationArc order="150" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityRegistrantName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="loc_deiEntityCentralIndexKey" />
      <link:presentationArc order="160" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCentralIndexKey" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPrimarySicNumber" xlink:label="loc_deiEntityPrimarySicNumber" />
      <link:presentationArc order="170" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPrimarySicNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="loc_deiEntityTaxIdentificationNumber" />
      <link:presentationArc order="180" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityTaxIdentificationNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="loc_deiEntityIncorporationStateCountryCode" />
      <link:presentationArc order="190" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityIncorporationStateCountryCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="loc_deiEntityAddressAddressLine1" />
      <link:presentationArc order="200" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine1" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine2" xlink:label="loc_deiEntityAddressAddressLine2" />
      <link:presentationArc order="210" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine2" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine3" xlink:label="loc_deiEntityAddressAddressLine3" />
      <link:presentationArc order="220" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressAddressLine3" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="loc_deiEntityAddressCityOrTown" />
      <link:presentationArc order="230" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCityOrTown" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="loc_deiEntityAddressStateOrProvince" />
      <link:presentationArc order="240" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressStateOrProvince" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCountry" xlink:label="loc_deiEntityAddressCountry" />
      <link:presentationArc order="250" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressCountry" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="loc_deiEntityAddressPostalZipCode" />
      <link:presentationArc order="260" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityAddressPostalZipCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CountryRegion" xlink:label="loc_deiCountryRegion" />
      <link:presentationArc order="270" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCountryRegion" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="loc_deiCityAreaCode" />
      <link:presentationArc order="280" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiCityAreaCode" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="loc_deiLocalPhoneNumber" />
      <link:presentationArc order="290" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiLocalPhoneNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Extension" xlink:label="loc_deiExtension" />
      <link:presentationArc order="300" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiExtension" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_WrittenCommunications" xlink:label="loc_deiWrittenCommunications" />
      <link:presentationArc order="310" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiWrittenCommunications" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SolicitingMaterial" xlink:label="loc_deiSolicitingMaterial" />
      <link:presentationArc order="320" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSolicitingMaterial" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementTenderOffer" xlink:label="loc_deiPreCommencementTenderOffer" />
      <link:presentationArc order="330" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_PreCommencementIssuerTenderOffer" xlink:label="loc_deiPreCommencementIssuerTenderOffer" />
      <link:presentationArc order="340" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiPreCommencementIssuerTenderOffer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="loc_deiSecurity12bTitle" />
      <link:presentationArc order="350" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12bTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_NoTradingSymbolFlag" xlink:label="loc_deiNoTradingSymbolFlag" />
      <link:presentationArc order="360" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiNoTradingSymbolFlag" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="loc_deiTradingSymbol" />
      <link:presentationArc order="370" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiTradingSymbol" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="loc_deiSecurityExchangeName" />
      <link:presentationArc order="380" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityExchangeName" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12gTitle" xlink:label="loc_deiSecurity12gTitle" />
      <link:presentationArc order="390" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurity12gTitle" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityReportingObligation" xlink:label="loc_deiSecurityReportingObligation" />
      <link:presentationArc order="400" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiSecurityReportingObligation" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AnnualInformationForm" xlink:label="loc_deiAnnualInformationForm" />
      <link:presentationArc order="410" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAnnualInformationForm" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditedAnnualFinancialStatements" xlink:label="loc_deiAuditedAnnualFinancialStatements" />
      <link:presentationArc order="420" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiAuditedAnnualFinancialStatements" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="loc_deiEntityWellKnownSeasonedIssuer" />
      <link:presentationArc order="430" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityWellKnownSeasonedIssuer" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="loc_deiEntityVoluntaryFilers" />
      <link:presentationArc order="440" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityVoluntaryFilers" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="loc_deiEntityCurrentReportingStatus" />
      <link:presentationArc order="450" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCurrentReportingStatus" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="loc_deiEntityInteractiveDataCurrent" />
      <link:presentationArc order="460" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityInteractiveDataCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="loc_deiEntityFilerCategory" />
      <link:presentationArc order="470" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityFilerCategory" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="loc_deiEntitySmallBusiness" />
      <link:presentationArc order="480" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntitySmallBusiness" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="loc_deiEntityEmergingGrowthCompany" />
      <link:presentationArc order="490" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityEmergingGrowthCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityExTransitionPeriod" xlink:label="loc_deiEntityExTransitionPeriod" />
      <link:presentationArc order="500" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityExTransitionPeriod" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAccountingStandard" xlink:label="loc_deiDocumentAccountingStandard" />
      <link:presentationArc order="510" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentAccountingStandard" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_OtherReportingStandardItemNumber" xlink:label="loc_deiOtherReportingStandardItemNumber" />
      <link:presentationArc order="520" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiOtherReportingStandardItemNumber" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="loc_deiEntityShellCompany" />
      <link:presentationArc order="530" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityShellCompany" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="loc_deiEntityPublicFloat" />
      <link:presentationArc order="540" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityPublicFloat" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityBankruptcyProceedingsReportingCurrent" xlink:label="loc_deiEntityBankruptcyProceedingsReportingCurrent" />
      <link:presentationArc order="550" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityBankruptcyProceedingsReportingCurrent" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="loc_deiEntityCommonStockSharesOutstanding" />
      <link:presentationArc order="560" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiEntityCommonStockSharesOutstanding" xlink:type="arc" />
      <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentsIncorporatedByReferenceTextBlock" xlink:label="loc_deiDocumentsIncorporatedByReferenceTextBlock" />
      <link:presentationArc order="570" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_deiCoverAbstract" xlink:to="loc_deiDocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" />
    </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>9
<FILENAME>tm233510d7_ex5-1img001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 tm233510d7_ex5-1img001.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0@)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1"  X 'D# 2(  A$! Q$!_\0
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&1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm139985653821904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover<br></strong></div></th>
<th class="th"><div>Feb. 23, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Feb. 23,  2023<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-37799<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">TACTILE SYSTEMS TECHNOLOGY, INC.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001027838<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">41-1801204<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">3701 Wayzata Blvd<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">Suite 300<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Minneapolis<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">55416<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">612<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">355-5100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, Par Value $0.001 Per Share<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">TCMD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Section 14a<br> -Number 240<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>tm233510d7_8k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="tcmd-20230223.xsd" xlink:type="simple"/>
    <context id="From2023-02-23to2023-02-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001027838</identifier>
        </entity>
        <period>
            <startDate>2023-02-23</startDate>
            <endDate>2023-02-23</endDate>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2023-02-23to2023-02-23">0001027838</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2023-02-23to2023-02-23">false</dei:AmendmentFlag>
    <dei:DocumentType contextRef="From2023-02-23to2023-02-23">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="From2023-02-23to2023-02-23">2023-02-23</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="From2023-02-23to2023-02-23">TACTILE SYSTEMS TECHNOLOGY, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2023-02-23to2023-02-23">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="From2023-02-23to2023-02-23">001-37799</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="From2023-02-23to2023-02-23">41-1801204</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2023-02-23to2023-02-23">3701 Wayzata Blvd</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2023-02-23to2023-02-23">Suite 300</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2023-02-23to2023-02-23">Minneapolis</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2023-02-23to2023-02-23">MN</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2023-02-23to2023-02-23">55416</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2023-02-23to2023-02-23">612</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2023-02-23to2023-02-23">355-5100</dei:LocalPhoneNumber>
    <dei:WrittenCommunications contextRef="From2023-02-23to2023-02-23">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="From2023-02-23to2023-02-23">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="From2023-02-23to2023-02-23">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="From2023-02-23to2023-02-23">false</dei:PreCommencementIssuerTenderOffer>
    <dei:Security12bTitle contextRef="From2023-02-23to2023-02-23">Common Stock, Par Value $0.001 Per Share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="From2023-02-23to2023-02-23">TCMD</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="From2023-02-23to2023-02-23">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityEmergingGrowthCompany contextRef="From2023-02-23to2023-02-23">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>12
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( -:#7%8'04UB@0   +$    0    9&]C4')O<',O87!P+GAM
M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG
M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGD<Z,STA)8*O4'J@)I9GF
M3?X.CD:?<@X>K7A.YNJQ<&4GPZ4A!0W_<FW>J=0U[R;UEA_6\#MI7E!+ P04
M    " #6@UQ62?"&1>X    K @  $0   &1O8U!R;W!S+V-O<F4N>&ULS9+/
M2L0P$(=?17)O)TU%)'1[43PI""XHWD(RNQML_I",M/OVIG6WB^@#>,S,+]]\
M ]/I*'5(^)Q"Q$06\]7D!I^ECAMV((H2(.L#.I7KDO"EN0O)*2K/M(>H](?:
M(PC.;\ A*:-(P0RLXDID?6>TU D5A73"&[WBXV<:%IC1@ ,Z])2AJ1M@_3PQ
M'J>A@PM@AA$FE[\+:%;B4OT3NW2 G9)3MFMJ',=Z;)=<V:&!MZ?'EV7=ROI,
MRFLLO[*5=(RX8>?)K^W=_?:!]8*+MN*B$K=;T<B6R^OF?7;]X7<1=L'8G?W'
MQF?!OH-?=]%_ 5!+ P04    " #6@UQ6F5R<(Q &  "<)P  $P   'AL+W1H
M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03<VEVV[29A.U.
M'X416(UL>621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X
M8-DOV]:[MR_>X%<R)!%!,!FGK_# "J5,7K5::0##.'W)$Q+#W(*+"$MX%,O6
M7.!;&B\CUNJTV]U6A&ELH1A'9&!]7BQH0-!445IO7R"TY1\S^!7+5(UEHP$3
M5T$FN8BT\OELQ?S:WCYES^DZ'3*!;C ;6"!_SF^GY$Y:B.%4PL3 :F<_5FO'
MT=)(@(+)?90%NDGVH],5"#(-.SJ=6,YV?/;$[9^,RMIT-&T:X./Q>#BVR]*+
M<!P$X%&[GL*=]&R_I$$)M*-IT&38]MJND::JC5-/T_=]W^N;:)P*C5M/TVMW
MW=..B<:MT'@-OO%/A\.NB<:KT'3K:28G_:YKI.D6:$)&X^MZ$A6UY4#3( !8
M<';6S-(#EEXI^G64&MD=N]U!7/!8[CF)$?[&Q036:=(9EC1&<IV0!0X -\31
M3%!\KT&VBN#"DM)<D-;/*;50&@B:R('U1X(AQ=RO_?67N\FD,WJ=?3K.:Y1_
M::L!I^V[F\^3_'/HY)^GD]=-0LYPO"P)\?LC6V&')VX[$W(Z'&="?,_V]I&E
M)3+/[_D*ZTX\9Q]6EK!=S\_DGHQR([O=]EA]]D]';B/7J<"S(M>41B1%G\@M
MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7
MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V<
M/!T3$LV4"P9!AI<D)A*I.7Y-2!/^*Z7:_IS30/"4+R3Z2I&/:;,CIW0FS>@S
M&L%&KQMUAVC2/'K^!?F<-0H<D1L= F<;LT8AA&F[\!ZO)(Z:K<(1*T(^8ADV
M&G*U%H&V<:F$8%H2QM%X3M*T$?Q9K#63/F#([,V1=<[6D0X1DEXW0CYBSHN0
M$;\>ACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0'
MHYI9";V$5FJ?JH<T/J@>,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y
M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RS<C'5*^3*=@Y
MG\#L_6@^GO'M^MDDA*^:62TC%I!+@;-!)+C\B\KP*L0)Z&1;)0G+5--E-XH2
MGD(;;NE3]4J5U^6ON2BX/%ODZ:^A=#XLS_D\7^>TS0LS0[=R2^JVE+ZU)CA*
M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D*
MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-#
MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B
M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P
MOFH]M!5.S_Y9K<B?#!%.%@L22&.4%Z9*HO,94[[G*TG$53B_13.V$I<8O./F
MQW%.4[@2=K8/ C*YNSFI>F4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W
MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2
MD 83 <V4R43P H)DIAR F/H+O?(,N2D5SJT^.7]%+(.&3E[2)1(4BK ,!2$7
M<N/O[Y-J=XS7^BR!;814,F35%\I#B<$],W)#V%0E\Z[:)@N%V^)4S;L:OB9@
M2\-Z;ITM)__;7M0]M!<]1O.CF> >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F
M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+
M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5
M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0    (
M -:#7%:IZ_T$:P0  "H1   8    >&PO=V]R:W-H965T<R]S:&5E=#$N>&UL
MC9AO;^)&$,:_RLJMJE9*@M?\34J0""%WZ *A,;WH6O7%8B^P.GO77:]#Z*?O
MK"$V3<V8-V ;S^.?9\?/C.EOE?Z>;C@WY"V.9'KK;(Q);AJ---CPF*57*N$2
M?EDI'3,#NWK=2!/-69@'Q5'#<]U.(V9".H-^?FRN!WV5F4A(/M<DS>*8Z=T=
MC]3VUJ'.^X%GL=X8>Z QZ"=LS7UN?D_F&O8:A4HH8BY3H231?'7K#.G-G=>V
M ?D97P7?ID?;Q-[*4JGO=F<2WCJN)>(1#XR58/#URD<\BJP2</Q]$'6*:]K
MX^UW]8?\YN%FEBSE(Q6]B-!L;IV>0T*^8EEDGM7V,S_<4 X8J"C-/\EV?VZK
MY9 @2XV*#\% $ NY_V9OAT0<!] 3 =XAP,NY]Q?**>^988.^5ENB[=F@9C?R
M6\VC 4Y(NRJ^T?"K@#@S&*E7KOL- U+V0",XA-WMP[P380]\>46\Y@7Q7*_Y
MW_ &$!087H'AY7I-#(/\.5RF1L-"_55%M%=H52O8ZKU)$Q;P6P?*,^7ZE3N#
MGWZ@'?=7A*]9\#4Q]<&]"C*H14,6NX17P>'AO<LO"$2K@&BA*D,@"'.*AXBM
MJRCP^!6+4HYPM N.]GG)F',M5$C&,B10?)5YP96*,JJKHTZ!UD$%Q]((LR,/
M(N)DEL7+ZMK&-5R77C:[W>MKA*=;\'3/X7GF:V$K&W(V8W%EHG"=Q7"TF#R.
MB?_-7XRG/EF,1Y]G3X]/G[Y=D,EL=(6@]@K4WCFH(UA8S2(RD2%_(U_XK@H6
M5W(A@Z[7[35["-9U@75]#M:"O9%)"&QB)0*6&_KI]<456_22]ESJN2T$C[JE
M@;KG $YDH'2B=,YV07P##P11FHQ4!@F%O*JP<MUKU._'&.21R]-S((=A"-Z8
M7KQOD$<XCSS):C)<LMEU*7EANW^@[9"[Z#7$0,L^0%$;QT$76U4)BDOZF8"E
M:+HN!E@V HI;^4? D=V#=5ZHK:R$P^6F0DK.$A6)%,,K6P3%/?XC7E&'<ZU>
MA0RJ5QK7G,XPM+)K4-SL/Z+-56K :/X0R>F' U=LMUNT@[&5;8/BGI^OXA#&
MVM,HN$"'>AA(V2\H;O2/*H"<S#=*8@VL1J39;E^V*5[P95N@N)N_:&$,EY"8
M.,[DP7S32BI<J&[\H&5+H+B#^_"X!,((N293*&\M6%3)@ZO4\7AE"_!PDYYK
M?AE >C@\7_LI$08UF&>?5JOJ]:O1JR4K?=_#3?I_9),TS8"L%A"7K04\FOMQ
M<UX( Z.:6A'J_;S\A?@\R*#>*H>.&B5;GS 5^$8%W\%<F"9?691Q\J-[!?.(
MG56)OV$:Q2Z[@(?;]D*ST):?OXN7JK+XZ@1&TWN,I#1\#S?G]XR1\5NP87+-
M3TZ8-4*SH7\__ UC*IW>.\OIQS'7:YNE3Z!@-M9!$B:KUQ87/%EOC:,W7_LO
MPI39*Z8DXBL0<J^ZH*OW+^;[':.2_&5XJ0R\6N>;&\[@6; GP.\KI<S[CGV_
M+OX>&?P+4$L#!!0    ( -:#7%:?H!OPL0(  .(,   -    >&PO<W1Y;&5S
M+GAM;-U7;6O;,!#^*T(_8&YB:N*1&+9 8;"-0O-A7Y58=@1Z\62Y<_KKI[-L
M)VEU9=V'L<VAR=T]NKM'=R>9KEMWDOSAR+DCO9*ZW="C<\W[)&D/1ZY8^\XT
M7'ND,E8QYU5;)VUC.2M;<%(R6=[<9(EB0M-BK3MUIUQ+#J;3;D-O:%*L*Z//
MEI0&@U_*%">/3&[HEDFQMV)8RY20IV!>@N%@I+'$>2I\0Q=@:9\"O @:L!SC
M**&-!6,2,H3O_;C\&3!IK5>%E#/!)0V&8MTPY[C5=UX9%@_&%Q 9Y=VI\0QK
MRTZ+Y2T].PP_/LG>V)+;.<V"3J9B+7D%=*RHC_#K3), Z)Q17B@%JXUF X?)
M8Q1\V .7\@%:^*VZBMU7)/3B4PEM(+#52?2$1C&$"0K$OXP68E^$O?VML*01
MC\9][/QN]*!_[XSC]Y97HA_TOIKS8]$7>'36-/+T08I:*Q[V_LL)BS6;_,C1
M6/'DL\&D'+R!6TH>N77B<&GY85FSX[V;IJFO<,[+?Y#SGZUSS36W3%Z2]J/_
M-U?Y+8R3\?1<'-&K SI;"5R$&_H5[E=YYD#VG9!.Z%$[BK+D^L4Y]>$=V_L+
M_"J^7U_RBG72[69P0\_R%UZ*3N7SJGNHR[CJ+'^&^VB1S;>PSR5TR7M>;D?5
MUOM!)%[P6<<'')XC=\,31S"?@,41P+ \& /,)WAA>?ZG_:S0_00,X[:*(BO4
M9X7Z!*\8LAT^6)ZX3^Z?^$[S/$VS#*OH=AMEL,7JEF7P%X^&<0,/+ ]D>ENM
M\6[C$_+Z'& ]?6U"L)WBDXCM%*\U(/&Z@4>>Q[N-Y0$/K O8[$#^>!Z8J;A/
MFD)7,6[8"<:1/,<0F,7XC&894IT,/O'^8*<D3?,\C@ 69Y"F& *G$4<P!L !
M0])T> \^>Q\ETWLJ.?]74_P$4$L#!!0    ( -:#7%:7BKL<P    !,"   +
M    7W)E;',O+G)E;'.=DKENPS ,0'_%T)XP!] AB#-E\18$^0%6H@_8$@6*
M19V_K]JE<9 +&7D]/!+<'FE [3BDMHNI&/T04FE:U;@!2+8ECVG.D4*NU"P>
M-8?20$3;8T.P6BP^0"X99K>]9!:G<Z17B%S7G:4]VR]/06^ KSI,<4)I2$LS
M#O#-TG\R]_,,-47E2B.56QIXT^7^=N!)T:$B6!::1<G3HAVE?QW']I#3Z:]C
M(K1Z6^CY<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ UH-<5JK$(A8S
M 0  (@(   \   !X;"]W;W)K8F]O:RYX;6R-4=%NPC ,_)4J'[ 6M"$-45Y
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MX_T,:3?D@6)8YL_X>\87_QO.\1'"[K\_L;S63AI_YHOA/UY_ 5!+ 0(4 Q0
M   ( -:#7%8'04UB@0   +$    0              "  0    !D;V-0<F]P
M<R]A<' N>&UL4$L! A0#%     @ UH-<5DGPAD7N    *P(  !$
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M;',O+G)E;'-02P$"% ,4    " #6@UQ6JL0B%C,!   B @  #P
M    @ %S$   >&PO=V]R:V)O;VLN>&UL4$L! A0#%     @ UH-<5B0>FZ*M
M    ^ $  !H              ( !TQ$  'AL+U]R96QS+W=O<FMB;V]K+GAM
M;"YR96QS4$L! A0#%     @ UH-<5F60>9(9 0  SP,  !,
M ( !N!(  %M#;VYT96YT7U1Y<&5S72YX;6Q02P4&      D "0 ^ @   A0
#

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>23</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>3</UnitCount>
  <MyReports>
    <Report instance="tm233510d7_8k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://tactilemedical.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" original="tm233510d7_8k.htm">tm233510d7_8k.htm</File>
    <File>tcmd-20230223.xsd</File>
    <File>tcmd-20230223_lab.xml</File>
    <File>tcmd-20230223_pre.xml</File>
    <File>tm233510d7_ex1-1.htm</File>
    <File>tm233510d7_ex5-1.htm</File>
    <File>tm233510d7_ex99-1.htm</File>
    <File>tm233510d7_ex99-2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="23">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>17
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "tm233510d7_8k.htm": {
   "axisCustom": 0,
   "axisStandard": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2021q4": 23
   },
   "contextCount": 1,
   "dts": {
    "inline": {
     "local": [
      "tm233510d7_8k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "tcmd-20230223_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "tcmd-20230223_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "tcmd-20230223.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"
     ]
    }
   },
   "elementCount": 59,
   "entityCount": 1,
   "hidden": {
    "http://xbrl.sec.gov/dei/2021q4": 2,
    "total": 2
   },
   "keyCustom": 0,
   "keyStandard": 23,
   "memberCustom": 0,
   "memberStandard": 0,
   "nsprefix": "TCMD",
   "nsuri": "http://tactilemedical.com/20230223",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm233510d7_8k.htm",
      "contextRef": "From2023-02-23to2023-02-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00000001 - Document - Cover",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://tactilemedical.com/role/Cover",
     "shortName": "Cover",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "span",
       "b",
       "p",
       "body",
       "html"
      ],
      "baseRef": "tm233510d7_8k.htm",
      "contextRef": "From2023-02-23to2023-02-23",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 0,
   "tag": {
    "dei_AmendmentDescription": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Description of changes contained within amended document.",
        "label": "Amendment Description"
       }
      }
     },
     "localname": "AmendmentDescription",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AnnualInformationForm": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form.",
        "label": "Annual Information Form"
       }
      }
     },
     "localname": "AnnualInformationForm",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditedAnnualFinancialStatements": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements.",
        "label": "Audited Annual Financial Statements"
       }
      }
     },
     "localname": "AuditedAnnualFinancialStatements",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CountryRegion": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Region code of country",
        "label": "Country Region"
       }
      }
     },
     "localname": "CountryRegion",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover [Abstract]"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAccountingStandard": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'.",
        "label": "Document Accounting Standard"
       }
      }
     },
     "localname": "DocumentAccountingStandard",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "accountingStandardItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r11",
      "r13",
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentPeriodStartDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format.",
        "label": "Document Period Start Date"
       }
      }
     },
     "localname": "DocumentPeriodStartDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentQuarterlyReport": {
     "auth_ref": [
      "r12"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an quarterly report.",
        "label": "Document Quarterly Report"
       }
      }
     },
     "localname": "DocumentQuarterlyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentRegistrationStatement": {
     "auth_ref": [
      "r0"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a registration statement.",
        "label": "Document Registration Statement"
       }
      }
     },
     "localname": "DocumentRegistrationStatement",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentShellCompanyEventDate": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Date of event requiring a shell company report.",
        "label": "Document Shell Company Event Date"
       }
      }
     },
     "localname": "DocumentShellCompanyEventDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentShellCompanyReport": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act.",
        "label": "Document Shell Company Report"
       }
      }
     },
     "localname": "DocumentShellCompanyReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "auth_ref": [
      "r3"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Documents incorporated by reference.",
        "label": "Documents Incorporated by Reference [Text Block]"
       }
      }
     },
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine2": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 2 such as Street or Suite number",
        "label": "Entity Address, Address Line Two"
       }
      }
     },
     "localname": "EntityAddressAddressLine2",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressAddressLine3": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 3 such as an Office Park",
        "label": "Entity Address, Address Line Three"
       }
      }
     },
     "localname": "EntityAddressAddressLine3",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCountry": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "ISO 3166-1 alpha-2 country code.",
        "label": "Entity Address, Country"
       }
      }
     },
     "localname": "EntityAddressCountry",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "countryCodeItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityBankruptcyProceedingsReportingCurrent": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not.  Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element.",
        "label": "Entity Bankruptcy Proceedings, Reporting Current"
       }
      }
     },
     "localname": "EntityBankruptcyProceedingsReportingCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Elected Not To Use the Extended Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r16"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPrimarySicNumber": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity.",
        "label": "Entity Primary SIC Number"
       }
      }
     },
     "localname": "EntityPrimarySicNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "sicNumberItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r2"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r17"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_Extension": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Extension number for local phone number.",
        "label": "Extension"
       }
      }
     },
     "localname": "Extension",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_NoTradingSymbolFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a security having no trading symbol.",
        "label": "No Trading Symbol Flag"
       }
      }
     },
     "localname": "NoTradingSymbolFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "trueItemType"
    },
    "dei_OtherReportingStandardItemNumber": {
     "auth_ref": [
      "r13"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS.",
        "label": "Other Reporting Standard Item Number"
       }
      }
     },
     "localname": "OtherReportingStandardItemNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "otherReportingStandardItemNumberItemType"
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.",
        "label": "Pre-commencement Issuer Tender Offer"
       }
      }
     },
     "localname": "PreCommencementIssuerTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_PreCommencementTenderOffer": {
     "auth_ref": [
      "r8"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.",
        "label": "Pre-commencement Tender Offer"
       }
      }
     },
     "localname": "PreCommencementTenderOffer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r1"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_Security12gTitle": {
     "auth_ref": [
      "r5"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(g) registered security.",
        "label": "Title of 12(g) Security"
       }
      }
     },
     "localname": "Security12gTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r4"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_SecurityReportingObligation": {
     "auth_ref": [
      "r9"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act.",
        "label": "Security Reporting Obligation"
       }
      }
     },
     "localname": "SecurityReportingObligation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "securityReportingObligationItemType"
    },
    "dei_SolicitingMaterial": {
     "auth_ref": [
      "r10"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.",
        "label": "Soliciting Material"
       }
      }
     },
     "localname": "SolicitingMaterial",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dei_WrittenCommunications": {
     "auth_ref": [
      "r18"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.",
        "label": "Written Communications"
       }
      }
     },
     "localname": "WrittenCommunications",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://tactilemedical.com/role/Cover"
     ],
     "xbrltype": "booleanItemType"
    }
   },
   "unitCount": 3
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r1": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r10": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14a",
   "Subsection": "12",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r11": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r12": {
   "Name": "Form 10-Q",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "308",
   "Subsection": "a",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r13": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r14": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r15": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r16": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r17": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r18": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "425",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r19": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r2": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r3": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-23",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r4": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r5": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "g",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r6": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12, 13, 15d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r7": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13e",
   "Subsection": "4c",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r8": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "14d",
   "Subsection": "2b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r9": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "15",
   "Subsection": "d",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>18
<FILENAME>0001104659-23-026756-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001104659-23-026756-xbrl.zip
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M$*!(!J%FE&^8YBSBXIG7'I>8\8UL#'<S'L,CEIXHMV -*D(3K\Z0@" ;XA-
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M)Y":RF;R[X/;E\,,U[S!;%H4)_7&!9+*P9T@C[#RJ8H(:^-Q/X3D:<6=-HW
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MWT<@CQ73!RD%W>#)$V88DKU'?8G+WUNH:J9?F)FZI Q2O:WB<M:ZG^R_X<R
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M&(4E_7$+<Y$ZW@EJ[=Q4>*$WT@1D(=2/.(3Z]T#!B0$Q/RBX:8D,8.@2H9"
M5!1'D;BG3T56(&_H<5$)9,:$8Q]1P,V-Q83Y0(M#'JD+X\!LL*GQ2@S6Q!5V
MWIF_)$''C@Y:+LJB'$%D_I'>P=/\(V@/";22:OO*\/S%HE\5[J8*>;_K>EG@
MM'+D:>; ];.-7R][+>\7)? KP#T^\JABGI/BIDV$9/BL#@'*PY!7)@"9G*((
M9Q:YO?1X>!"_HD80L"\(6+R.&.2^7?2O-RZ@=PCNQ]L$;!5HM 7-093[$1@Y
M&>NB# I],_)^022_HQBPK# A[I^NFY[YH".SRZDO>X&^J#MA_ T+2$FDE,32
M!'FS"*O\.##?1;,01G[9'E5XP$3%+GJIZQ!1NUN@R(L]^?7=S4:?RF+L*1ZM
M6ES:T'+M(X>X-_LL^KJYO>7?-9*D^!>. (U\APEJ3ES^\@S4(I 6P.CN9$]V
MK9E: NWP)9)O^ZJI0R\8$M^4PUTDDB,1O'(9F;(P.G+D3@GVI;.]%81Q'>PS
ME> 4I%CN;ZAA4#S@7HTZGE_& _L0E?T8Y#QQGBCO\0":@Y[BA0A\1P0A\\B(
MXV/8@PC"P ([$,U'V\.V 9&DQ2O(8B.V@]2]W$%V+Y5*(>]5&UZH$&" V 77
M9-[ORKS?AKS_D>?]VUM>XF_S=RMP"#R^]EDXK13,2)KNG:-T&"\$+Q"<\'BG
M+3>+ S,*13; ?<L6L0VS1,U5#$/<2?&G8#@2(O",@3G-S]F&8%:4D_ZEI('R
M&>$)Q#/ :;\1AM!J@'420A[%&K='C-D=(D&9N!3 I<W+5'S#W-M=BT-2(\]6
M6EZ6D4ZGX^I^7LT=[/H*F,X<-@+ MK>:/K09&V7IJTTT7ALC0+,F3]N8Z R;
M\KI=UM?^&<MESL9?/*/SS71^T8D-W;WM+5T\\H9ZUN./EU_YO:BA;<L7U,R$
M-(,2:$827+0U2C8';6-[:VH<(HUD#$.PK2/(,@F7-[\BVJ-MRB0@):& #NCR
MW(%_RM;K#KDE$#9]S8C$Q5?NKL7GKQ-7<Z@=/'G@[W)N;\'OP53]HVT7Z19H
M*H_O02?$C4Z@KTUD#$\@3_#H>AC"PN7=($/\ AD_D J3F82H\_7)1RRW4J,Q
M)SY\7K6RHRX!N^SIZ0Z#=,%B+1M6.J[J\QY+-$.JZG>G+C=%37+:Q;(.'_0T
MG.,L:,<K:%0V6J.VMT+2$JZ?@PX:)YK:YAM*Z/^A63@TR[UC:%87Q:XJOZ;M
MODOP]7$CK$WQ=:T@SF.WF@YA7PK 7_,"Z[3P&6+!X\=4P<$0"!=XM=*$\9J_
M+ 8WR*>^>#YVX$Y"KGI4\^*GB&X)P&S362@UCQABI.4>R973SN<]GP0?5/&!
M#PM[IZ@%[ZT+-9_=%_EO5Q!^)#_S(V$'XO<ZF5;>IF[>%<+PA34;_1:NX W.
M)N[HNQ*F/X,/'U<LGKNN_G5:.ZZU/$%>5JI_;?1,Q<<[)O&LTOLWKA;T?JYN
MUIZOFWGX<](L/'V0F^D\/5FT"Q_P,SO]:M#&ED-XB;1G,.13$D5E%LI'V."*
M5_Y><]%^[;MM43?JUR'Q""/O?8L#-9W.*BG]X(Z,E;B2Z#&@!M*AHR1^V^MY
M+Q(1G;3L>8D@%DOALN),F[ 1(69HR>8^=L722"*J-I*8LF1C#,]Z<_6'\OWE
M..BI@S4P>"+-)U;,_D9QK$AB729;0B:8@+!0!<*6/H2YQU37#1+D=8-@UD/G
MYU>_CZ-J^N.SM&R9K@P<UV IVI&5&5DFF,](=]^ X_F\;[ \OOQM3)V1<25"
MXX8,C9\M&^V]$+!'!N)OPD%URD'U=W)0_64.OI#%_ KS%/XBAS?EBWB1MMA"
M]"OXX/:QK()6^,UB46;=(8,VT;F%\6J[5QJJB5?G(_%6;MU[:=GN^P7Q_]\!
M76,']!.E)<W:M\M2Z[I1;;YM.O(*@/,'7U;<(;Z:V_AP^!\K<+PT>/'H5M1I
MJSU92)D[*:,/C0G2\)#O]HBC5_+]AUXUW04ZH<&2I?,VZ6&CX^\WB!C/Z\#K
M'T->E!7@\)#U+(<^$?VS5V)?G0J&ZQ_1/A6 \0K1UYBZR<KL,^\#]-/T<B*Z
M<KJYZ:R<9GGLSBH;K4[SUUT6YM?>G/_.RS7>H1)Z(]M&23R>%)ZEY*6\_#E*
M,_L;)37I)M$1+1X[/+PK)="%12#1ITO*[[^D1-$/-\CU\!P^'?WE'B60UTQK
MH77Q2H>H5RW]ML!)/41U40MR"^@<N^SCQ%'O$M2\S]&])/_[*^*<._^+1,45
M_]I+[OA.G( 5]_8#?R6&G(U/[O74]VZ_]*/W,UG2Q_=J_;%VVGUL#NWR]TGY
M[-32W?[8,!NG/XW.>>.+Q=1LP_IVW!L\F4]FN5)MU?,/#]]Z@^'^TZ12LH>J
MT;OMC4?6S_R/M-XXL))G]>/!O:D;YU7&QLGK4WOXXU:_&-/3/DN?/N4/?K:/
M+VJU^_QMW3BMW38:U3X>U;O.X\,^Z7]7;BCK.S>UT^NSG_OXYN1/YVSTI?%C
M<JS;V+H=[]^>N2?U?G5D]D>3FR^UTE!/6T;F"VWDOKET]&=Z,');7R:WP\?;
M=FILG%=NQ@_MD\G-0#].DG'R)^[W?TAV_!=02P,$%     @ UH-<5A:L'\,/
MH@  0(@# !0   !T;3(S,S4Q,&0W7V5X,2TQ+FAT;>R]:7/;6)8V^)T1_ ^8
MBHX:*0)62;*=FW,R0NDER]'.3(?M[.J*B?D DJ"$- BPL$A6_?HYZ[WG8B$I
MF7++_>I=LBP2!"[N<M;G/.?'OW_X]<U/T\F/?W]Y]@+^-\+_\^.'UQ_>O/SI
MQ[_Q_\*W?Y.O?_SY]Q?_C-Y_^.>;E__/7Y9ET?P0G1ROF^A#MDKKZ+?T*GI7
MKI(BY@_BZ'U:9<N_P _AIV]O^KMGT2JISK/BAP@O/7X6->FGYE&29^?PT3PM
MFK3ZRT]_+6;U^MF/?WM[%P^ILO.+YB\__?CS3R\_762SK.&GG1R=_/BWGW^Z
MHX=^D3?3A_SQVXN7[_[Q[O6'U[_]$IW]\N[ERU]?_O;A?\.;?3A[_N'UFY?1
M^W^^__#RU_?1AY?/__[;[V]^_^6?,3__]6_/C_XWO.AI_/3X.#X^/H[>7R05
MW*Q<1L_+U:HLHO=-.?^XM\=_J2U9+-+JJLJ:K#B/SLZK-%W!-U_+6XC(>)7.
MJC:IKOE9IX_CZ/3X]/']?8F__/2/+,^S9!7]G"=9Q7?_:[):/\.]M$Z*ZSAZ
M<_3F:(]'YB\_G3P]CGXKJ^8B>I==IE6=+=+H;9[\.]GC,YY?9//DO-0S#^]8
ME%D=?7,,__<^+\>;9)'!Y4FQB'Z![9_C(?CA_@Y8#D$&9Q=_?WST-"M !B?S
M)LO3Z/UUW:2K.OJ0SB^*,B_/KW4]BOE1'"71BS1/KD!X32?SLEJ75=)D(+X.
MFHLT^FN^^%=;/I-=^->*_CJ,HW55KLL:!MB445;7;4IS5:=YCI]<EVT<X<];
ME29I%>49#&,192 8YQ?IHH61G407:97"#^RS_O"_<<^;3I(B2LY!')TG38HR
MULO=VLG=.<O=&N4N##&IHLLDAZ']Q_'1\?%)M(9!T,7=5W/"VK\?W VOD?<>
M'E^3%M,)2WW](<X"S&A#/R[7-(]R*_-:<=2N<9KPG1:+#*]*\NCQMT\[[V.'
MMFE$O].#NF,YBC[8Q\)H547A4N'/^7?N4Y@87 Y8H"I=IE4%BX6#K"/SJ. 1
M_(3N>&$<0P.&6\U@3MJF;N#YJ%V2)6Z+\^P2_TB7RW3>X%7XHSK)4[V!&9X=
MEPRU,SRSBON4E5_FO)K9PK>;7<..+I99!6<W:V &5!M'5UES,9UT=A5>/$^K
M F<3OUJWU?PBJ>5D]B8TQJE;EGE>7M5?G6@[.1(=^=G_?9>>@UQBD8<[%\0+
M3C%O;;<:,%7K*@6) GL/IW,)<G5!R\ SFLY;-)GD;+W\!!-?G-/O5R =!Z2I
M?.SD!@G*SKVFDS,X$;!H)]\_?DS+E<#0%BE*&#G!%4C1FE\$/P+QV.;T*K4Y
M?CJ$!C<5/^A@#@L/YPT4?WX=!R?(OPH\W0I@O+N;*A"R,E,1_/&JK%8\BO>/
M'D<'KU#K_%;*&CU^_/C1Z3??GW[W+<C5K)CG+9]^U"'U&@;1PM)7*8X;=VYI
M]NA1]+Z=7P0/GD[<D^V4J,QM8"?!80%1,X=O1*K 6]HGXW59L80QTQWAJV5$
M)M8"C]<"#T[=)@4)HW<PP?P:3QX?G\41_/?GJ*SP?Y]/)T.KAM,FP@[V2Z/K
M,#)Y=MAP)1YS-^8BK>OH0-8E&$CTV@_?+!%85ELEI-WOD=ON<I-GM+'@!VT-
MM^#?\^X ^;+26[R%Q<I660$&=O36K:'<(EJE25&S</(+++//ZA^_&A[&]NEH
M+N"2<H5?C,Y(<-9^!@DXG?2&>>B.D!EDW:[7.0]DD:"M,NQ'Q'R28(:'=ZT_
MGN&L=88PG=!4T84X2C.76P8W_%B=6IP'$%!5W? R'L!V725@W">7298G,SB;
M[;I$)?^O-JV;Z00F6G5%58_L_I-O'P_**-SMA_AD4#X%KA/<F,2B:*Y$32!4
M0'6H@8ZBUX&),)V@G&71BJ;1;%:EEQDMQ,CI&3FIWYP>S [YWZ,GU.Z1X*?1
MB$;PMB'\LD"!P8<M!:6K1TW6@Y9]9(>#M00V,@@'$39H/_/9@!4&6;?36(ZB
ML^#QM/)P^EOKO'MSP;ZK<^G=09!!#X\WIA<=/O&P<WAJS<8=>#T:)IN["_>N
M^+-%.6_Q&20=Q/& G\SLFS4RLW:E7\/0HI-3W$R!XAF7QZ0I9.\Y>4)G7#\=
M62UY0;V25FAX,J+>7*#.Y-,]Q].]2JYA7E@VA)L'7DD6AY29+$P<?&A6#)\D
M7WF9H-_1V8.SM?;&]'1R\Z7MO\W.*XLW]2LKIQDM?=#<.'TTEX,+Y<PF;_8\
MN4NSAY643*5]N#\:J&W0\?#O/$NW[]:CZ'FRSIHDS_Z-/TK1@"=1/&N;J"A!
MNZ3+K' :%B:&YO8BN>2#@7H!3G"-OE%*4H5FCF^T18'*#/F%N\=NT%]\$/__
M>O0H>I6E^>*'Z&URGCZ#ZT$[P9S";:-'CR0W\N.+U_^ES^0[/6K*-5QRNF[T
MWH]F9=.4JQ^B;_"S65G!PKO/?LX3\$Q/X.%UF6<+&$#P#H]J6#%^D:'HJ'L$
M/?1XX)GP&;_4CW^#H0Z,&E1:\O'1+ 4E#0]:TZO:FWXS<%-\.SM2,X=V28)'
MFOG\&TXHS^%]W 3##MX9R=YUE965*J@SD'79G.P7O%UT ))!#M)T,DO!CV7=
M;+RVA??:V#)";Q=U8V:M12L4O$\'SYYW+ZW3!LTKN +^. .#YU-T%GA/;_E'
MT\F+K)[G9=V"['@+6PY60(7*#^#YC C=348GG>PT 3$@CUJ"'G^DNG[=,\.#
MV1FQDXZ?;K#I)%SG7U1B=?=8G@QO)35\PNT3N"O1MS_ 7*R/5D>@%/!9_RRK
MC]'SK+DF5R0F'W=P6;ZZV3C=6^3$_O?'/WYZ*RX$^1/&*P$%V0E4_?BW/W[Z
MZN;MQU>___8AT!7+9)7EUS]LNW='K_SEIX/D<&_3_C<<%08.IQ.5>F3V#\;E
M1Z+!(EYM))'"7>5EYAQV\"V<X^#-L""DS9862.*DSFH?]0 !7,./V#J+HZND
MJD 0::3,^2BUD:T:M\"!M[,_35@8G$H.E_<OC\V+K]U67%;E*HQ"TZ!(5J(+
M4+2K&;POC'9H9HRX7Z_+&MZS^]I_K6JRPZ,"HTV#J8VDP=@9:I-T) .A)R="
M[>'T! [J/TY.CTY/O[JS\MKG-4*-/+8WV1(/TQ%[W9;1KKL2$TW[W98=VUZ2
M0F:71D.;=#KI)&<X,!9NE2C'D!B&2E9EB^$0M[W >$YR]LS &\MPRHH%>74+
M]!HR<$1HN(MTGI-Y)%+:+12\Y#JY1FT)\KP8E1WJT,BU.MO!V+^Z[?NAL^W0
M<T\_I=4\J\?6<&"Y:"$SE@I7%V6.5D0E:XT?X]Z1KS%.3#L5+F#7@,-(%UD%
M>[)!G_G:&*\V(M$+.<!"ZAK!PN F<=O+OI/L7%EOB;/+#WC'^IV,%_K<JQ>9
MG5>F(WMUD<TO> /++,&QFZ64X9,I7+B#2B]!?^!$7&%8;3@MR7[W HSFRU13
M,.LD6^  8WDFQU<D>[CR-P?9@G>74,QS,,IQ,"_P6[21^9AR*E+LY4/:UCP+
MN+GAKFE2Y1D9RDG1OT\!ZY8GC?T>YA]F;MEBR*2%*^&@3B>XC*//Y#][T299
MDX.VH,/.@0!Z(9@#?D>8(-!.S;HL6"XF\SEXO0D&)(PW W(3PR$UV6?O.50K
ML=UC&A%\#.\ASRDQE'&%&YYDH<0I(_4W^D:=6U394H<<HZQ[^PIFD\(:(&D;
M$&!)#9+MJG2SA'N]#AV_<)O ,&4CP-UAVV?+C-T[BKQ\;;)FCV;E[$[-2G(4
M*74O29CN^F=%0SH&%FV5?$PQO]?.P.."!5O"D&'3=/+YL)E+..9^WX>9'KK:
M*G@*ITKTZ\]V<<X!VAZX @5.LH#-C@HIEM D[%K8>P1"H.'8@91Z8C&ZYJ6>
M/,D$TFQ*& 8S_UB45WFZ.+>V[,CDH'#B!SMSW)LY%&NMRO;\@I1&LEQF>6;D
MN[G1_\G[>[[O_?TVN>9]M2R##>'D%&7-4*%FJ(/ 0JR7M-&C;+5*%[A$L*5\
M5FW9ROXGA0E"&&TR+Z(Z)E;?OIU.9,]1OJ"[^-[J\@ CV"ESSJJ]26#?K2QP
M\!])\S$#$^_-F[=X_<GQ#\?'T=G1KT=QM%N$XSNP)CC="=,#=R!13GI!!'$5
MK?-D[HP^TKKPH;D.)7=,.K2C'I?9$HZ8E?DLP4D8Q*JL@[GIZ!<Z4G3D.)MI
ME!/:! ,S&9@5SC%PRL6FGLF^H'?K+M]T$LH\^DW'X.H?6^<FIKGD2*W]3Q,6
MFLPD:D(UKP;!NKMKA^SR79  UH2)-1SF,M?!LY>ZK/+P2)\=(L\(22$[9,A0
MBG%<6R%F9QX29W]\_U%=NZ4S3A_2&?_GI3/>=LZ-5_XS#]1;J$R2;3^=D'<A
M/QDY%DY8!DGF4(4EYPEH@L;;S7W=XR24ZJW 6 ,?JC]2G\TE+X-TFNK()OD$
MKZ=1@0%X""N,W(LUF9%%"RJ57+M071XA2)D&WXTOAZ^JAA0IF60.AA3%&N$G
M*%%?I!3&*V$*/E0MS(BW;G-&%X5F&]_;^T(XBU4[;^ZQ$+IS,VQQM]'KFUC5
M:.G/2>6#^$-;S&G]-2Q]@R8W1<>JE=O>>5J<,SH)]BI8]7"::+^G%09AKFFC
M6RMC $\1.#2R"?%^Z6J=4P)/L+L''G$X<  6*3H<F4/KLOLA6UN?<,AF#QI0
M"(, LZD MQY<&?9P0#*@:08?+UKXE XV6VL(EF?W* S TG?7HJ/7X-"5Q9&1
M+(H%[4PR/!\&@D_4T6ZXGP2"\.,\/4_R&(4!&F27:=U(H)9E#-MJBM[ 0[E*
MP(BIR,O#W__95EF]R&C6.MX7GTR8U+K-&0]-8,'RJM"IJ2T>FD2,WIU<,)4:
MN+9PEXP,>$+*?:05DYOA.5JG=)CD%;)SS@53:"E9KZL$7,U<5XXD8#+GZ.K
MKAB,4ML8<5'Z(:'THCD&=U#^V+ ]*8A.&5I!AUUF<*H'(C4A,#_>:=PX"EYE
MG44+0N2HE+G%='*5\?S"IL#\.=Q(SJBJP!FX^<MLT(/W"R3A-YCN60H?+#MC
M_^KD\.,]9U]__..G=V$R@R7&/WR:+9PQRKT&V':7#.&#(:F0P?P+"N%[7"K
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M(A$6@RPL^NCZ1NE$WM;6]?W<17M("WXE:<$- J ?R''.YY8-?S-32UAQ]A&
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MF(PG8.CTEJ(OP]VQ84=C /.NMG3LT0BTQ1P:A;8Y#DRT#W+><G"/:'*Y8TN
MI*"-6V-PFM, (TU1*%O'0D_XF?!:;C^R]JI$BUI\]155<F$*&*Z'&S?PFC@_
M_-.VR!JO@\[QIY2*,'?$?CD+]1;23QG=#6FW4(7@4A84A5[GR"Y)H!<-S6R>
M=)Z7&\WZ(1,Y+])9TY42@E[Q0B+63(AR@G4IP:1\9#KYF&$46^C!8N)%2:A%
M%*I=H0&(N5)7^>4[!!>E+'F>,)M+L-AN(,[&2>10\!;1[Q%4>IGFY7HE%7AE
M?AGB67":1V_"BC'AK( 8A<HZP4V,4J38@G^#2(#IY;?J6SPQYJ%AV!=ECA$]
M*2>5]8ZM*6.,&"*P+<5RVRZ_&09!=9[$%_;,(&>*-).S86IEB][RTH$CAXHV
MF@1H36$>S8;GA;^Z8,@%9@W*1K<FZ!M.'X,2JOA(Z9P)$BNK34*D$X?=X<U$
M++55)5$?7]^(OOXLEQI+!&54*4=\,&H *RB"*1Q#I!B7&\TN7@0S/##%T989
MKMO:A*S@@-;\1C :%\5Q):F.Y&1@U#>>.#[]?!\9+QD-RPR1>NFG-:90<.+
M1"[Q9"I6;)[DR8KV:F?-U>J<H=@"28,"US/5T?LE,Q$2;35C>4Q_KEO.X'#9
M-J\7IS8(DS/'?*\4H^%&XD!.4LTRE'I<NGR.#R]P+R9YIQ18 (>-LX-C!_;
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M+?WZ?2 J&^E+@VN&JBIH8&%"QS6F?KM!(U4FO?!1$#*20B5SLW[#/^YZ8_N
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M*\)*!\4"7!'A>X$.' ?:_CN9?+:I@B87]J:0$1U^<XV\/>?04\BNA%]?(9Q
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M4IQWBO&,]&*&K 'Q)<O@J+S']\*M#IJO$7:PD0R3CE@Q[("52XI!L<QA"Y-
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M9^'T/Y]^XTF1"%???(/IKA1X>"?/!$"DOC-:9D&?L0<PDRW&453]+?+B, +
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M%Y/F#?J21B+=$I%]RPW7H^>88G<7D_QR*_A>?QJK<T+)%0QQ66IWI[ -C%9
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M$,YEDK?.W^$Z=1?DU>V-#!X*5R5N=_<C(JAEA583RKMJ74B!BQ'Q%J 2&,^
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MM5C!N3*VFE(V>)NJBU30EB#KK) 8,I:'U&G.K36[+Q@8<Y8VP]PU"VFID>A
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M+!$#H]227B(X-5SL:JBD8IEUIO*)81HY,)FJ%$4)MER 6LEQ'NH@ C#TH$Q
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MXK%C]YR8D_IT\-Z-RZOKYJ!P49<IS,13U?]R'YL07RHU]&1$JSKZ2MIDHZ%
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M+W]_0H&!FZ[@*L)O%T[P(DJ=NK^FU]WBS+X**ZS^>7$]&;J.-V>A3KT3; Z
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MK)YYN;P+=JGI]S)'-(IF;]PN?A5VQ"D'W/'&]-!?7[N*-7@=+-P5#"++>R7
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M,@PCP;[C,62Y$CR?,0!MA=G/)DJ_W^VR#R**-#O#6L6.19*+[)FYONZR:U5
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M^#^"WG/R",P:<$PB,@>FWCHP%G>8V!,1-ALJDR#,T9RK#,9.)3$-:(B:2'@
M#Q7,EMU* (8DZO8Y8D(5P"S86$^X\4_+8]]$19&Z)4^&*BB,E_;8IGSQ "PT
M&Q0>56BTL-YM^-F#&1$\!!;;<$(DTI:QR&^%2-@'&462QVA/N,S<D..BM,4N
M.A>=X\Y"V/^\")$FKT&OV:B%]^,2:+U\59I#$6ARZ-" 9+X2.C>$CZV9 U=<
M4/"J"@?/+%22!4S)9YDJIC/VEL_9:Y*I]]I\'^,S4M4OFV0J9CGBR& R_5Q
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ME8D;*6[QQ*@4\QSKC#R('+;"L]E :10WU(T0W1P=QJ&F).!19'QO=2%3$2U
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MLY'RN9F(3$VGOLIDJF]P37N&S@7E?UZ6?4 14 XA:):4<_7Z4:9>3TI*(+*
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M9WQ^%WWSY0X#GQ8]6_1',?:O9.B/:?X+4$L#!!0    ( -:#7%9TM R?<PP
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MW922W R(IZM\UA;A'B ,/"W_V&@?G9%]<6O:L@L.I[I08F;='6DME[4.I !
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M,RYX<V102P$"% ,4    " #6@UQ6]_V"=_\*  !LAP  %0
M@ %Q P  =&-M9"TR,#(S,#(R,U]L86(N>&UL4$L! A0#%     @ UH-<5K $
M)JI9!P  S5@  !4              ( !HPX  '1C;60M,C R,S R,C-?<')E
M+GAM;%!+ 0(4 Q0    ( -:#7%:@ 0DI<Q0  ,MM   1              "
M 2\6  !T;3(S,S4Q,&0W7SAK+FAT;5!+ 0(4 Q0    ( -:#7%86K!_##Z(
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H,S,U,3!D-U]E>#DY+3(N:'1M4$L%!@     (  @ #@(  ._S      $!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
